The Briefing Room

Exclusive Content => News => Topic started by: PeteS in CA on March 15, 2020, 05:15:12 pm

Title: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 15, 2020, 05:15:12 pm

February 6, 2017 - DARPA launched the Pandemic Prevention Platform, an effort to create a standardized process to create medical countermeasures to a viral outbreak within 60 days, preventing the outbreak from becoming a pandemic; https://www.darpa.mil/news-events/2017-02-06a (https://www.darpa.mil/news-events/2017-02-06a)

February 22, 2018 - DARPA names the research institutions that will be participating in DARPA's Pandemic Prevention Platform, launched in 2017; https://globalbiodefense.com/2018/02/22/stopping-pandemic-x-darpa-names-researchers-working-to-halt-outbreaks/ (https://globalbiodefense.com/2018/02/22/stopping-pandemic-x-darpa-names-researchers-working-to-halt-outbreaks/)

December 31, 2019 - WHO found a translation of a Chinese news report on ProMED about the outbreak in Wuhan; WHO's China office found a Wuhan Municipal Health Commission media statement about the outbreak in Wuhan; https://www.who.int/news-room/detail/29-06-2020-covidtimeline (https://www.who.int/news-room/detail/29-06-2020-covidtimeline)

December 31, 2019 - Taiwanese health officials alerted WHO of the infectivity of coronavirus; https://dailycaller.com/2020/03/20/who-taiwan-coronavirus-warning/ (https://dailycaller.com/2020/03/20/who-taiwan-coronavirus-warning/) , https://www.ft.com/content/2a70a02a-644a-11ea-a6cd-df28cc3c6a68 (https://www.ft.com/content/2a70a02a-644a-11ea-a6cd-df28cc3c6a68)

December 31, 2019 - Taiwan started boarding planes arriving from Wuhan, China to screen passengers for symptoms; https://jamanetwork.com/journals/jama/fullarticle/2762689 (https://jamanetwork.com/journals/jama/fullarticle/2762689)

January 4, 2020 - CDC Director Robert Redfield offers to send technical experts to China: https://www.washingtonpost.com/politics/2020/04/03/how-much-pressure-did-trump-put-china-access-concerning-coronavirus/ (https://www.washingtonpost.com/politics/2020/04/03/how-much-pressure-did-trump-put-china-access-concerning-coronavirus/) (behind paywall)

January 6, 2020 - CDC issued a Level 1 travel notice for Wuhan, China; https://afludiary.blogspot.com/2020/01/cdc-issues-level-1-watch-travel-notice.html (https://afludiary.blogspot.com/2020/01/cdc-issues-level-1-watch-travel-notice.html)

January 6, 2020 - CDC renewed the offer to send team to China; https://www.forbes.com/sites/lisettevoytko/2020/01/28/cdc-offers-china-help-as-coronavirus-outbreak-grows-according-to-report/#5b15af734ee4 (https://www.forbes.com/sites/lisettevoytko/2020/01/28/cdc-offers-china-help-as-coronavirus-outbreak-grows-according-to-report/#5b15af734ee4)

January 7, 2020 - CDC established a coronavirus incident management system; https://www.cdc.gov/vaccines/videos/coronavirus/COVID-19-webinar.pdf (https://www.cdc.gov/vaccines/videos/coronavirus/COVID-19-webinar.pdf)

January 7, 2020 - NIH and Moderna agreed to work on developing a vaccine against what came to be called Covid-19; https://www.hhs.gov/about/news/2020/12/18/hhs-dod-statements-fda-authorization-moderna-vaccine.html (https://www.hhs.gov/about/news/2020/12/18/hhs-dod-statements-fda-authorization-moderna-vaccine.html)

January 8, 2020 - CDC alert to clinicians to ask patients with "severe respiratory illness" whether they had traveled to Wuhan; https://emergency.cdc.gov/han/han00424.asp (https://emergency.cdc.gov/han/han00424.asp)

January 10, 2020 - WHO recommends against international travel restrictions; https://www.who.int/news-room/articles-detail/who-advice-for-international-travel-and-trade-in-relation-to-the-outbreak-of-pneumonia-caused-by-a-new-coronavirus-in-china/ (https://www.who.int/news-room/articles-detail/who-advice-for-international-travel-and-trade-in-relation-to-the-outbreak-of-pneumonia-caused-by-a-new-coronavirus-in-china/)

January 11 and 12, 2020 - Covid-19 coronavirus DNA sequence communicated to WHO; https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)

January 12, 2020 - WHO claimed, "At this stage, there is no infection among healthcare workers, and no clear evidence of human to human transmission"; https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)

January 13, 2020 - WHO claimed "there has been no suggestion of human to human transmission of this new coronavirus"; https://www.who.int/thailand/news/detail/13-01-2020-thailand-responding-to-the-novel-coronavirus (https://www.who.int/thailand/news/detail/13-01-2020-thailand-responding-to-the-novel-coronavirus)

January 13, 2020 - Moderna produced its first "prototype" sample of its vaccine; https://nymag.com/intelligencer/2020/12/moderna-covid-19-vaccine-design.html (https://nymag.com/intelligencer/2020/12/moderna-covid-19-vaccine-design.html)

January 14, 2020 - WHO claimed "there is no clear evidence of human-to-human transmission"; https://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand-ex-china/en/ (https://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand-ex-china/en/)

January 14, 2020 - China/WHO claimed no evidence of  human to human transmission of corona virus; https://twitter.com/WHO/status/1217043229427761152 (https://twitter.com/WHO/status/1217043229427761152) , "World Health Organization (WHO)
@WHO
Jan 14
Preliminary investigations conducted by the Chinese authorities have found no clear evidence of human-to-human transmission of the novel #coronavirus (2019-nCoV) identified in #Wuhan, #China."

January 15, 2020 - Nancy Pelosi signed impeachment articles and doled out impeachment pens; https://apnews.com/3cd46ae3f694b21c0cf83af3f0c4f1c7 (https://apnews.com/3cd46ae3f694b21c0cf83af3f0c4f1c7)

January 17, 2020 - The US started screening arriving passengers from China; JFK, SFO, LAX https://www.businessinsider.com/new-disease-virus-china-us-airports-screening-cdc-2020-1 (https://www.businessinsider.com/new-disease-virus-china-us-airports-screening-cdc-2020-1) ,  https://www.cdc.gov/media/releases/2020/p0117-coronavirus-screening.html (https://www.cdc.gov/media/releases/2020/p0117-coronavirus-screening.html) ; O'Hare and Hartsfield-Jackson
January 22, 2020 - https://www.washingtonpost.com/nation/2020/01/21/us-screenings-coronavirus-expanded-airports-atlanta-chicago/ (https://www.washingtonpost.com/nation/2020/01/21/us-screenings-coronavirus-expanded-airports-atlanta-chicago/)

January 20, 2020 - Dr. Fauci announces the National Institutes of Health working developing a vaccine for coronavirus; https://www.cnn.com/2020/01/20/health/coronavirus-nih-vaccine-development/index.html (https://www.cnn.com/2020/01/20/health/coronavirus-nih-vaccine-development/index.html)

January 20, 2020 - CDC activated its emergency operations center; https://emergency.cdc.gov/recentincidents/index.asp?cid=EPR-homepage (https://emergency.cdc.gov/recentincidents/index.asp?cid=EPR-homepage)

January 20, 2020 - First acknowledgement by China and WHO of human-human transmission of coronavirus; https://abcnews.go.com/Health/human-human-transmission-coronavirus-reported-china/story?id=68403105 (https://abcnews.go.com/Health/human-human-transmission-coronavirus-reported-china/story?id=68403105)

January 20, 2020 - First confirmed coronavirus case in the US announced; https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html (https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html)

January 22, 2020 - US CDC issues a “(Travel) Watch Level 2 Alert (Practice Enhanced Precautions)” for the pneumonia caused by the novel coronavirus; https://china.usembassy-china.org.cn/health-alert-update-novel-coronavirus-in-china-3/ (https://china.usembassy-china.org.cn/health-alert-update-novel-coronavirus-in-china-3/)

January 22, 2020 - Pharmaceuticals company Moderna working with US government to develop vaccine; https://www.cnbc.com/2020/01/22/moderna-is-working-on-a-vaccine-for-chinas-deadly-coronavirus.html (https://www.cnbc.com/2020/01/22/moderna-is-working-on-a-vaccine-for-chinas-deadly-coronavirus.html) , https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development)

January 23, 2020 - CDC sought “special emergency authorization” from FDA to allow states to use its coronavirus test; https://www.reuters.com/article/us-china-health-cdc-idUSKBN1ZM2XS (https://www.reuters.com/article/us-china-health-cdc-idUSKBN1ZM2XS)

January 26, 2020 - While warning that the coronavirus would come to NYC, New York City Health Commisioner Dr. Oxiris Barbot advised people, "We are encouraging New Yorkers to go about their everyday lives and suggest practicing everyday precautions that we do through the flu season," and, "We are very clear: We wish New Yorkers a Happy Lunar New Year and we encourage people to spend time with their families and go about their celebration"; https://www.nytimes.com/2020/01/27/nyregion/new-york-city-coronavirus.html (https://www.nytimes.com/2020/01/27/nyregion/new-york-city-coronavirus.html)

January 23, 2020 - Wuhan and other cities in Hubei Province shut down travel; http://www.xinhuanet.com/english/2020-01/23/c_138728067.htm (http://www.xinhuanet.com/english/2020-01/23/c_138728067.htm) , https://news.cgtn.com/news/2020-01-27/5-million-people-left-Wuhan-before-the-lockdown-where-did-they-go--NACCu9wItW/index.html (https://news.cgtn.com/news/2020-01-27/5-million-people-left-Wuhan-before-the-lockdown-where-did-they-go--NACCu9wItW/index.html)

January 27, 2020 - US CDC issues highest-level travel health notice, Level 3, recommending that travelers avoid all nonessential travel to China; State Department raises its own travel advisory for all of China to Level 3 of 4, urging U.S. citizens to “reconsider travel”, while retaining its Level 4 travel advisory for Hubei Province; https://www.cdc.gov/media/releases/2020/s0128-travelers-avoid-china.html (https://www.cdc.gov/media/releases/2020/s0128-travelers-avoid-china.html) , https://china.usembassy-china.org.cn/travel-alert-level-4-do-not-travel-to-hubei/ (https://china.usembassy-china.org.cn/travel-alert-level-4-do-not-travel-to-hubei/)

January 28, 2020 - CDC renewed offer to send team to China; https://thehill.com/changing-america/well-being/prevention-cures/480314-us-looks-to-send-health-experts-to-china-amid (https://thehill.com/changing-america/well-being/prevention-cures/480314-us-looks-to-send-health-experts-to-china-amid) , https://www.hhs.gov/about/leadership/secretary/speeches/2020-speeches/remarks-at-coronavirus-press-briefing.html (https://www.hhs.gov/about/leadership/secretary/speeches/2020-speeches/remarks-at-coronavirus-press-briefing.html)

January 28, 2020 - AbCellera is mobilizing its pandemic response platform against the outbreak of Covid-19; Since 2018, under the DARPA Pandemic Prevention Platform (P3) program, AbCellera has been leading a team of partners to establish a platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen; https://www.abcellera.com/news/2020-01-abcellera-mobilizing-a-response-to-novel-coronavirus (https://www.abcellera.com/news/2020-01-abcellera-mobilizing-a-response-to-novel-coronavirus)

January 28, 2020 - Clover Biopharmaceuticals announced that it has initiated development of a vaccine for Covid-19; http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=40 (http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=40)

January 28, 2020 - CytoDyn announced that it is exploring leronlimab as a potential treatment to enhance immune response and control in patients infected with Covid-19; https://www.cytodyn.com/newsroom/press-releases/detail/379/leronlimab-under-evaluation-for-potential-treatment-of (https://www.cytodyn.com/newsroom/press-releases/detail/379/leronlimab-under-evaluation-for-potential-treatment-of)

January 29, 2020 - White House announced the formation of the Coronavirus Task Force; https://thehill.com/policy/healthcare/480627-white-house-announces-task-force-to-monitor-coronavirus (https://thehill.com/policy/healthcare/480627-white-house-announces-task-force-to-monitor-coronavirus) , https://www.whitehouse.gov/briefings-statements/statement-press-secretary-regarding-presidents-coronavirus-task-force/ (https://www.whitehouse.gov/briefings-statements/statement-press-secretary-regarding-presidents-coronavirus-task-force/)

January 29, 2020 - US personnel evacuated from Wuhan; https://abcnews.go.com/US/us-chartering-evacuation-flight-wuhan-coronavirus-zone-california/story?id=68571310 (https://abcnews.go.com/US/us-chartering-evacuation-flight-wuhan-coronavirus-zone-california/story?id=68571310)

January 30, 2020 - World Health Organization declared coronavirus a public health emergency of international concern; https://www.cnn.com/2020/01/30/health/coronavirus-who-public-health-emergency-international-concern-declaration/index.html (https://www.cnn.com/2020/01/30/health/coronavirus-who-public-health-emergency-international-concern-declaration/index.html)

January 30, 2020 - Dr. Nancy Messonnier, director of the Center for the National Center for Immunization and Respiratory Diseases, said, "We are preparing as if this was the next pandemic"; https://abcnews.go.com/Health/delta-suspends-us-flights-china-amid-coronavirus/story?id=68666037 (https://abcnews.go.com/Health/delta-suspends-us-flights-china-amid-coronavirus/story?id=68666037)

January 31, 2020 - In reference to Lunar New Year celebration activities, Barbara Ferrer, Los Angeles County Department of Public Health Director, said, "There is no need to panic and there is no need for people to cancel their activities."; https://mynewsla.com/hollywood/2020/01/28/health-official-says-coronavirus-is-no-need-for-panic-in-los-angeles-county/ (https://mynewsla.com/hollywood/2020/01/28/health-official-says-coronavirus-is-no-need-for-panic-in-los-angeles-county/)

January 31, 2020 - Vaxart Announces start of development of Covid-19 oral vaccine; https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-initiation-coronavirus-vaccine-program (https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-initiation-coronavirus-vaccine-program)

January 31, 2020 - Trump declared a public health emergency; https://abcnews.go.com/Health/delta-suspends-us-flights-china-amid-coronavirus/story?id=68666037 (https://abcnews.go.com/Health/delta-suspends-us-flights-china-amid-coronavirus/story?id=68666037) , https://www.hhs.gov/about/news/2020/01/31/secretary-azar-declares-public-health-emergency-us-2019-novel-coronavirus.html (https://www.hhs.gov/about/news/2020/01/31/secretary-azar-declares-public-health-emergency-us-2019-novel-coronavirus.html)

January 31, 2020 - State Department raised the travel advisory for China to Level 4, do not travel; https://www.usatoday.com/story/travel/2020/01/31/coronavirus-china-flight-ban-delta-cuts-all-flights-white-house/4620989002/ (https://www.usatoday.com/story/travel/2020/01/31/coronavirus-china-flight-ban-delta-cuts-all-flights-white-house/4620989002/)

January 31, 2020 - State Department ordered the departure of all under-age-21 family members of US personnel in China; https://travel.state.gov/content/travel/en/traveladvisories/traveladvisories/china-travel-advisory.html (https://travel.state.gov/content/travel/en/traveladvisories/traveladvisories/china-travel-advisory.html)

January 31, 2020 - People entering the US from China forbidden; Announced January 31, effective February 2; https://www.cnn.com/2020/02/02/us/coronavirus-us-travel-restrictions/index.html (https://www.cnn.com/2020/02/02/us/coronavirus-us-travel-restrictions/index.html) , https://www.whitehouse.gov/presidential-actions/proclamation-suspension-entry-immigrants-nonimmigrants-persons-pose-risk-transmitting-2019-novel-coronavirus/ (https://www.whitehouse.gov/presidential-actions/proclamation-suspension-entry-immigrants-nonimmigrants-persons-pose-risk-transmitting-2019-novel-coronavirus/) ; https://www.whitehouse.gov/briefings-statements/press-briefing-members-presidents-coronavirus-task-force/ (https://www.whitehouse.gov/briefings-statements/press-briefing-members-presidents-coronavirus-task-force/) This effectively ended flights from and to China, for obvious reasons.

January 31, 2020 - Biden referred to "Donald Trump’s record of hysteria and xenophobia - hysterical xenophobia - and fearmongering" while criticizing Trump's China travel restrictions; https://thehill.com/homenews/campaign/481028-biden-slams-trump-for-cutting-health-programs-before-coronavirus-outbreak (https://thehill.com/homenews/campaign/481028-biden-slams-trump-for-cutting-health-programs-before-coronavirus-outbreak)

February 1, 2020 - The day after Trump announced the China travel shutdown Joe Biden Tweeted, "Donald Trump’s record of hysteria, xenophobia, and fear-mongering"; https://twitter.com/JoeBiden/status/1223727977361338370?s=20 (https://twitter.com/JoeBiden/status/1223727977361338370?s=20)

February 2, 2020 - NYC Health Commissioner Dave A. Chokshi encouraged New Yorkers, "As we gear up to celebrate the #LunarNewYear in NYC,... there is no reason for anyone to change their holiday plans, avoid the subway, or certain parts of the city because of #coronavirus; https://twitter.com/NYCHealthCommr/status/1224043155852537863 (https://twitter.com/NYCHealthCommr/status/1224043155852537863)

February 3, 2020 - WHO Director-General states that a travel ban is not needed; https://www.reuters.com/article/us-china-health-who-idUSKBN1ZX1H3 (https://www.reuters.com/article/us-china-health-who-idUSKBN1ZX1H3) , https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-technical-briefing-on-2019-novel-coronavirus (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-technical-briefing-on-2019-novel-coronavirus)

February 3, 2020 - CDC had a team ready to travel to China; https://www.reuters.com/article/us-china-health-who-mission-idUSKBN1ZX2BV (https://www.reuters.com/article/us-china-health-who-mission-idUSKBN1ZX2BV)

February 4, 2020 - HHS, Regeneron Collaborate to Develop 2019-nCoV Treatment; https://www.hhs.gov/about/news/2020/02/04/hhs-regeneron-collaborate-to-develop-2019-ncov-treatment.html (https://www.hhs.gov/about/news/2020/02/04/hhs-regeneron-collaborate-to-develop-2019-ncov-treatment.html) , https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody (https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody)

February 4, 2020 - Rep. Ami Bera claimed Trump's China travel restrictions would "create prejudices" and cause people to "harbor anxieties toward" Chinese people; https://www.politico.com/states/california/story/2020/02/04/coronavirus-quarantine-travel-ban-could-backfire-experts-fear-1258757 (https://www.politico.com/states/california/story/2020/02/04/coronavirus-quarantine-travel-ban-could-backfire-experts-fear-1258757)

February 5, 2020 - First House of Representatives hearing about Covid-19; https://www.cnbc.com/2020/02/05/watch-us-house-panel-holds-hearing-on-the-coronavirus-outbreak.html (https://www.cnbc.com/2020/02/05/watch-us-house-panel-holds-hearing-on-the-coronavirus-outbreak.html)

February 5, 2020 - Rep. Eliot Engel claimed Trump's China travel restrictions would "stoke" "discriminatory" and "racist" responses; https://foreignaffairs.house.gov/2020/2/engel-statement-at-coronavirus-outbreak-subcommittee-hearing (https://foreignaffairs.house.gov/2020/2/engel-statement-at-coronavirus-outbreak-subcommittee-hearing)

February 6, 2020 - Shipping of CDC 2019 coronavirus test kits begins; https://www.cdc.gov/media/releases/2020/p0206-coronavirus-diagnostic-test-kits.html (https://www.cdc.gov/media/releases/2020/p0206-coronavirus-diagnostic-test-kits.html)

February 7, 2020 - NYC Health Commisioner Dr. Oxiris Barbot advised people, "So we’re telling New Yorkers, go about your lives, take the subway, go out, enjoy life, but practice everyday precautions"; https://news.grabien.com/story-flashback-nyc-health-commissioner-urged-new-yorkers-gather-p (https://news.grabien.com/story-flashback-nyc-health-commissioner-urged-new-yorkers-gather-p) (the link includes context of her advice and video of her comments)

February 9, 2020 - NYC Health Commissioner Oxiris Barbot encouraged New Yorkers, "I want to remind everyone to enjoy the (Lunar New Year) parade and not change any plans due to misinformation spreading about #coronavirus."; https://twitter.com/NYCHealthCommr/status/1226508570646269954 (https://twitter.com/NYCHealthCommr/status/1226508570646269954)

February 10, 2020 - Clover Biopharmaceuticals announced that it has produced a vaccine candidate that has produced an immune system response in patients who have recovered from Covid-19; http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=41 (http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=41)

February 11, 2020 - HHS expands partnership with Janssen Research & Development for vaccine development; https://www.hhs.gov/about/news/2020/02/11/hhs-janssen-join-forces-on-coronavirus-vaccine.html (https://www.hhs.gov/about/news/2020/02/11/hhs-janssen-join-forces-on-coronavirus-vaccine.html)

February 16, 2020 - Medigen Vaccine Biologics (Taiwan) and US NIH entered a collaboration agreement to develop a Covid-19 vaccine; http://www.medigenvac.com/public/en/news/detail/52?from_sort=2 (http://www.medigenvac.com/public/en/news/detail/52?from_sort=2)

February 18, 2020 - HHS to work with Sanofi Pasteur to develop coronavirus vaccine and treatment; https://www.statnews.com/2020/02/18/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/ (https://www.statnews.com/2020/02/18/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/)

February 18, 2020 - HHS to work with Janssen Research to develop a Covid-19 vaccine; https://www.hhs.gov/about/news/2020/02/18/hhs-janssen-collaborate-to-develop-coronavirus-therapeutics.html (https://www.hhs.gov/about/news/2020/02/18/hhs-janssen-collaborate-to-develop-coronavirus-therapeutics.html)

February 24, 2020 - Nancy Pelosi invited Californians to "come to Chinatown"; https://sanfrancisco.cbslocal.com/2020/02/24/coronavirus-speaker-house-nancy-pelosi-tours-san-franciscos-chinatown/ (https://sanfrancisco.cbslocal.com/2020/02/24/coronavirus-speaker-house-nancy-pelosi-tours-san-franciscos-chinatown/)

February 24, 2020 - Clover Biopharmaceuticals announced an agreement with GlaxoSmithKline to test its vaccine with GSK's adjuvant; http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=42 (http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=42)

February 25, 2020 - An NIH clinical trial of Remdesivir begun; at University of Nebraska Medical Center, https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins)

February 25, 2020 - Vir Biotechnology and WuXi Biologics today announced collaboration on the clinical development, manufacturing, and commercialization of Vir’s human monoclonal antibodies for the potential treatment of COVID-19; https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-wuxi-biologics-announce-collaboration (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-wuxi-biologics-announce-collaboration)

February 26, 2020 - Experimental vaccine submitted for testing; Moderna, https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html (https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html)

February 26, 2020 - Nancy Pelosi referred to Trump's China travel shut down as, "scare tactics about people coming back to our country"; https://twitter.com/ABCPolitics/status/1232717882020245504 (https://twitter.com/ABCPolitics/status/1232717882020245504)

February 29, 2020 - Testing labs allowed to use tests whose FDA Emergency Use Authorization requests are still pending; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics)

February 29, 2020 - Level 4 travel advisory to Italy, South Korea; https://www.usatoday.com/story/travel/2020/02/29/coronavirus-trump-adds-travel-restrictions-italy-south-korea/4914822002/ (https://www.usatoday.com/story/travel/2020/02/29/coronavirus-trump-adds-travel-restrictions-italy-south-korea/4914822002/)

February 29, 2020 - Iran travel ban announced; https://www.statnews.com/2020/02/29/trump-administration-expands-coronavirus-travel-ban-to-include-iran/ (https://www.statnews.com/2020/02/29/trump-administration-expands-coronavirus-travel-ban-to-include-iran/)

March 3, 2020 - WHO Director-General claimed, "COVID-19 does not transmit as efficiently as influenza, from the data we have so far"; https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020 (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020)

March 4, 2020 - CDC widened criteria for who should be tested for coronavirus; https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html (https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html)

March 4, 2020 - HHS announced intent to purchase 500 million N95 respirators over the next 18 months for the Strategic National Stockpile; https://www.hhs.gov/about/news/2020/03/04/hhs-to-procure-n95-respirators-to-support-healthcare-workers-in-covid-19-outbreaks.html (https://www.hhs.gov/about/news/2020/03/04/hhs-to-procure-n95-respirators-to-support-healthcare-workers-in-covid-19-outbreaks.html)

March 4, 2020 - In a press conference, NYC Health Commisioner Dr. Oxiris Barbot advised "So, there's no indication that being in a car, being in the subways with someone who's potentially sick is a risk factor ..."; https://www1.nyc.gov/office-of-the-mayor/news/118-20/transcript-mayor-de-blasio-new-yorkers-city-s-covid-19-preparedness (https://www1.nyc.gov/office-of-the-mayor/news/118-20/transcript-mayor-de-blasio-new-yorkers-city-s-covid-19-preparedness)

March 5, 2020 - City of New York Mayor de Blasio encouraged residents to "get out on the town"; https://twitter.com/BilldeBlasio/status/1234648718714036229 (https://twitter.com/BilldeBlasio/status/1234648718714036229)

March 5, 2020 - Barbara Ferrer, director of the Los Angeles County Public Health Department, said, "The public can continue to enjoy all that L.A. County has to offer, including the Los Angeles Marathon"; https://www.latimes.com/california/story/2020-03-07/coronavirus-cancels-many-events-but-l-a-marathon-and-coachella-still-on-here-is-why (https://www.latimes.com/california/story/2020-03-07/coronavirus-cancels-many-events-but-l-a-marathon-and-coachella-still-on-here-is-why)

March 08, 2020 - CytoDyn Inc. announced that it has submitted an investigational new drug (IND) application to the US FDA to conduct a Phase 2 clinical trial with leronlimab as a therapy for patients with respiratory complications from COVID-19; https://www.cytodyn.com/newsroom/press-releases/detail/391/cytodyn-files-ind-and-protocol-for-phase-2-clinical-trial (https://www.cytodyn.com/newsroom/press-releases/detail/391/cytodyn-files-ind-and-protocol-for-phase-2-clinical-trial) ; IND modified, March 16, https://www.cytodyn.com/newsroom/press-releases/detail/395/cytodyn-files-modified-ind-and-protocol-for-phase-2 (https://www.cytodyn.com/newsroom/press-releases/detail/395/cytodyn-files-modified-ind-and-protocol-for-phase-2)

March 9, 2020 - AbbVie confirmed the company is working with European health authorities and the US FDA, CDC, N and BARDA to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19; https://news.abbvie.com/news/press-releases/abbvie-partnering-with-global-authorities-to-determine-efficacy-hiv-drug-in-treating-covid-19.htm (https://news.abbvie.com/news/press-releases/abbvie-partnering-with-global-authorities-to-determine-efficacy-hiv-drug-in-treating-covid-19.htm)

March 9, 2020 - HHS announced funding support to Hologic for the advanced development of a high-volume Covid-19 test; https://www.hhs.gov/about/news/2020/03/09/hhs-supports-development-of-first-high-throughput-covid-19-diagnostic-test.html (https://www.hhs.gov/about/news/2020/03/09/hhs-supports-development-of-first-high-throughput-covid-19-diagnostic-test.html)

March 10, 2020 - Emergent BioSolutions Inc. announced an agreement with Novavax, Inc. for development and manufacturing services to bring Novavax’s experimental COVID-19 vaccine candidate into clinical testing; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing)

March 10, 2020 - Trump and VP Pence met with health insurance companies and secured commitment to waive co-pays for coronavirus testing; https://www.nbcnews.com/video/trump-pence-meet-with-insurance-executives-agree-to-waive-copays-extend-treatment-80407109506 (https://www.nbcnews.com/video/trump-pence-meet-with-insurance-executives-agree-to-waive-copays-extend-treatment-80407109506)

March 10, 2020 - Army signed agreement with Gilead on experimental COVID-19 treatment; https://www.militarytimes.com/news/your-military/2020/03/10/army-signs-agreement-with-drug-giant-gilead-on-experimental-covid-19-treatment/ (https://www.militarytimes.com/news/your-military/2020/03/10/army-signs-agreement-with-drug-giant-gilead-on-experimental-covid-19-treatment/)

March 10, 2020 - OyaGen, Inc. announced experimental treatment has been studied by National Institute of Allergy and Infectious Diseases; http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf (http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf) , "OYA1", not yet tested on humans

March 11, 2020 - World Health Organization declared the coronavirus outbreak a global pandemic; https://www.cnbc.com/2020/03/11/who-declares-the-coronavirus-outbreak-a-global-pandemic.html (https://www.cnbc.com/2020/03/11/who-declares-the-coronavirus-outbreak-a-global-pandemic.html)

March 11, 2020 - Trump suspended travel from Europe; https://news.yahoo.com/trump-suspends-travel-from-europe-for-30-days-as-coronavirus-cases-continue-to-grow-014314635.html (https://news.yahoo.com/trump-suspends-travel-from-europe-for-30-days-as-coronavirus-cases-continue-to-grow-014314635.html)

March 11, 2020 - Emergent BioSolutions announced it has initiated development of two plasma derived polyclonal antibody therapeutics for treatment and prevention of COVID-19; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-initiates-development-plasma-derived (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-initiates-development-plasma-derived)

March 11, 2020 - Vir Biotechnology and the NIH will work together to identify and optimize combinations of antibodies against coronaviruses, including SARS-CoV-2, SARS and MERS, as well as antibodies that may be effective across additional types of coronaviruses; https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-research-collaboration-national (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-research-collaboration-national)

March 12, 2020 - Vir Biotechnology announced that it has signed a letter of intent with Biogen Inc. for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of COVID-19; https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-intent-collaborate-biogen (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-intent-collaborate-biogen)

March 12, 2020 - AbCellera and Eli Lilly announced an agreement to develop antibody products for treatment and prevention of COVID-19; part of a 2018 DARPA program with AbCellera; http://lilly.mediaroom.com/2020-03-12-AbCellera-and-Lilly-to-Co-develop-Antibody-Therapies-for-the-Treatment-of-COVID-19 (http://lilly.mediaroom.com/2020-03-12-AbCellera-and-Lilly-to-Co-develop-Antibody-Therapies-for-the-Treatment-of-COVID-19) , https://www.msn.com/en-us/finance/companies/eli-lilly-joins-race-to-develop-coronavirus-treatment/ar-BB116BNR (https://www.msn.com/en-us/finance/companies/eli-lilly-joins-race-to-develop-coronavirus-treatment/ar-BB116BNR)

March 12, 2020 - Medicago announced they have produced a Virus-Like Particle (VLP) of the coronavirus gene; production of the VLP is the first step in developing a vaccine for COVID-19; https://www.medicago.com/en/newsroom/medicago-announces-production-of-a-viable-vaccine-candidate-for-covid-19/ (https://www.medicago.com/en/newsroom/medicago-announces-production-of-a-viable-vaccine-candidate-for-covid-19/)

March 13, 2020 - Trump declared National Emergency; https://www.msn.com/en-us/news/politics/what-trumps-emergency-declaration-over-coronavirus-means-for-arizona/ar-BB11a6RO (https://www.msn.com/en-us/news/politics/what-trumps-emergency-declaration-over-coronavirus-means-for-arizona/ar-BB11a6RO) , https://www.whitehouse.gov/presidential-actions/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/ (https://www.whitehouse.gov/presidential-actions/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/)

March 13, 2020 - Janssen Pharmaceutical entered collaboration with the Beth Israel Deaconess Medical Center (BIDMC) for development of a COVID-19 vaccine; https://www.jnj.com/johnson-johnson-announces-collaboration-with-the-beth-israel-deaconess-medical-center-to-accelerate-covid-19-vaccine-development (https://www.jnj.com/johnson-johnson-announces-collaboration-with-the-beth-israel-deaconess-medical-center-to-accelerate-covid-19-vaccine-development)

March 13, 2020 - Trump announced public-private partnerships for drive-through testing; https://abcnews.go.com/Health/wireStory/trump-announces-public-private-partnership-increase-national-coronavirus-69587547 (https://abcnews.go.com/Health/wireStory/trump-announces-public-private-partnership-increase-national-coronavirus-69587547)

March 13, 2020 - FDA granted emergency approval for faster coronavirus test; https://thehill.com/policy/healthcare/other/487393-fda-grants-emergency-approval-for-faster-coronavirus-test (https://thehill.com/policy/healthcare/other/487393-fda-grants-emergency-approval-for-faster-coronavirus-test)

March 13, 2020 - FDA emergency approval for Thermo-Fisher coronavirus test (within 24 hours of applying); https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-thermo-fisher (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-thermo-fisher)

March 13, 2020 - Public-private partnerships allowed to open up drive-through testing collection sites; https://www.mercurynews.com/2020/03/13/in-declaring-national-emergency-trump-pledges-drive-thru-testing-greater-flexibility-for-doctors/ (https://www.mercurynews.com/2020/03/13/in-declaring-national-emergency-trump-pledges-drive-thru-testing-greater-flexibility-for-doctors/)

March 13, 2020 - FDA granted Roche AG an emergency approval for automated coronavirus testing kits; https://www.bloomberg.com/news/articles/2020-03-13/roche-gets-clearance-for-coronavirus-test-that-s-10-times-faster (https://www.bloomberg.com/news/articles/2020-03-13/roche-gets-clearance-for-coronavirus-test-that-s-10-times-faster)

March 13, 2020 - HHS announced funding support to DiaSorin Molecular and Qiagen for the development of a high-speed Covid-19 tests; https://www.hhs.gov/about/news/2020/03/13/hhs-funds-development-covid-19-diagnostic-tests.html (https://www.hhs.gov/about/news/2020/03/13/hhs-funds-development-covid-19-diagnostic-tests.html)

March 14, 2020 - European travel ban extended to include the UK and Ireland; https://www.politico.com/news/2020/03/14/white-house-adds-uk-ireland-to-travel-ban-129470 (https://www.politico.com/news/2020/03/14/white-house-adds-uk-ireland-to-travel-ban-129470)

March 16, 2020 - Pfizer announced partnership to develop BioNTech’s mRNA-based COVID-19 vaccines; https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine (https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine)

March 16, 2020 - Testing begins of Moderna's experimental coronavirus vaccine; at Kaiser Permanente Washington Health Research Institute, https://www.kpwashingtonresearch.org/news-and-events/recent-news/news-2020/kaiser-permanente-launches-coronavirus-vaccine-study-seattle (https://www.kpwashingtonresearch.org/news-and-events/recent-news/news-2020/kaiser-permanente-launches-coronavirus-vaccine-study-seattle) , https://www.hhs.gov/about/news/2020/03/16/hhs-secretary-azar-statement-on-launch-of-phase-1-covid-19-vaccine-trial.html (https://www.hhs.gov/about/news/2020/03/16/hhs-secretary-azar-statement-on-launch-of-phase-1-covid-19-vaccine-trial.html) , https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins)

March 16, 2020 - FDA allowing states to authorize use of tests developed by labs in their states; https://seekingalpha.com/news/3552325-fda-to-allow-states-to-authorize-coronavirus-tests (https://seekingalpha.com/news/3552325-fda-to-allow-states-to-authorize-coronavirus-tests)

March 16, 2020 - CytoDyn filed a modified IND and protocol for its Phase 2 clinical trial with leronlimab as a therapy for patients with respiratory complications from COVID-19; https://www.cytodyn.com/newsroom/press-releases/detail/395/cytodyn-files-modified-ind-and-protocol-for-phase-2 (https://www.cytodyn.com/newsroom/press-releases/detail/395/cytodyn-files-modified-ind-and-protocol-for-phase-2)

March 17, 2020 - Defense Department to give HHS up to 5M respirator masks, 2,000 ventilators; https://www.defense.gov/Explore/News/Article/Article/2115200/dod-poised-to-provide-masks-ventilators-labs-to-hhs-for-coronavirus-fight/ (https://www.defense.gov/Explore/News/Article/Article/2115200/dod-poised-to-provide-masks-ventilators-labs-to-hhs-for-coronavirus-fight/)

March 18, 2020 - HHS to suspended regulation against doctors practicing across state lines; https://www.medicaleconomics.com/news/coronavirus-response-doctors-can-now-practice-across-state-lines (https://www.medicaleconomics.com/news/coronavirus-response-doctors-can-now-practice-across-state-lines)

March 18, 2020 - Temporary closure of U.S.-Canada border to non-essential traffic; 2020, https://www.citynews1130.com/2020/03/18/trump-announces-temporary-u-s-canada-border-closure-amid-virus-pandemic/ (https://www.citynews1130.com/2020/03/18/trump-announces-temporary-u-s-canada-border-closure-amid-virus-pandemic/)

March 18, 2020 - HUD foreclosures and evictions suspended for a at least 60 days; 2020, https://www.hud.gov/sites/dfiles/OCHCO/documents/20-04hsgml.pdf (https://www.hud.gov/sites/dfiles/OCHCO/documents/20-04hsgml.pdf)

March 18, 2020 - Vaxart announced today an agreement with Emergent BioSolutions to help develop and manufacture Vaxart’s Covid-19 oral vaccine; https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions (https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions) , https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing-0 (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing-0)

March 18, 2020 - Trump invoked the Defense Production Act delegating to the Secretary of HHS the task of determining what products and components are critical in responding to Covid-19 and President Trump's authority, as necessary, to contract for, facilitate or compel production of, and distribute where needed those products; https://www.whitehouse.gov/presidential-actions/executive-order-prioritizing-allocating-health-medical-resources-respond-spread-covid-19/ (https://www.whitehouse.gov/presidential-actions/executive-order-prioritizing-allocating-health-medical-resources-respond-spread-covid-19/) , https://www.hhs.gov/about/news/2020/03/18/secretary-azar-statement-president-trumps-invoking-defense-production-act.html (https://www.hhs.gov/about/news/2020/03/18/secretary-azar-statement-president-trumps-invoking-defense-production-act.html)

March 18, 2020 - Pernod Ricard USDA began producing hand sanitizer at all of its US distilleries, in coordination with and assisted by the White House Task Force; https://www.prnewswire.com/news-releases/pernod-ricard-usa-produces-hand-sanitizer-to-help-us-combat-covid-19-virus-301026216.html (https://www.prnewswire.com/news-releases/pernod-ricard-usa-produces-hand-sanitizer-to-help-us-combat-covid-19-virus-301026216.html)

March 18, 2020 - HHS announced funding support to Mesa Biotech for the advanced development of a high-speed point-of-care Covid-19 test; https://www.hhs.gov/about/news/2020/03/18/hhs-supports-mesa-biotech-develop-rapid-diagnostic-detect-novel-coronavirus-infections.html (https://www.hhs.gov/about/news/2020/03/18/hhs-supports-mesa-biotech-develop-rapid-diagnostic-detect-novel-coronavirus-infections.html)

March 18, 2020 - HHS announced a partnership to develop a high-speed fill-and-finish process for vaccines and injectable drugs for the Strategic National Stockpile; https://www.hhs.gov/about/news/2020/03/18/hhs-announces-new-public-private-partnership-to-develop-us-based-high-speed-emergency-drug-packaging-solutions.html (https://www.hhs.gov/about/news/2020/03/18/hhs-announces-new-public-private-partnership-to-develop-us-based-high-speed-emergency-drug-packaging-solutions.html)

March 19, 2020 - Carnival Cruise Lines ships available for hospital use (non-corona virus patients); https://www.mercurynews.com/2020/03/19/cruise-line-offers-up-ships-for-use-as-temporary-hospitals/ (https://www.mercurynews.com/2020/03/19/cruise-line-offers-up-ships-for-use-as-temporary-hospitals/)

March 19, 2020 - State Department global level 4 health advisory, avoid all international travel; https://travel.state.gov/content/travel/en/traveladvisories/ea/travel-advisory-alert-global-level-4-health-advisory-issue.html (https://travel.state.gov/content/travel/en/traveladvisories/ea/travel-advisory-alert-global-level-4-health-advisory-issue.html)

March 19, 2020 - CytoDyn Inc. announced that two Covid-19 patients were treated with leronlimab at a leading medical center in the New York City area under an emergency IND) granted by the US FDA; https://www.cytodyn.com/newsroom/press-releases/detail/397/u-s-food-and-drug-administration-fda-grants-emergency (https://www.cytodyn.com/newsroom/press-releases/detail/397/u-s-food-and-drug-administration-fda-grants-emergency) ; two additional patients March 23, https://www.cytodyn.com/newsroom/press-releases/detail/398/two-additional-coronavirus-patients-treated-at-leading-new (https://www.cytodyn.com/newsroom/press-releases/detail/398/two-additional-coronavirus-patients-treated-at-leading-new) ; Results from first seven patients, March 27, https://www.cytodyn.com/newsroom/press-releases/detail/399/leronlimab-used-in-seven-patients-with-severe-covid-19 (https://www.cytodyn.com/newsroom/press-releases/detail/399/leronlimab-used-in-seven-patients-with-severe-covid-19)

March 20, 2020 - US, Mexico agree to restrict nonessential cross-border traffic; https://www.wesh.com/article/us-and-mexico-coordinating-on-plan-to-restrict-travel-across-the-border-1/31794143 (https://www.wesh.com/article/us-and-mexico-coordinating-on-plan-to-restrict-travel-across-the-border-1/31794143)

March 20, 2020 - HHS, DOD, and Fedex coordinated an airlift from Copan Diagnostics in Italy of 500,000 swabs and sample kits used in the COVID-19 testing process; https://www.hhs.gov/about/news/2020/03/20/hhs-dod-coordinate-international-airlift-of-covid-19-supplies.html (https://www.hhs.gov/about/news/2020/03/20/hhs-dod-coordinate-international-airlift-of-covid-19-supplies.html)

March 21, 2020 - Anheuser-Busch InBev announced on Saturday it plans to begin producing and distributing hand sanitizer in the US; https://www.fool.com/investing/2020/03/23/anheuser-busch-starts-making-hand-sanitizer-alongs.aspx (https://www.fool.com/investing/2020/03/23/anheuser-busch-starts-making-hand-sanitizer-alongs.aspx)

March 22, 2020 - Governors remain in command of National Guard, Federals pay 100% of operations cost (all states); https://www.thewrap.com/trump-fema-will-pay-100-of-cost-for-national-guard-in-new-york-california-washington/ (https://www.thewrap.com/trump-fema-will-pay-100-of-cost-for-national-guard-in-new-york-california-washington/)

March 23, 2020 - Trump invoked the Defense Production Act to forbid hoarding, speculating, and price-gouging of PPE and sanitizing products; https://www.whitehouse.gov/presidential-actions/executive-order-preventing-hoarding-health-medical-resources-respond-spread-covid-19/ (https://www.whitehouse.gov/presidential-actions/executive-order-preventing-hoarding-health-medical-resources-respond-spread-covid-19/)

March 24, 2020 - Army ordered three army hospitals to deploy to New York and Washington; https://armyupdate.com/index.php/2020/03/25/army-medical-hospitals-deploying-to-n-y-and-washington-state/ (https://armyupdate.com/index.php/2020/03/25/army-medical-hospitals-deploying-to-n-y-and-washington-state/)

March 24, 2020 - Ology Bioservices, Inovio Partner To Manufacture COVID-19 Vaccine With $11.9M DOD Grant; http://ir.inovio.com/news-releases/news-releases-details/2020/Ology-Bioservices-Inovio-Partner-To-Manufacture-COVID-19-DNA-Vaccine-With-119-Million-Department-of-Defense-Grant/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/Ology-Bioservices-Inovio-Partner-To-Manufacture-COVID-19-DNA-Vaccine-With-119-Million-Department-of-Defense-Grant/default.aspx)

March 24, 2020 - Clover Biopharmaceuticals announced an agreement with Dynavax to test its vaccine with Dynavax's adjuvant; http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=43 (http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=43)

March 25, 2020 - Grifols announced that it has entered into a formal collaboration with the US FDA and BARDA to collect plasma from convalescent COVID-19 patients, process it into a hyperimmune globulin, and support the necessary preclinical and clinical studies to determine if it can successfully be used to treat COVID-19; https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19 (https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19)

March 25, 2020 - Vir Biotechnology announced it has identified multiple human monoclonal antibody treatment candidates that neutralize the COVID-19 virus; https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-proceeding-two-clinical-development-candidates (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-proceeding-two-clinical-development-candidates)

March 26, 2020 - Trump announced the USNS Comfort will depart for NYC; https://news.usni.org/2020/03/26/usns-comfort-departs-for-new-york-on-saturday-with-trump-modly-in-attendance (https://news.usni.org/2020/03/26/usns-comfort-departs-for-new-york-on-saturday-with-trump-modly-in-attendance)

March 27, 2020 - Executive order delegating to the Secretaries of HHS, DHS, and Defense President Trump's authority to make or guarantee loans, purchase and commit to purchase, and other actions to obtain and facilitate the domestic manufacture of PPE, ventilators, and other medical necessities; https://www.whitehouse.gov/presidential-actions/eo-delegating-additional-authority-dpa-respect-health-medical-resources-respond-spread-covid-19/ (https://www.whitehouse.gov/presidential-actions/eo-delegating-additional-authority-dpa-respect-health-medical-resources-respond-spread-covid-19/)

March 27, 2020 - Sanofi and Translate Bio collaborate to develop COVID-19 vaccine; https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00 (https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00) https://investors.translate.bio/news-releases/news-release-details/sanofi-pasteur-and-translate-bio-collaborate-develop-novel-mrna (https://investors.translate.bio/news-releases/news-release-details/sanofi-pasteur-and-translate-bio-collaborate-develop-novel-mrna)

March 27, 2020 - Trump signed a Defense Production Act order to General Motors to make ventilators; https://www.cnbc.com/2020/03/27/trump-orders-general-motors-to-make-ventilators-under-defense-production-act.html (https://www.cnbc.com/2020/03/27/trump-orders-general-motors-to-make-ventilators-under-defense-production-act.html), https://www.whitehouse.gov/presidential-actions/memorandum-order-defense-production-act-regarding-general-motors-company/ (https://www.whitehouse.gov/presidential-actions/memorandum-order-defense-production-act-regarding-general-motors-company/)

March 27, 2020 - Under DPA order, GM and Ventec partnering to produce ventilators; GM will also produce surgical masks at its Warren, MI, ramping up to 50K a day in two weeks, with potential to produce up to 100K per day; https://www.venteclife.com/news/ventec-life-systems-and-gm-partner-to-mass-produce-critical-care-ventilators-in-response-to-covid19-pandemic (https://www.venteclife.com/news/ventec-life-systems-and-gm-partner-to-mass-produce-critical-care-ventilators-in-response-to-covid19-pandemic)

March 27, 2020 - Trump announced that Boeing offered three "Dreamlifter" cargo aircraft to transport medical supplies; https://defpost.com/boeing-offers-dreamlifter-large-cargo-freighter-to-transport-critical-supplies-amid-covid-19-crisis/ (https://defpost.com/boeing-offers-dreamlifter-large-cargo-freighter-to-transport-critical-supplies-amid-covid-19-crisis/)

March 27, 2020 - Emory University began enrolling participants for a phase one clinical trial of potential coronavirus vaccine; https://news.emory.edu/stories/2020/03/coronavirus_vteu_modernastart/index.html (https://news.emory.edu/stories/2020/03/coronavirus_vteu_modernastart/index.html)

March 27, 2020 - USNS Mercy arrived in the port of Los Angeles; https://losangeles.cbslocal.com/2020/03/27/coronavirus-usns-mercy-arrives-port-of-los-angeles/ (https://losangeles.cbslocal.com/2020/03/27/coronavirus-usns-mercy-arrives-port-of-los-angeles/)

March 29, 2020 - Army Corps of Engineers completed construction of 2,900 bedroom temporary hospital at Javits Center in NYC; https://www.6sqft.com/temporary-hospital-javits-center-nyc-coronavirus/ (https://www.6sqft.com/temporary-hospital-javits-center-nyc-coronavirus/)

March 29, 2020 - Trump announced on-going study of 1,100 NY patients being treated with Hydroxychloroquine; https://www.cnbc.com/2020/03/30/trump-says-us-officials-should-have-good-idea-if-malaria-drug-works-on-coronavirus-in-three-days.html (https://www.cnbc.com/2020/03/30/trump-says-us-officials-should-have-good-idea-if-malaria-drug-works-on-coronavirus-in-three-days.html)

March 29, 2020 - First FEMA "Project Airbridge" shipment from abroad, landed at JFK airport (masks, face shields, and other medical supplies); https://www.reuters.com/article/us-health-coronavirus-trump-airlift-idUSKBN21G0LB (https://www.reuters.com/article/us-health-coronavirus-trump-airlift-idUSKBN21G0LB)

March 29, 2020 - Trump announced Cigna and Humana are waiving co-pays for coronavirus treatment; https://thehill.com/policy/healthcare/490100-health-insurers-cigna-humana-waive-out-of-pocket-costs-for-coronavirus (https://thehill.com/policy/healthcare/490100-health-insurers-cigna-humana-waive-out-of-pocket-costs-for-coronavirus)

March 29, 2020 - HHS accepted 30 million doses of Hydroxychloroquine, donated by Sandoz, and one million doses of Chloroquine, donated by Bayer Pharmaceuticals, for clinical trials and possible treatment of coronavirus patients; https://www.hhs.gov/about/news/2020/03/29/hhs-accepts-donations-of-medicine-to-strategic-national-stockpile-as-possible-treatments-for-covid-19-patients.html (https://www.hhs.gov/about/news/2020/03/29/hhs-accepts-donations-of-medicine-to-strategic-national-stockpile-as-possible-treatments-for-covid-19-patients.html)

March 30, 2020 - FDA approved Battelle’s process for decontaminating tens of thousands of N95 masks per day; https://www.wtol.com/article/news/health/coronavirus/fda-approves-use-of-battelles-mask-sterilizing-technology-at-full-capacity/512-265af79c-a9b5-4833-95b1-c4da65e81a91 (https://www.wtol.com/article/news/health/coronavirus/fda-approves-use-of-battelles-mask-sterilizing-technology-at-full-capacity/512-265af79c-a9b5-4833-95b1-c4da65e81a91) , https://www.hhs.gov/about/news/2020/03/30/secretary-azar-statement-on-fda-authorization-of-mask-sterilization-procedure.html (https://www.hhs.gov/about/news/2020/03/30/secretary-azar-statement-on-fda-authorization-of-mask-sterilization-procedure.html) , (FDA has slow-walked this approval since 2016!)

March 30, 2020 - Trump announced MyPillow, Honeywell, Jockey, Procter & Gamble, and United Technologies will manufacture PPE; https://www.politico.com/news/2020/03/30/my-pillow-lindell-trump-coronavirus-156335 (https://www.politico.com/news/2020/03/30/my-pillow-lindell-trump-coronavirus-156335)

March 30, 2020 - Ford Motor Company committed to producing 50,000 ventilators in the next 100 days; https://www.cnbc.com/2020/03/30/ford-ge-plan-to-produce-50000-ventilators-in-100-days.html (https://www.cnbc.com/2020/03/30/ford-ge-plan-to-produce-50000-ventilators-in-100-days.html)

March 30, 2020 - HHS accelerated clinical trial of a potential coronavirus vaccine developed by Janssen Research & Development; https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html (https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html)

March 30, 2020 - Johnson & Johnson announced selection of a lead COVID-19 vaccine candidate and an expansion of the partnership between the Janssen Pharmaceutical and BARDA; https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use (https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use)

March 30, 2020 - USNS Comfort arrived in New York Harbor; https://www.usatoday.com/story/news/nation/2020/03/31/usns-comfort-crowds-watch-hospital-ship-arrive-new-york-city/5093608002/ (https://www.usatoday.com/story/news/nation/2020/03/31/usns-comfort-crowds-watch-hospital-ship-arrive-new-york-city/5093608002/)

March 30, 2020 - USNS Mercy began treating patients in Los Angeles; https://www.navy.mil/submit/display.asp?story_id=112504, (https://www.navy.mil/submit/display.asp?story_id=112504,) (3 days from arrival to start of treating)

March 30, 2020 - Under DPA, Honeywell has begun expansion of its Phoenix, AZ which produces N95 masks; https://www.honeywell.com/en-us/newsroom/pressreleases/2020/03/honeywell-further-expands-n95-face-mask-production-by-adding-manufacturing-capabilities-in-phoenix (https://www.honeywell.com/en-us/newsroom/pressreleases/2020/03/honeywell-further-expands-n95-face-mask-production-by-adding-manufacturing-capabilities-in-phoenix)

March 30, 2020 - CytoDyn announced that 10 patients with severe COVID-19 have received treatment with leronlimab; https://www.cytodyn.com/newsroom/press-releases/detail/401/three-additional-patients-with-severe-covid-19-treated-with (https://www.cytodyn.com/newsroom/press-releases/detail/401/three-additional-patients-with-severe-covid-19-treated-with)

March 31, 2020 - CytoDyn announced that the FDA had approved Phase II trials of leronlimab with mild and moderately ill Covid-19 patients; https://www.cytodyn.com/newsroom/press-releases/detail/402/fda-clears-cytodyns-phase-2-randomized-trial-to-treat (https://www.cytodyn.com/newsroom/press-releases/detail/402/fda-clears-cytodyns-phase-2-randomized-trial-to-treat)

March 31, 2020 - In response to March 27 DPA order, GM repurposing Kokomo, IN factory to produce Ventec ventilators; https://www.kokomotribune.com/news/gm-hiring-local-workers-to-build-ventilators-in-kokomo/article_4818254c-72bb-11ea-9c48-9b461b7fcc9e.html (https://www.kokomotribune.com/news/gm-hiring-local-workers-to-build-ventilators-in-kokomo/article_4818254c-72bb-11ea-9c48-9b461b7fcc9e.html)

April 1, 2020 - White House, HHS, FDA worked with Senator Rob Portman to acquire, authorize use of two million gowns donated to the Strategic National Stockpile by Cardinal Health; 2020, https://riponadvance.com/stories/portman-coordinates-cardinal-healths-gown-donation-to-strategic-national-stockpile/ (https://riponadvance.com/stories/portman-coordinates-cardinal-healths-gown-donation-to-strategic-national-stockpile/)

April 1, 2020 - USNS Comfort began treating its first patients; https://www.navy.mil/submit/display.asp?story_id=112526 (https://www.navy.mil/submit/display.asp?story_id=112526)

April 1, 2020 - VA opened East Orange, NJ medical center to non-veteran coronavirus patients; https://connectingvets.radio.com/articles/covid19-va-opens-hospital-beds-to-new-jersey-non-veterans (https://connectingvets.radio.com/articles/covid19-va-opens-hospital-beds-to-new-jersey-non-veterans)

April 1, 2020 - Merck & Co., Pfizer Inc., and Eli Lilly and Company (NYSE: LLY) announced volunteer programs allowing licensed medical professionals employees to aid in fighting COVID-19 while still being paid; https://www.pfizer.com/news/press-release/press-release-detail/medical-professionals-across-merck-co-inc-pfizer-inc-and (https://www.pfizer.com/news/press-release/press-release-detail/medical-professionals-across-merck-co-inc-pfizer-inc-and)

April 2, 2020 - Trump invoked the Defense Production Act to direct 3M to produce more N95 masks; https://www.npr.org/2020/04/03/826945445/defense-production-act-would-compel-3m-to-change-mask-production-and-export (https://www.npr.org/2020/04/03/826945445/defense-production-act-would-compel-3m-to-change-mask-production-and-export), https://www.whitehouse.gov/presidential-actions/memorandum-order-defense-production-act-regarding-3m-company/ (https://www.whitehouse.gov/presidential-actions/memorandum-order-defense-production-act-regarding-3m-company/)

April 2, 2020 - Trump invoked the Defense Production Act to help GE, Hill-Rom, Medtronic, ResMed, eRoyal Philips, and Vyaire Medical get the supplies to make ventilators; https://www.cnbc.com/2020/04/03/coronavirus-trump-used-defense-production-act-on-these-companies-so-far.html (https://www.cnbc.com/2020/04/03/coronavirus-trump-used-defense-production-act-on-these-companies-so-far.html), https://www.whitehouse.gov/presidential-actions/memorandum-order-defense-production-act-regarding-purchase-ventilators/ (https://www.whitehouse.gov/presidential-actions/memorandum-order-defense-production-act-regarding-purchase-ventilators/)

April 2, 2020 - Pence announced that Blue Cross Blue Shield will waive out of pocket costs for coronavirus treatment; https://www.aarp.org/health/health-insurance/info-2020/coronavirus-insurers-treatment-costs.html (https://www.aarp.org/health/health-insurance/info-2020/coronavirus-insurers-treatment-costs.html)

April 2, 2020 - DOJ and HHS distributed 192,000 N95 masks confiscated from price gougers to health care workers in New York and New Jersey; https://www.hhs.gov/about/news/2020/04/02/doj-and-hhs-partner-to-distribute-more-than-half-a-million-medical-supplies-confiscated-from-price-gougers.html (https://www.hhs.gov/about/news/2020/04/02/doj-and-hhs-partner-to-distribute-more-than-half-a-million-medical-supplies-confiscated-from-price-gougers.html)

April 2, 2020 - FDA issued Emergency Use Authorization for the first coronavirus antibody test, developed by Cellex; https://www.usatoday.com/story/news/2020/04/02/fda-oks-first-coronavirus-blood-test-track-immunity-test-vaccines/5116281002/ (https://www.usatoday.com/story/news/2020/04/02/fda-oks-first-coronavirus-blood-test-track-immunity-test-vaccines/5116281002/)

April 2, 2020 - Amgen and Adaptive Biotechnologies today announced a collaboration to develop an antibody treatmen to revent or treat COVID-19; https://investors.adaptivebiotech.com/news-releases/news-release-details/amgen-and-adaptive-biotechnologies-announce-strategic (https://investors.adaptivebiotech.com/news-releases/news-release-details/amgen-and-adaptive-biotechnologies-announce-strategic) , https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/ (https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/)

April 2, 2020 - Emergent BioSolutions announced a formal partnership with the US government to expedite development of a plasma-derived polyclonal antibody therapy for patients with COVID-19; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive)

April 2, 2020 - Vanda Pharmaceuticals announced the initiation of Phase III clinical study to investigate the efficacy and safety of tradipitant to treat inflammatory lung injury associated with severe COVID-19 infection; https://vandapharmaceuticalsinc.gcs-web.com/node/14056/pdf (https://vandapharmaceuticalsinc.gcs-web.com/node/14056/pdf)

April 3, 2020 - The FDA announced a partnership, funded by BARDA, with the Mayo Clinic and American Red Cross to collect plasma from recovered Covid-19 patients for the development of convalescent plasma and hyperimmune globulin therapies for Covid-19; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19)

April 3, 2020 - Trump announced Anthem will waive co-pays for coronavirus treatment for 60 days; https://ir.antheminc.com/news-releases/news-release-details/anthem-waives-cost-share-covid-19-treatment?field_nir_news_date_value (https://ir.antheminc.com/news-releases/news-release-details/anthem-waives-cost-share-covid-19-treatment?field_nir_news_date_value)[min]=

April 3, 2020 - Trump announced that uninsured Americans will have their coronavirus treatment covered, using funding from the CARES Act; https://www.insidecompensation.com/2020/04/06/cares-act-expands-covid-19-testing-and-other-health-and-welfare-benefits/ (https://www.insidecompensation.com/2020/04/06/cares-act-expands-covid-19-testing-and-other-health-and-welfare-benefits/)

April 3, 2020 - Trump invoked the Defense Production Act to forbid export of PPE masks and gloves; https://www.whitehouse.gov/presidential-actions/memorandum-allocating-certain-scarce-threatened-health-medical-resources-domestic-use/ (https://www.whitehouse.gov/presidential-actions/memorandum-allocating-certain-scarce-threatened-health-medical-resources-domestic-use/)

April 5, 2020 - Trump announced Washington has returned 400 ventilators to the strategic national stockpile;https://www.seattletimes.com/seattle-news/health/washington-sending-over-400-ventilators-for-non-coronavirus-patients-to-new-york-harder-hit-states/ (https://www.seattletimes.com/seattle-news/health/washington-sending-over-400-ventilators-for-non-coronavirus-patients-to-new-york-harder-hit-states/)

April 5, 2020 - Trump announced the government has stockpiled 29 million doses of Hydroxychloroquine; https://www.newsweek.com/trump-says-us-has-stockpiled-29m-hydroxychloroquine-pills-amid-pandemic-it-may-not-work-then-1496232 (https://www.newsweek.com/trump-says-us-has-stockpiled-29m-hydroxychloroquine-pills-amid-pandemic-it-may-not-work-then-1496232)

April 5, 2020 - Secretary Wilkie announced the VA is making 1,500 beds available at VA hospitals; https://www.stripes.com/news/veterans/va-is-preparing-1-500-hospital-beds-for-non-veteran-patients-1.625045 (https://www.stripes.com/news/veterans/va-is-preparing-1-500-hospital-beds-for-non-veteran-patients-1.625045)

April 5, 2020 - FEMA and The Army Corps of Engineers completed first stage of renovations at McCormick Place Pavilion in Chicago, 500 additional hospital beds; https://chicago.suntimes.com/coronavirus/2020/4/2/21206013/mccormick-place-coronavirus-hospital-todd-semonite-army-corps-engineers (https://chicago.suntimes.com/coronavirus/2020/4/2/21206013/mccormick-place-coronavirus-hospital-todd-semonite-army-corps-engineers)

April 6, 2020 - Trump announced an agreement with 3M to produce, import 55.5 million N95 masks a month the next three months; https://www.cnbc.com/2020/04/06/coronavirus-trump-and-3m-strike-deal-to-bring-55point5-million-masks-a-month-to-us.html (https://www.cnbc.com/2020/04/06/coronavirus-trump-and-3m-strike-deal-to-bring-55point5-million-masks-a-month-to-us.html)

April 6, 2020 - Trump approved Governor Murphy’s request to allow New Jersey patients aboard the USNS Comfort; https://wcbs880.radio.com/articles/news/usns-comfort-to-treat-covid-patients-from-ny-nj (https://wcbs880.radio.com/articles/news/usns-comfort-to-treat-covid-patients-from-ny-nj)

April 6, 2020 - INOVIO Started Phase 1 Clinical Trial Of Its COVID-19 Vaccine; http://ir.inovio.com/news-and-media/news/press-release-details/2020/INOVIO-Initiates-Phase-1-Clinical-Trial-Of-Its-COVID-19-Vaccine-and-Plans-First-Dose-Today/default.aspx (http://ir.inovio.com/news-and-media/news/press-release-details/2020/INOVIO-Initiates-Phase-1-Clinical-Trial-Of-Its-COVID-19-Vaccine-and-Plans-First-Dose-Today/default.aspx)

April 6, 2020 - Trump announced The Army Corps of Engineers is building 22 field hospitals and alternative care sites in 18 states; https://www.nao.usace.army.mil/Media/News-Stories/Article/2138309/usace-to-begin-construction-on-alternate-care-facilities-in-virginia/ (https://www.nao.usace.army.mil/Media/News-Stories/Article/2138309/usace-to-begin-construction-on-alternate-care-facilities-in-virginia/)

April 6, 2020 - Department of Education announced a streamlined process for states to use federal education funding for distance learning; https://www.ed.gov/news/press-releases/secretary-education-betsy-devos-authorizes-new-funding-flexibilities-support-continued-learning-during-covid-19-national-emergency (https://www.ed.gov/news/press-releases/secretary-education-betsy-devos-authorizes-new-funding-flexibilities-support-continued-learning-during-covid-19-national-emergency)

April 6, 2020 - Ridgeback Biotherapeutics announced that the FDA approved Ridgeback to initiate human clinical testing of Ridgeback's oral antiviral treatment for patients with COVID-19; https://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html (https://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html)

April 6, 2020 - Vir Biotechnology and GlaxoSmithKline announced they will be collaborating to research and develop antibody treatments for Covid-19; https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus (https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus) , https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/ (https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/)

April 8, 2020 - Under the DPA, HHS announced contract with Philips to produce 2,500 ventilators for Strategic National Stockpile by end of May; https://www.hhs.gov/about/news/2020/04/08/hhs-announces-ventilator-contract-with-philips-under-defense-production-act.html (https://www.hhs.gov/about/news/2020/04/08/hhs-announces-ventilator-contract-with-philips-under-defense-production-act.html)

April 8, 2020 - HHS announced agreement with DuPont and FedEx to manufacture, deliver 2.25M new Tyvek Protective Suits to Strategic National Stockpile; https://www.hhs.gov/about/news/2020/04/08/hhs-provide-millions-tyvek-protective-suits-us-healthcare-workers.html (https://www.hhs.gov/about/news/2020/04/08/hhs-provide-millions-tyvek-protective-suits-us-healthcare-workers.html)

April 8, 2020 - HHS authorized pharmacists to order, administer coronavirus tests; https://www.hhs.gov/about/news/2020/04/08/hhs-statements-on-authorizing-licensed-pharmacists-to-order-and-administer-covid-19-tests.html (https://www.hhs.gov/about/news/2020/04/08/hhs-statements-on-authorizing-licensed-pharmacists-to-order-and-administer-covid-19-tests.html)

April 8, 2020 - CSL Behring and SAB Biotherapeutics announced their partnership to develop an antibody treatment for Covid-19; https://www.cslbehring.com/newsroom/2020/sab-covid-19 (https://www.cslbehring.com/newsroom/2020/sab-covid-19)

April 8, 2020 -  Mesoblast Limited announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled Phase II trial in 240 patients with acute respiratory distress syndrome caused by COVID-19; http://investorsmedia.mesoblast.com/static-files/e63bf0d5-7dd5-46c0-8381-c2e24bacb130 (http://investorsmedia.mesoblast.com/static-files/e63bf0d5-7dd5-46c0-8381-c2e24bacb130)

April 8, 2020 - HHS announced the first contract with GM to produce 30,000 ventilators to be delivered to the National Stockpile by the end of August; https://www.hhs.gov/about/news/2020/04/08/hhs-announces-ventilator-contract-with-gm-under-defense-production-act.html (https://www.hhs.gov/about/news/2020/04/08/hhs-announces-ventilator-contract-with-gm-under-defense-production-act.html)

April 8, 2020 - OncoImmune has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized COVID-19 patients with severe clinical symptoms; http://oncoimmune.com/index.php?option=com_k2&view=item&id=1079:oncoimmune-receives-fda-approval-for-covid-19-clinical-trial&Itemid=316 (http://oncoimmune.com/index.php?option=com_k2&view=item&id=1079:oncoimmune-receives-fda-approval-for-covid-19-clinical-trial&Itemid=316)

April 10, 2020 - Trump administration working to bring blood-based serology tests to market so Americans can determine if they have had the coronavirus; https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html (https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html)

April 10, 2020 - Trump announced will be establishing an “Opening Our Country Council”; https://www.politico.com/news/2020/04/10/trump-members-opening-our-country-council-179324 (https://www.politico.com/news/2020/04/10/trump-members-opening-our-country-council-179324)

April 10, 2020 - Sanofi to donate 100 million doses of hydroxychloroquine to 50 countries; https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-10-07-55-20 (https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-10-07-55-20)

April 10, 2020 - Eli Lilly announced an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, to study the efficacy and safety of baricitinib as a treatment for hospitalized patients with COVID-19; testing has started; http://lilly.mediaroom.com/2020-04-10-Lilly-Begins-Clinical-Testing-of-Therapies-for-COVID-19 (http://lilly.mediaroom.com/2020-04-10-Lilly-Begins-Clinical-Testing-of-Therapies-for-COVID-19)

April 10, 2020 - FDA approved an emergency authorization for a blood purification device to treat coronavirus patients; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-blood-purification-device-treat-covid-19 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-blood-purification-device-treat-covid-19)

April 12, 2020 - FDA issued an emergency authorization for devices from Advanced Sterilization Products, which can decontaminate ~4 million N95 respirators each day; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-decontaminate-millions-n95 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-decontaminate-millions-n95)

April 13, 2020 - FDA clears first saliva test to help diagnose new virus; https://abcnews.go.com/Health/wireStory/us-clears-saliva-test-diagnose-virus-70127442 (https://abcnews.go.com/Health/wireStory/us-clears-saliva-test-diagnose-virus-70127442)

April 13, 2020 - HHS announced new contracts for ventilator production under the DPA to General Electric, Hill-Rom, Medtronic, ResMed, and Vyaire, mentioned in Trump's April 2 DPA order, as well as contracts with Hamilton and Zoll, also under the DPA; https://www.hhs.gov/about/news/2020/04/13/hhs-announces-new-ventilator-contracts-orders-now-totaling-over-130000-ventilators.html (https://www.hhs.gov/about/news/2020/04/13/hhs-announces-new-ventilator-contracts-orders-now-totaling-over-130000-ventilators.html)

April 13, 2020 - DoD announced it was buying 60 Battelle decontamination systems which can sanitize 80,000 N95 respirators per day; https://www.defense.gov/Newsroom/Releases/Release/Article/2148352/dod-contract-for-60-n95-critical-care-decontamination-units-415m-contract-each/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2148352/dod-contract-for-60-n95-critical-care-decontamination-units-415m-contract-each/)

April 14, 2020 - Trump announced a halt to WHO funding while its mistakes, mismanagement of the coronavirus outbreak are reviewed; https://www.cnbc.com/2020/04/14/trump-calls-for-halt-to-us-funding-for-world-health-organization-amid-coronavirus-outbreak.html (https://www.cnbc.com/2020/04/14/trump-calls-for-halt-to-us-funding-for-world-health-organization-amid-coronavirus-outbreak.html)

April 14, 2020 - Trump announced the members of the Great American Economic Revival Industry Groups, who will advise on how to re-open the economy; https://wtop.com/business-finance/2020/04/new-trump-panel-to-explore-path-to-reopening-us-economy/ (https://wtop.com/business-finance/2020/04/new-trump-panel-to-explore-path-to-reopening-us-economy/)

April 14, 2020 - FEMA confirmed it sent out 19.1 million doses of hydroxychloroquine to cities across the country; https://www.newsweek.com/hydroxychloroquine-tablets-shipped-fema-1498014 (https://www.newsweek.com/hydroxychloroquine-tablets-shipped-fema-1498014)

April 14, 2020 - EPA announced it has temporarily waived certain approvals for manufacturers producing coronavirus disinfectants; https://ethanol.org/ethanol-essentials/covid-19 (https://ethanol.org/ethanol-essentials/covid-19)

April 14, 2020 - GM began mass production on an order of 30,000 Ventec ventilators, 600 ventilators to be shipped this month, the full order to be completed by August; https://www.autoweek.com/news/industry-news/a32169651/gm-starts-ventilator-production-in-under-a-month/ (https://www.autoweek.com/news/industry-news/a32169651/gm-starts-ventilator-production-in-under-a-month/)

April 14, 2020 - Sanofi and GSK to develop a COVID-19 vaccine; https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00 (https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00)

April 15, 2020 - CytoDyn announced the treatment of the first patient with leronlimab in its Phase 2b/3 trial for severe and critical COVID-19; https://www.cytodyn.com/newsroom/press-releases/detail/417/first-patient-treated-with-leronlimab-in-phase-2b3-trial (https://www.cytodyn.com/newsroom/press-releases/detail/417/first-patient-treated-with-leronlimab-in-phase-2b3-trial)

April 16, 2020 - Moderna awarded up to $483M by BARDA to accelerate development of mRNA coronavirus vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million)

April 16, 2020 - Enrollment was completed for Moderna's Phase I trial and additional test groups were added to the trial; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million)

April 16, 2020 - IVI, INOVIO, and KNIH Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea; http://ir.inovio.com/news-releases/news-releases-details/2020/IVI-INOVIO-and-KNIH-to-Partner-with-CEPI-in-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-in-South-Korea/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/IVI-INOVIO-and-KNIH-to-Partner-with-CEPI-in-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-in-South-Korea/default.aspx)

April 16, 2020 - Trump announced phased “opening up America again” guidelines; https://www.cnbc.com/2020/04/16/coronavirus-trump-issuing-guidelines-on-reopening-parts-of-us-amid-outbreak.html (https://www.cnbc.com/2020/04/16/coronavirus-trump-issuing-guidelines-on-reopening-parts-of-us-amid-outbreak.html)

April 16, 2020 - Remdesivir doing well in University of Chicago clinical trial;  https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/ (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/)

April 16, 2020 - Under the DPA, HHS announced a $336 million contract with GE for 50,000 ventilators to be produced by July 13; https://www.hhs.gov/about/news/2020/04/16/hhs-announces-ventilator-contract-with-ge-under-defense-production-act.html (https://www.hhs.gov/about/news/2020/04/16/hhs-announces-ventilator-contract-with-ge-under-defense-production-act.html)

April 17, 2020 - NIH announced a public-private partnership with leading biopharmaceutical companies to speed up the development of coronavirus vaccines and therapies; https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options (https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options)

April 17, 2020 - GM announced that they delivered the first GM-Ventec ventilators to Chicago hospitals; https://investor.gm.com/news-releases/news-release-details/first-general-motors-ventec-critical-care-ventilators-delivered (https://investor.gm.com/news-releases/news-release-details/first-general-motors-ventec-critical-care-ventilators-delivered)

April 17, 2020 - Under DPA, Honeywell has begun production of N95 face masks in a new facility in Rhode Island; https://www.honeywell.com/en-us/newsroom/pressreleases/2020/04/honeywell-begins-production-of-n95-face-masks-in-smithfield-ri (https://www.honeywell.com/en-us/newsroom/pressreleases/2020/04/honeywell-begins-production-of-n95-face-masks-in-smithfield-ri)

April 17, 2020 - Incyte announced the initiation of a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolitinib in patients aged =12 years with COVID-19 associated cytokine storm; https://investor.incyte.com/news-releases/news-release-details/incyte-announces-initiation-phase-3-ruxcovid-study-evaluating (https://investor.incyte.com/news-releases/news-release-details/incyte-announces-initiation-phase-3-ruxcovid-study-evaluating)

April 20, 2020 - USNS Comfort started admitting patients from New Jersey; https://www.naval-technology.com/news/covid-19-usns-comfort-starts-admitting-patients-from-new-jersey/ (https://www.naval-technology.com/news/covid-19-usns-comfort-starts-admitting-patients-from-new-jersey/)

April 20, 2020 - US, Canada, and Mexico extended non-essential travel restrictions for an additional 30 days; https://www.usnews.com/news/business/articles/2020-04-20/volvo-reopens-some-plants-some-countries-ease-restrictions (https://www.usnews.com/news/business/articles/2020-04-20/volvo-reopens-some-plants-some-countries-ease-restrictions)

April 20, 2020 - DOJ cleared antitrust hurdles to AmerisourceBergen and other distributors distributing hydroxychloroquine; https://www.newsweek.com/doj-clears-us-drug-companies-distribute-hydroxychloroquine-coronavirus-patients-1499002 (https://www.newsweek.com/doj-clears-us-drug-companies-distribute-hydroxychloroquine-coronavirus-patients-1499002)

April 20, 2020 - Coordinated by White House equipment czar Peter Navarro, Owens & Minor provided specialized fabric, UPS transported it to NYC, where several manufacturers will sew them into 400K surgical gowns by May 23; https://nypost.com/2020/04/20/nyc-garment-districts-to-produce-surgical-gowns-amid-coronavirus/ (https://nypost.com/2020/04/20/nyc-garment-districts-to-produce-surgical-gowns-amid-coronavirus/)

April 20, 2020 - Alexion Pharmaceuticals announced plans for a global Phase 3 study to investigate ULTOMIRIS (ravulizumab-cwvz) in adults with COVID-19 hospitalized with severe pneumonia or acute respiratory distress syndrome; the US FDA; has accepted Alexion's investigational new drug (IND) application;https://ir.alexion.com/news-releases/news-release-details/alexion-announces-plans-initiate-phase-3-study-ultomirisr (https://ir.alexion.com/news-releases/news-release-details/alexion-announces-plans-initiate-phase-3-study-ultomirisr)

April 20, 2020 - Grifols announced it has begun selecting donors who have recovered from COVID-19 to donate their plasma in select US cities; https://www.grifols.com/en/view-news/-/news/people-who-have-recovered-from-covid-19-can-now-donate-their-convalescent-plasma-in-select-grifols-us-plasma-donor-centers (https://www.grifols.com/en/view-news/-/news/people-who-have-recovered-from-covid-19-can-now-donate-their-convalescent-plasma-in-select-grifols-us-plasma-donor-centers)

April 20, 2020 - OncoImmune initiated its Phase III clinical trial of CD24Fc in hospitalized COVID-19 patients at the University of Maryland Baltimore Medical Center; http://oncoimmune.com/index.php?option=com_k2&view=item&id=1078:oncoimmune-starts-phase-iii-clinical-trial-testing-the-power-of-dampening-inflammation-to-virus-induced-cellular-injury-in-severe-covid-19-patients&Itemid=316 (http://oncoimmune.com/index.php?option=com_k2&view=item&id=1078:oncoimmune-starts-phase-iii-clinical-trial-testing-the-power-of-dampening-inflammation-to-virus-induced-cellular-injury-in-severe-covid-19-patients&Itemid=316)

April 21, 2020 - Under the DPA, DOD to invest $133 million to increase US domestic N95 mask production by over 39 million over the next 90 days; three companies were awarded contracts, 3M , O&M Halyard, and Honeywell; https://www.defense.gov/Newsroom/Releases/Release/Article/2158351/dod-details-133-million-defense-production-act-title-3-covid-19-project/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2158351/dod-details-133-million-defense-production-act-title-3-covid-19-project/)

April 21, 2020 - FDA has now authorized more than 50 coronavirus diagnostic tests and four antibody tests; https://abcnews.go.com/Health/wireStory/types-testing-covid-19-infections-70253488 (https://abcnews.go.com/Health/wireStory/types-testing-covid-19-infections-70253488)

April 21, 2020 - FDA authorized first at-home coronavirus test; https://www.cbsnews.com/news/coronavirus-test-pixel-fda-approval/ (https://www.cbsnews.com/news/coronavirus-test-pixel-fda-approval/)

April 22, 2020 - Trump signed executive order suspending immigration for 60 Days; https://theglobalherald.com/trump-signs-executive-order-to-suspend-immigration-for-60-days/404377/ (https://theglobalherald.com/trump-signs-executive-order-to-suspend-immigration-for-60-days/404377/)

April 22, 2020 - Pfizer and BioNTech announced approval to begin Phase 1/2 trial of BioNTech’s COVID-19 vaccines in Germany; https://www.pfizer.com/news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates (https://www.pfizer.com/news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates)

April 22, 2020 - Valneva and Dynavax announced collaboration to advance COVID-19 vaccine development using Dynavax's adjuvant; https://investors.dynavax.com/news-releases/news-release-details/valneva-and-dynavax-announce-collaboration-advance-vaccine (https://investors.dynavax.com/news-releases/news-release-details/valneva-and-dynavax-announce-collaboration-advance-vaccine)

April 23, 2020 - University of Oxford researchers began Phase I trial of a COVID-19 vaccine; https://www.ox.ac.uk/news/2020-04-23-oxford-covid-19-vaccine-begins-human-trial-stage (https://www.ox.ac.uk/news/2020-04-23-oxford-covid-19-vaccine-begins-human-trial-stage) , https://www.bbc.com/news/health-52394485 (https://www.bbc.com/news/health-52394485) , https://www.vaccitech.co.uk/oxford-covid-19-vaccine-begins-human-trial-stage/ (https://www.vaccitech.co.uk/oxford-covid-19-vaccine-begins-human-trial-stage/)

April 23, 2020 - Vaccitech and the University of Oxford announced an agreement with biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of Oxford's COVID-19 vaccine; https://www.vaccitech.co.uk/vaccitech-and-oxford-university-announce-landmark-partnership-with-astrazeneca-for-the-development-and-large-scale-distribution-of-the-covid-19-vaccine-candidate/ (https://www.vaccitech.co.uk/vaccitech-and-oxford-university-announce-landmark-partnership-with-astrazeneca-for-the-development-and-large-scale-distribution-of-the-covid-19-vaccine-candidate/)

April 23, 2020 - Johnson & Johnson announced a collaboration between the Janssen Pharmaceutical and Emergent BioSolutions, Inc. to support the manufacturing of its COVID-19 vaccine; https://www.jnj.com/johnson-johnson-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate-in-support-of-the-companys-goal-to-supply-more-than-one-billion-vaccine-doses-globally (https://www.jnj.com/johnson-johnson-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate-in-support-of-the-companys-goal-to-supply-more-than-one-billion-vaccine-doses-globally)

April 23, 2020 - Inovio vaccine began human trials; https://news.yahoo.com/coronavirus-vaccine-trial-participant-signed-225702313.html (https://news.yahoo.com/coronavirus-vaccine-trial-participant-signed-225702313.html)

April 23, 2020 - Emergent BioSolutions announced an agreement to support the manufacturing of Johnson & Johnson’s (Janssen Pharmaceutical) COVID-19 vaccine; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing)

April 24, 2020 - To date, the FDA has issued 44 individual emergency use authorizations for test kit manufacturers and laboratories; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-24-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-24-2020)

April 27, 2020 - HHS Launches COVID-19 Uninsured Program Portal allowing health care providers who have conducted COVID-19 testing or provided treatment for uninsured individuals to submit claims for reimbursement; https://www.hhs.gov/about/news/2020/04/27/hhs-launches-covid19-uninsured-program-portal.html (https://www.hhs.gov/about/news/2020/04/27/hhs-launches-covid19-uninsured-program-portal.html)

April 28, 2020 - Inovio announced that its Phase I US clinical trial for its COVID-19 DNA vaccine is fully enrolled, with all 40 healthy volunteers having received their first dose; http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Completes-Enrollment-in-the-Phase-1-US-Trial-of-INO-4800-for-COVID-19-DNA-Vaccine-Interim-Results-Expected-in-June/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Completes-Enrollment-in-the-Phase-1-US-Trial-of-INO-4800-for-COVID-19-DNA-Vaccine-Interim-Results-Expected-in-June/default.aspx)

April 29, 2020 - Pfizer and BioNTech announced that the first cohort of BioNTech’s Phase 1/2 clinical trial has been dosed; https://www.pfizer.com/news/press-release/press-release-detail/biontech-and-pfizer-announce-completion-dosing-first-cohort (https://www.pfizer.com/news/press-release/press-release-detail/biontech-and-pfizer-announce-completion-dosing-first-cohort)

April 29, 2020 - DOD will invest $75.5 million in DPA funding to increase swab production by 20 million per month starting in May; Puritan Medical Products was awarded the contract; https://www.defense.gov/Newsroom/Releases/Release/Article/2170355/dod-details-75-million-defense-production-act-title-3-puritan-contract/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2170355/dod-details-75-million-defense-production-act-title-3-puritan-contract/)

April 29, 2020 - NIH announced that in clinical trials, Remdesivir improved patient recovery time; https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates)

April 30, 2020 - AstraZeneca and Oxford University announce agreement for COVID-19 vaccine; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html)

April 30, 2020 - FDA approved EUA for a ventilator developed by the National Aeronautics and Space Administration (NASA), which is tailored to treat patients with COVID-19; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-includes-ventilator-developed-nasa-ventilator-emergency-use (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-includes-ventilator-developed-nasa-ventilator-emergency-use)

May 1, 2020 - Moderna and Lonza announce worldwide collaboration to manufacture Moderna’s coronavirus vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-and-lonza-announce-worldwide-strategic-collaboration (https://investors.modernatx.com/news-releases/news-release-details/moderna-and-lonza-announce-worldwide-strategic-collaboration)

May 1, 2020 - Under the DPA and CARES Act, DOD in coordination with HHS, has signed a $126 million contract award with 3M for the increased production of 26 million N95 medical-grade masks per month, starting in October 2020; https://www.defense.gov/Newsroom/Releases/Release/Article/2178152/dod-awards-126-million-contract-to-3m-increasing-production-of-n95-masks/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2178152/dod-awards-126-million-contract-to-3m-increasing-production-of-n95-masks/) , https://www.congress.gov/116/meeting/house/110794/witnesses/HHRG-116-AS00-Wstate-LordE-20200610.pdf (https://www.congress.gov/116/meeting/house/110794/witnesses/HHRG-116-AS00-Wstate-LordE-20200610.pdf)

May 1, 2020 - Under the DPA and CARES Act, DOD in coordination with HHS, has signed a $20.1 million contract award with Moldex for increased production capacity by 5 million N95 masks per month; https://www.congress.gov/116/meeting/house/110794/witnesses/HHRG-116-AS00-Wstate-LordE-20200610.pdf (https://www.congress.gov/116/meeting/house/110794/witnesses/HHRG-116-AS00-Wstate-LordE-20200610.pdf)

May 1, 2020 - FDA granted EUA for remdesivir to treat COVID-19; https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gileads-investigational-antiviral-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-covid19 (https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gileads-investigational-antiviral-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-covid19)

May 4, 2020 - Junshi Biosciences and Eli Lilly have entered into an agreement to develop therapeutic antibodies for prevention and treatment of COVID-19; http://lilly.mediaroom.com/index.php?s=9042&item=138041 (http://lilly.mediaroom.com/index.php?s=9042&item=138041)

May 4, 2020 - Mayo Clinic was awarded a $26 million contract from BARDA for the Expanded Access Program (EAP) for convalescent plasma to fight COVID-19; https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-receives-26-million-from-barda-for-covid-19-convalescent-plasma-expanded-access-program/ (https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-receives-26-million-from-barda-for-covid-19-convalescent-plasma-expanded-access-program/)

May 5, 2020 - Mesoblast announced that the first patients have been dosed in the 300-patient Phase 2/3 trial in the United States of Mesoblast’s remestemcel-L in COVID-19 infected patients; http://investorsmedia.mesoblast.com/static-files/12fa62d6-49e1-4b1d-8fb7-0c3e184602ab (http://investorsmedia.mesoblast.com/static-files/12fa62d6-49e1-4b1d-8fb7-0c3e184602ab)

May 5, 2020 - Pfizer and BioNTech announced that the first participants have been dosed in the US in the Phase 1/2 clinical trial; https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program (https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program)

May 6, 2020 - Humanigen announced that the first COVID-19 patient has been dosed in its Phase III test of Lenzilumab, whether it prevents and treats cytokine storm in COVID-19 patients; https://www.humanigen.com/press/First-Patient-Dosed-in-FDA-Approved-Phase-III-Lenzilumab-Study-for-COVID-19 (https://www.humanigen.com/press/First-Patient-Dosed-in-FDA-Approved-Phase-III-Lenzilumab-Study-for-COVID-19)

May 6, 2020 - The FDA approved the start of Phase II testing of Moderna's vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna (https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna)

May 6, 2020 - Coordinated through the DPA, Bath Iron Works finalized a contract with Puritan Medical Products to deliver 30 industrial machines to help meet demand for COVID-19 testing clinical swabs; https://www.mainebiz.biz/article/biw-signs-contract-to-build-swab-machines-for-puritan-medical-products (https://www.mainebiz.biz/article/biw-signs-contract-to-build-swab-machines-for-puritan-medical-products)

May 7, 2020 - 3M announced that it received two more U.S. Department of Defense contracts to expand US production of N95 respirator masks; https://www.massdevice.com/3m-wins-govt-contracts-to-further-expand-u-s-respirator-production/ (https://www.massdevice.com/3m-wins-govt-contracts-to-further-expand-u-s-respirator-production/) , https://investors.3m.com/news/news-details/2020/3M-Awarded-Department-of-Defense-Contracts-to-Further-Expand-US-Production-of-N95-Respirators/default.aspx (https://investors.3m.com/news/news-details/2020/3M-Awarded-Department-of-Defense-Contracts-to-Further-Expand-US-Production-of-N95-Respirators/default.aspx)

May 7, 2020 - HHS deployed 50 portable kidney dialysis machines to New York City and Long Island ICUs to provide surge capacity for for COVID-19 patients who have suffered acute kidney injury; https://www.hhs.gov/about/news/2020/05/07/hhs-deploys-new-portable-dialysis-machines-to-new-york-for-covid-19-response.html (https://www.hhs.gov/about/news/2020/05/07/hhs-deploys-new-portable-dialysis-machines-to-new-york-for-covid-19-response.html)

May 8, 2020 - To date, the FDA has issued 58 individual emergency use authorizations for test kit manufacturers and laboratories; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-4-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-4-2020)

May 8, 2020 - FDA issued an EUA for the Duke Decontamination System to decontaminate compatible N95 or N95-equivalent respirators for reuse by health care personnel; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-8-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-8-2020)

May 8, 2020 - FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory developed test with the option of using home-collected saliva samples; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva)

May 9, 2020 - HHS announced distribution of donated remdesivir for hospitalized patients with COVID-19; https://www.hhs.gov/about/news/2020/05/09/hhs-ships-first-doses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html (https://www.hhs.gov/about/news/2020/05/09/hhs-ships-first-doses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html)

May 12, 2020 - Moderna receives FDA Fast Track designation for coronavirus vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna (https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna)

May 12, 2020 - ApiJect Systems awarded $138M for pre-filled COVID-19 vaccine syringes; https://www.upi.com/Defense-News/2020/05/12/ApiJect-Systems-awarded-138M-for-syringes-for-COVID-19-vaccine/5001589324444/ (https://www.upi.com/Defense-News/2020/05/12/ApiJect-Systems-awarded-138M-for-syringes-for-COVID-19-vaccine/5001589324444/)

May 15, 2020 - Trump announced Operation Warp Speed, and a goal to have a vaccine approved and in parge-scale distribution by the end of 2020; https://www.usatoday.com/story/news/health/2020/05/15/coronavirus-operation-warp-speed-could-deliver-vaccine-years-end-trump/5199969002/ (https://www.usatoday.com/story/news/health/2020/05/15/coronavirus-operation-warp-speed-could-deliver-vaccine-years-end-trump/5199969002/) , https://www.hhs.gov/about/news/2020/05/15/trump-administration-announces-framework-and-leadership-for-operation-warp-speed.html (https://www.hhs.gov/about/news/2020/05/15/trump-administration-announces-framework-and-leadership-for-operation-warp-speed.html) , https://www.hhs.gov/about/news/2020/06/16/fact-sheet-explaining-operation-warp-speed.html (https://www.hhs.gov/about/news/2020/06/16/fact-sheet-explaining-operation-warp-speed.html)

May 21, 2020 - Trump Administration’s Operation Warp Speed accelerates AstraZeneca COVID-19 vaccine to be available beginning in October; https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazeneca-covid-19-vaccine-to-be-available-beginning-in-october.html (https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazeneca-covid-19-vaccine-to-be-available-beginning-in-october.html)

May 21, 2020 - Under Operation Warp Speed, US secures 300 million doses, almost a third, of potential AstraZeneca COVID-19 vaccine; https://business.financialpost.com/technology/u-s-secures-300-million-doses-of-potential-astrazeneca-covid-19-vaccine-3 (https://business.financialpost.com/technology/u-s-secures-300-million-doses-of-potential-astrazeneca-covid-19-vaccine-3) , https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazeneca-covid-19-vaccine-to-be-available-beginning-in-october.html (https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazeneca-covid-19-vaccine-to-be-available-beginning-in-october.html)

May 21, 2020 - Under Operation Warp Speed,  AstraZeneca received support of more than $1B from the US Biomedical Advanced Research and Development Authority for development, production, and delivery of the vaccine, starting in the fall; development Phase III clinical trial with 30,000 participants and a paediatric trial; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html)

May 22, 2020 - University of Oxford researchers began Phase II/III trial of a COVID-19 vaccine; https://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials (https://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials)

May 25, 2020 - Novavax Began Phase 1/2 Clinical Trial of COVID-19 Vaccine; https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine (https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine)

May 26, 2020 - IAVI and Merck collaborate to develop Covid-19 vaccine; https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/IAVI-and-Merck-Collaborate-to-Develop-Vaccine-Against-SARS-CoV-2/default.aspx (https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/IAVI-and-Merck-Collaborate-to-Develop-Vaccine-Against-SARS-CoV-2/default.aspx)

May 26, 2020 - Merck and Ridgeback Biotherapeutics announced a collaboration agreement to develop Ridgeback's orally available antiviral treatment for patients with COVID-19, which is about to enter Phase I testing; https://www.merck.com/news/merck-and-ridgeback-bio-collaborate-to-advance-development-of-novel-antiviral-candidate-eidd-2801/ (https://www.merck.com/news/merck-and-ridgeback-bio-collaborate-to-advance-development-of-novel-antiviral-candidate-eidd-2801/)

May 27, 2020 - Novavax acquired Praha Vaccines with an annual production capacity of over 1 billion doses; https://ir.novavax.com/news-releases/news-release-details/novavax-expands-large-scale-global-manufacturing-capacity (https://ir.novavax.com/news-releases/news-release-details/novavax-expands-large-scale-global-manufacturing-capacity)

May 28, 2020 - FDA issued an Emergency Use Authorization for the Stryker Sustainability Solutions (SSS) VHP N95 Respirator Decontamination System; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-28-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-28-2020)

May 28, 2020 - Under the DPA, DOD in support of HHS signed a $2.2 million contract with Hollingsworth & Vose to increase US production of 27.5 million N95 ventilator filters and 3.1 million N95 respirators per month starting in August; https://www.defense.gov/Newsroom/Releases/Release/Article/2200654/dod-announces-defense-production-act-title-3-covid-19-ppe-project-22-million-in/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2200654/dod-announces-defense-production-act-title-3-covid-19-ppe-project-22-million-in/)

May 29, 2020 - Moderna announces first participants dosed in Phase 2 study of coronavirus vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase)

June 1, 2020 - Gilead Sciences announced results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia; https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19 (https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19)

June 1, 2020 - Eli Lilly and AbCellera announced patients have been dosed in the Phase 1 study of an antibody treatment to fight COVID-19; http://lilly.mediaroom.com/index.php?s=9042&item=138053 (http://lilly.mediaroom.com/index.php?s=9042&item=138053) , https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment (https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment)

June 1, 2020 - To date, the FDA has authorized 117 tests under EUAs, which include 101 molecular tests, 15 antibody tests, and 1 antigen test; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-1-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-1-2020)

June 1, 2020 - HHS adds $628 million to contract with Emergent BioSolutions to secure CDMO contract manufacturing capacity for Operation Warp Speed; https://www.hhs.gov/about/news/2020/06/01/hhs-adds-628-million-contract-emergent-biosolutions-secure-manufacturing-capacity-operation-warp-speed.html (https://www.hhs.gov/about/news/2020/06/01/hhs-adds-628-million-contract-emergent-biosolutions-secure-manufacturing-capacity-operation-warp-speed.html)

June 1, 2020 - Emergent BioSolutions announced that it has a task order under an existing contract with BARDA to deploy its contract development and manufacturing to support the US government’s Operation Warp Speed efforts to accelerate delivery of COVID-19 vaccines; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-joins-us-governments-warp-speed-program (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-joins-us-governments-warp-speed-program)

June 2, 2020 - FDA added a second ventilator developed by NASA to the list of authorized ventilators, under EUA; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-2-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-2-2020)

June 4, 2020 - Novavax announced an up to $60M contract with the US DOD for Novavax’ COVID-19 vaccine; https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-department-defense-contract-covid-19-vaccine (https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-department-defense-contract-covid-19-vaccine)

June 5, 2020 - AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Antibody Therapy to Prevent and Treat COVID-19; https://news.abbvie.com/news/press-releases/abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-to-develop-monoclonal-antibody-therapy-to-prevent-and-treat-covid-19.htm (https://news.abbvie.com/news/press-releases/abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-to-develop-monoclonal-antibody-therapy-to-prevent-and-treat-covid-19.htm)

June 8, 2020 - Eli Lilly announced partner Junshi Biosciences dosed the first volunteer in a study of an antibody treatment to fight COVID-19; http://lilly.mediaroom.com/index.php?s=9042&item=138057 (http://lilly.mediaroom.com/index.php?s=9042&item=138057)

June 8, 2020 - FDA added the BioMedInnovations SuppleVent Ventilator to the list of ventilators authorized under EUA; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-8-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-8-2020)

June 10, 2020 - FDA issued an EUA to Illumina, Inc. for the first COVID-19 diagnostic test utilizing next generation sequence technology; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-next-generation-sequence-test-diagnosing-covid-19 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-next-generation-sequence-test-diagnosing-covid-19)

June 10, 2020 - Under the DPA, Operation Warp Speed funded increased manufacturing capacity at Corning and SiO2 Materials Science for vials for COVID-19 vaccines and treatments and for future needs; https://www.hhs.gov/about/news/2020/06/11/operation-warp-speed-ramps-up-us-based-manufacturing-capacity-for-vials-for-covid-19-vaccines-and-treatments.html (https://www.hhs.gov/about/news/2020/06/11/operation-warp-speed-ramps-up-us-based-manufacturing-capacity-for-vials-for-covid-19-vaccines-and-treatments.html)

June 10, 2020 - Janssen Pharmaceutical accelerating its Phase 1/2a trial of its COVID-19 vaccine to the second half of July; https://www.jnj.com/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-1-2a-clinical-trial-to-begin-in-second-half-of-july (https://www.jnj.com/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-1-2a-clinical-trial-to-begin-in-second-half-of-july)

June 11, 2020 - Regeneron Pharmaceuticals started the first clinical trial of its dual antibody cocktail for prevention and treatment of COVID-19; https://investor.regeneron.com/news-releases/news-release-details/regeneron-begins-first-clinical-trials-anti-viral-antibody (https://investor.regeneron.com/news-releases/news-release-details/regeneron-begins-first-clinical-trials-anti-viral-antibody)

June 11, 2020 - Grifols announced the start of production of its anti-Covid-19 hyperimmune immunoglobulin with antibodies from the plasma of people who have overcome the disease; https://www.grifols.com/en/view-news/-/news/grifols-continues-to-lead-initiatives-to-combat-covid-19-with-the-development-of-the-first-specific-drug (https://www.grifols.com/en/view-news/-/news/grifols-continues-to-lead-initiatives-to-combat-covid-19-with-the-development-of-the-first-specific-drug)

June 11, 2020 - Enrollment of the younger adults group of Moderna's Phase II trial was completed; https://investors.modernatx.com/news-releases/news-release-details/moderna-advances-late-stage-development-its-vaccine-mrna-1273 (https://investors.modernatx.com/news-releases/news-release-details/moderna-advances-late-stage-development-its-vaccine-mrna-1273)

June 11 & 27, 2020 - Emergent BioSolutions announced it will support the manufacturing of AstraZeneca’s COVID-19 vaccine; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing-0 (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing-0) ; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-astrazeneca-expand (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-astrazeneca-expand)

June 12, 2020 - FDA issued an EUA for Cue Health Inc.’s Cue COVID-19 Test for use at the Point of Care (sample not sent to lab); https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-12-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-12-2020)

June 15, 2020 - Eli Lilly announced that the first patient enrolled in a Phase 3 study baricitinib in hospitalized adults with COVID-19; http://lilly.mediaroom.com/index.php?s=9042&item=138065 (http://lilly.mediaroom.com/index.php?s=9042&item=138065)

June 19, 2020 - Clover Pharmaceuticals and GlaxoSmithKline began Phase I study of Clover's vaccine and GSK's adjuvant; https://www.gsk.com/en-gb/media/press-releases/gsk-covid-19-vaccine-development-collaboration-with-clover-biopharmaceuticals-begins-clinical-trials/ (https://www.gsk.com/en-gb/media/press-releases/gsk-covid-19-vaccine-development-collaboration-with-clover-biopharmaceuticals-begins-clinical-trials/)

June 19, 2020 - Clover Biopharmaceuticals began Phase I clinical trials in Perth, Australia for its COVID-19 vaccine, separate trials with GlaxoSmithKline's and Dynavax's adjuvants; http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=48 (http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=48)

June 19, 2020 - Ridgeback Biotherapeutics announced the start of two Phase 2 clinical trials of their anti-viral treatment for COVID-19; https://www.businesswire.com/news/home/20200619005038/en/Ridgeback-Biotherapeutics-Announces-Launch-Phase-2-Trials (https://www.businesswire.com/news/home/20200619005038/en/Ridgeback-Biotherapeutics-Announces-Launch-Phase-2-Trials)

June 19, 2020 - Under the DPA, DOD in coordination with HHS signed a $13.5 million contract with Lydall, Inc. to increase domestic capacity of meltblown filtration media, a key component in N95 masks; https://www.defense.gov/Newsroom/Releases/Release/Article/2245825/dod-awards-135-million-contract-to-lydall-inc-to-increase-domestic-production-o/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2245825/dod-awards-135-million-contract-to-lydall-inc-to-increase-domestic-production-o/)

June 23, 2020 - INOVIO announced it has received $71 million funding from the DOD for large-scale manufacture of the company's devices that deliver vaccine directly into the skin; http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Receives-71-Million-Contract-From-US-Department-of-Defense-To-Scale-Up-Manufacture-of-CELLECTRA-3PSP-Smart-Device-and-Procurement-of-CELLECTRA-2000-for-COVID-19-DNA-Vaccine/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Receives-71-Million-Contract-From-US-Department-of-Defense-To-Scale-Up-Manufacture-of-CELLECTRA-3PSP-Smart-Device-and-Procurement-of-CELLECTRA-2000-for-COVID-19-DNA-Vaccine/default.aspx)

June 24, 2020 - AstraZeneca began a vaccine trial in South Africa; https://thehill.com/policy/international/504328-large-scale-coronavirus-vaccine-trial-begins-in-south-africa (https://thehill.com/policy/international/504328-large-scale-coronavirus-vaccine-trial-begins-in-south-africa) , https://www.wits.ac.za/covid19/covid19-news/latest/the-first-covid-19-vaccine-trial-in-south-africa-begins.html (https://www.wits.ac.za/covid19/covid19-news/latest/the-first-covid-19-vaccine-trial-in-south-africa-begins.html) , https://www.ovg.ox.ac.uk/news/trial-of-oxford-covid-19-vaccine-in-south-africa-begins (https://www.ovg.ox.ac.uk/news/trial-of-oxford-covid-19-vaccine-in-south-africa-begins)

June 25, 2020 - Moderna and Catalent announced collaboration for fill-finish of Moderna's Covid-19 vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-and-catalent-announce-collaboration-fill-finish (https://investors.modernatx.com/news-releases/news-release-details/moderna-and-catalent-announce-collaboration-fill-finish)

June 26, 2020 - Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed; https://investors.vaxart.com/news-releases/news-release-details/vaxarts-covid-19-vaccine-selected-us-governments-operation-warp (https://investors.vaxart.com/news-releases/news-release-details/vaxarts-covid-19-vaccine-selected-us-governments-operation-warp)

June 29, 2020 - FDA issued EUAs for SARS-CoV-2 molecular diagnostic tests from Inform Diagnostics, Inc. and Diagnostic Solutions Laboratory, LLC; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-29-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-29-2020)

June 29, 2020 - FDA added the Stewart & Stevenson Healthcare Technologies, LLC: Apollo ABVM and SAGICO USA, LLC: V2O SAGICO SYSTEM to the list of ventilators authorized under EUA; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-29-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-29-2020)

June 30, 2020 - FDA issued an Emergency Use Authorization to LifeHope Labs for its molecular-based Covid-19 test; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-30-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-30-2020)

June 30, 2020 - To date, the FDA has authorized 157 tests under EUAs; these include 132 molecular tests, 24 antibody tests, and 1 antigen test; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-30-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-30-2020)

June 30, 2020 - HHS extends COVID-19 testing public-private partnership with CVS, Rite-Aid, Walgreens, Quest services at Walmart) and eTrueNorth services at Kroger, Health Mart, and Walmart); https://www.hhs.gov/about/news/2020/06/30/hhs-extends-covid-19-testing-public-private-partnership.html (https://www.hhs.gov/about/news/2020/06/30/hhs-extends-covid-19-testing-public-private-partnership.html) , https://www.hhs.gov/coronavirus/community-based-testing-sites/index.html (https://www.hhs.gov/coronavirus/community-based-testing-sites/index.html)

July 1, 2020 - Trial of Oxford/AstraZeneca vaccine began in Brazil; https://www.ovg.ox.ac.uk/news/trial-of-oxford-covid-19-vaccine-starts-in-brazil (https://www.ovg.ox.ac.uk/news/trial-of-oxford-covid-19-vaccine-starts-in-brazil) , https://www.labroots.com/trending/microbiology/18040/oxford-covid-19-vaccine-enters-phase-3-clinical-trials (https://www.labroots.com/trending/microbiology/18040/oxford-covid-19-vaccine-enters-phase-3-clinical-trials) ; approved June 2, https://www.ox.ac.uk/news/2020-06-04-brazilian-health-regulatory-agency-approves-trial-oxford-covid-19-vaccine (https://www.ox.ac.uk/news/2020-06-04-brazilian-health-regulatory-agency-approves-trial-oxford-covid-19-vaccine)

July 2, 2020 - In a Henry Ford Health System study, treatment with hydroxychloroquine cut the death rate significantly in patients hospitalized with COVID-19; 91% received the drug within 48 hours of admission; https://www.henryford.com/news/2020/07/hydro-treatment-study (https://www.henryford.com/news/2020/07/hydro-treatment-study)

July 3, 2020 - CytoDyn Inc. announced an exclusive Distribution and Supply Agreement with American Regent, Inc. for the  distribution of leronlimab for the treatment of COVID-19 in the US; https://www.cytodyn.com/newsroom/press-releases/detail/444/cytodyn-announces-execution-of-exclusive-agreement-with (https://www.cytodyn.com/newsroom/press-releases/detail/444/cytodyn-announces-execution-of-exclusive-agreement-with)

July 6, 2020 - CSL Behring announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy of its monoclonal antibody to treat patients with respiratory distress in patients with COVID-19 related pneumonia; https://www.cslbehring.com/newsroom/2020/csl-312-covid-19-trial-first-patient (https://www.cslbehring.com/newsroom/2020/csl-312-covid-19-trial-first-patient)

July 6, 2020 - Emergent BioSolutions announced a five-year manufacturing services agreement with Janssen Pharmaceuticals (Johnson & Johnson) for large-scale manufacturing for Johnson & Johnson’s COVID-19 vaccine; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-five-year-agreement-large-scale-drug (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-five-year-agreement-large-scale-drug)

July 6, 2020 - FDA granted an EUA for the BD Veritor Plus System rapid, point-of-care, Covid-19 diagnostic test; https://www.hhs.gov/about/news/2020/07/06/ash-adm-brett-giroir-md-statement-on-fda-eua-approval-of-the-bd-veritor-portable.html (https://www.hhs.gov/about/news/2020/07/06/ash-adm-brett-giroir-md-statement-on-fda-eua-approval-of-the-bd-veritor-portable.html)

July 6, 2020 - Regeneron announced the start of a Phase 3 trial to evaluate whether its polyclonal antibody treatment will prevent infection among uninfected people who have had close exposure to a COVID-19 patient; Regeneron also moved into the Phase 2/3 portion of its Phase 1/2/3 trials of with hospitalized and non-hospitalized patients with COVID-19; https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention (https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention)

July 7, 2020 - HHS and DOD announced a $1.6 billion agreement with Novavax for commercial-scale manufacturing of the company’s COVID-19 vaccine, purchase of 100M doses; https://www.hhs.gov/about/news/2020/07/07/hhs-dod-collaborate-novavax-produce-millions-covid-19-investigational-vaccine-doses-commercial-scale-manufacturing-demonstration-projects.html (https://www.hhs.gov/about/news/2020/07/07/hhs-dod-collaborate-novavax-produce-millions-covid-19-investigational-vaccine-doses-commercial-scale-manufacturing-demonstration-projects.html) , https://ir.novavax.com/news-releases/news-release-details/novavax-announces-16-billion-funding-operation-warp-speed (https://ir.novavax.com/news-releases/news-release-details/novavax-announces-16-billion-funding-operation-warp-speed)

July 7, 2020 - HHS and DOD announced an aggreement with Regeneron for commercial-scale manufacturing of the company’s COVID-19 anti-viral antibody treatment; https://www.hhs.gov/about/news/2020/07/07/hhs-dod-collaborate-regeneron-large-scale-manufacturing-demonstration-project-covid-19-investigational-therapeutic-treatment.html (https://www.hhs.gov/about/news/2020/07/07/hhs-dod-collaborate-regeneron-large-scale-manufacturing-demonstration-project-covid-19-investigational-therapeutic-treatment.html)

July 7, 2020 - GSK and Medicago collaborating to develop an adjuvanted COVID-19 vaccine; https://www.gsk.com/en-gb/media/press-releases/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine/ (https://www.gsk.com/en-gb/media/press-releases/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine/)

July 8, 2020 - Enrollment of the older adults group of Moderna's Phase II trial was completed; https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-2-study-its-mrna-vaccine (https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-2-study-its-mrna-vaccine)

July 8, 2020 - Medicago and Dynavax collaborating to develop an adjuvanted COVID-19 vaccine; https://www.medicago.com/en/newsroom/dynavax-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-vaccine-candidate/ (https://www.medicago.com/en/newsroom/dynavax-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-vaccine-candidate/)

July 8, 2020 - Becton, Dickinson announced the formation of a public-private partnership with BARDA, part of HHS, to develop new manufacturing lines for hundreds of millions of syringes and needles to support current and future pandemic vaccination efforts; https://www.bd.com/en-us/company/news-and-media/press-releases/2020-07-08-bd-partners-with-u-s-government-on-70-million-manufacturing-infrastructure-project-for-mass-vaccination-campaigns (https://www.bd.com/en-us/company/news-and-media/press-releases/2020-07-08-bd-partners-with-u-s-government-on-70-million-manufacturing-infrastructure-project-for-mass-vaccination-campaigns)

July 8, 2020 - Emergent BioSolutions announced collaboration with ImmunoTek Bio Centers and Mount Sinai Health System to develop, manufacture, and conduct clinical trials of Emergent BioSolutions' plasma-derived polyclonal antibody therapy for patients with COVID-19; https://investors.emergentbiosolutions.com/news-releases/news-release-details/mount-sinai-health-system-emergent-biosolutions-and-immunotek (https://investors.emergentbiosolutions.com/news-releases/news-release-details/mount-sinai-health-system-emergent-biosolutions-and-immunotek)

July 9, 2020 - Moderna and ROVI announce collaboration for outside-of-the-US Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-and-rovi-announce-collaboration-ous-fill-finish (https://investors.modernatx.com/news-releases/news-release-details/moderna-and-rovi-announce-collaboration-ous-fill-finish)

July 13, 2020 - Pfizer Inc. and BioNTech announced that two of the companies’ COVID-19 vaccine candidates received Fast Track designation from the US FDA; both are currently undergoing Phase 1/2 clinical studies; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-fast-track-designation-two (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-fast-track-designation-two)

July 13, 2020 - Medicago began Phase I clinical trials for its COVID-19 vaccine, separate trials with GlaxoSmithKline's and Dynavax's adjuvants; https://www.medicago.com/en/newsroom/medicago-begins-phase-i-clinical-trials-for-its-covid-19-vaccine-candidate/ (https://www.medicago.com/en/newsroom/medicago-begins-phase-i-clinical-trials-for-its-covid-19-vaccine-candidate/)

July 13, 2020 - Under the DPA, DOD in coordination with HHS awarded Renco Corp. a NTE $22.4 million contract with Lydall, Inc. to increase domestic production capacity of Nitrile beutadine rubber gloves; https://www.defense.gov/Newsroom/Contracts/Contract/Article/2272447/ (https://www.defense.gov/Newsroom/Contracts/Contract/Article/2272447/)

July 14, 2020 - HHS announced a large-scale procurement of FDA-authorized rapid point-of-care diagnostic test instruments and tests for nursing homes in COVID-19 hotspot geographic areas; https://www.hhs.gov/about/news/2020/07/14/trump-administration-announces-initiative-more-faster-covid-19-testing-nursing-homes.html (https://www.hhs.gov/about/news/2020/07/14/trump-administration-announces-initiative-more-faster-covid-19-testing-nursing-homes.html)

July 14, 2020 - Moderna's Covid-19 vaccine produced T-cells as well as antibodies; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-publication-new-england-journal-medicine (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-publication-new-england-journal-medicine) , https://www.nejm.org/doi/full/10.1056/NEJMoa2022483 (https://www.nejm.org/doi/full/10.1056/NEJMoa2022483)

July 15, 2020 - Rensselaer Polytechnic Institute announced research indicating that the common blood thinner heparin could be used as a "decoy" to hinder the multiplication of the coronavirus; https://www.newswise.com/coronavirus/common-fda-approved-drug-may-effectively-neutralize-virus-that-causes-covid-19/?article_id=734746 (https://www.newswise.com/coronavirus/common-fda-approved-drug-may-effectively-neutralize-virus-that-causes-covid-19/?article_id=734746)

July 19, 2020 - Under the DPA, DOD in coordination with HHS awarded Crosstex International a $3.5 million contract to increase domestic production capacity of surgical masks; https://www.defense.gov/Newsroom/Releases/Release/Article/2279253/dod-awards-35-million-contract-to-crosstex-international-inc-to-increase-domest/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2279253/dod-awards-35-million-contract-to-crosstex-international-inc-to-increase-domest/)

July 20, 2020 - BioNTech and Pfizer announced initial data from their Phase 1/2 trial showed the COVID-19 vaccine produced both antibodies and T-cells in patients; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-update-german (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-update-german)

July 20, 2020 - Oxford University COVID-19 vaccine produced both antibodies and T-cells in patients; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-i-ii-trial.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-i-ii-trial.html)

July 22, 2020 - Pfizer and BioNTech announced an agreement with the US HHS Department and the DoD under Operation Warp Speed to begin delivering 300 million doses of COVID-19 vaccine in 2021, with the US government receiving 100 million doses of the vaccine; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-us-government-600 (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-us-government-600) , https://www.bloomberg.com/news/articles/2020-07-22/pfizer-biontech-receive-u-s-order-for-covid-vaccine (https://www.bloomberg.com/news/articles/2020-07-22/pfizer-biontech-receive-u-s-order-for-covid-vaccine) , https://www.hhs.gov/about/news/2020/07/22/us-government-engages-pfizer-produce-millions-doses-covid-19-vaccine.html (https://www.hhs.gov/about/news/2020/07/22/us-government-engages-pfizer-produce-millions-doses-covid-19-vaccine.html)

July 23, 2020 - Novavax and FUJIFILM Diosynth Biotechnologies announced today an agreement to manufacture COVID-19 vaccine, with the first batch already started at FUJIFILM's facility in North Carolina; https://ir.novavax.com/news-releases/news-release-details/novavax-and-fujifilm-diosynth-biotechnologies-initiate-large (https://ir.novavax.com/news-releases/news-release-details/novavax-and-fujifilm-diosynth-biotechnologies-initiate-large)

July 23, 2020 - Medigen Vaccine Biologics and Dynavax announced collaboration to advance COVID-19 vaccine development using Dynavax's adjuvant; https://investors.dynavax.com/news-releases/news-release-details/dynavax-and-medigen-announce-collaboration-develop-novel (https://investors.dynavax.com/news-releases/news-release-details/dynavax-and-medigen-announce-collaboration-develop-novel) , http://www.medigenvac.com/public/en/news/detail/57?from_sort=2 (http://www.medigenvac.com/public/en/news/detail/57?from_sort=2)

July 23, 2020 - Under the DPA, DOD in coordination with HHS awarded Pall Corporation a NTE $4.9 million contract to increase domestic production capacity of ventilator filters; https://www.defense.gov/Newsroom/Releases/Release/Article/2286217/dod-awards-49-million-contract-to-pall-corporation-to-increase-industrial-base/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2286217/dod-awards-49-million-contract-to-pall-corporation-to-increase-industrial-base/)

July 25, 2020 - Under the DPA, DOD in coordination with HHS signed a $2.75 million contract with NPS to increase domestic capacity of meltblown filtration media, a key component in N95 masks; https://www.defense.gov/Newsroom/Releases/Release/Article/2288304/dod-awards-275-million-contract-to-nps-to-increase-domestic-production-of-meltb/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2288304/dod-awards-275-million-contract-to-nps-to-increase-domestic-production-of-meltb/)

July 25, 2020 - Under the DPA, DOD in coordination with HHS signed a $7.6 million contract with Hologic, Inc. to increase domestic production of consumables for sample collection and testing for Covid-19;https://www.defense.gov/Newsroom/Releases/Release/Article/2288926/dod-hhs-award-76-million-contract-to-hologic-inc-to-expand-domestic-production/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2288926/dod-hhs-award-76-million-contract-to-hologic-inc-to-expand-domestic-production/) , https://www.hhs.gov/about/news/2020/07/26/hhs-dod-invest-7-6m-hologic-expand-production-custom-sample-collection-processing-consumables-covid-19-tests.html (https://www.hhs.gov/about/news/2020/07/26/hhs-dod-invest-7-6m-hologic-expand-production-custom-sample-collection-processing-consumables-covid-19-tests.html)

July 26, 2020 - Moderna announced a modification to its contract with BARDA for additional funding to support late development, including the expanded Phase 3 study of its COVID-19 vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-expansion-barda-agreement-support-larger-phase (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-expansion-barda-agreement-support-larger-phase)

July 27, 2020 - Moderna announced announced that the Phase 3 study of its COVID-19 vaccine has begun dosing participants; the randomized, placebo-controlled trial will include some 30,000 US participants; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid)

July 27, 2020 - Pfizer and BioNTech announced the start of a global Phase 2/3 clinical study of its COVID-19 vaccine, which will include up to 30,000 participants; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0 (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0)

July 27, 2020 - As part of the agreement between Novavax and FUJIFILM and of Operation Warp Speed, mass production of the Novavax COVID-19 vaccine will be done at FUJIFILM's Texas A & M University facility; https://www.kxxv.com/brazos/u-s-chooses-texas-a-m-bio-manufacturing-center-for-production-of-covid-19-vaccine-candidates (https://www.kxxv.com/brazos/u-s-chooses-texas-a-m-bio-manufacturing-center-for-production-of-covid-19-vaccine-candidates) , https://www.hhs.gov/about/news/2020/07/27/hhs-reserves-and-rapidly-expands-manufacturing-capacity-for-covid-19-vaccines-at-texas-center.html (https://www.hhs.gov/about/news/2020/07/27/hhs-reserves-and-rapidly-expands-manufacturing-capacity-for-covid-19-vaccines-at-texas-center.html)

July 27, 2020 - Humanigen announced that the National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health have executed an agreement for a Big Effect Trial as part of the Phase III test of Lenzilumab, whether it prevents and treats cytokine storm in COVID-19 patients; https://www.humanigen.com/press/National-Institutes-of-Health-Selects-Humanigen%E2%80%99s-Lenzilumab-for-its-COVID-19-Big-Effect-Trial (https://www.humanigen.com/press/National-Institutes-of-Health-Selects-Humanigen%E2%80%99s-Lenzilumab-for-its-COVID-19-Big-Effect-Trial)

July 28, 2020 - Grifols announced it has delivered the first batches of its anti-Covid-19 hyperimmune globulin for clinical trials, in collaboration with the US FDA and BARDA; https://www.grifols.com/en/view-news/-/news/grifols-delivers-first-manufactured-batches-of-its-anti-sars-cov-2-hyperimmune-globulin-for-clinical-trials (https://www.grifols.com/en/view-news/-/news/grifols-delivers-first-manufactured-batches-of-its-anti-sars-cov-2-hyperimmune-globulin-for-clinical-trials)

July 29, 2020 - FDA granted NeuroRx and partner Relief Therapeutics an expanded access protocol for their experimental Covid-19 respiratory failure treatment; RLF-100 is designed to inhibit pro-inflammatory cytokines and protect alveolar cells in the lungs; https://www.neurorxpharma.com/news/fda-approves-expanded-access-to-wilmington-companys-experimental-covid-19-therapy/ (https://www.neurorxpharma.com/news/fda-approves-expanded-access-to-wilmington-companys-experimental-covid-19-therapy/)

June 29, 2020 - HHS announced an agreement to secure large supplies of remdesivir for the US from Gilead Sciences through September; https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-new-supplies-remdesivir-united-states.html (https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-new-supplies-remdesivir-united-states.html)

July 30, 2020 - Janssen Research (Johnson & Johnson) COVID-19 vaccine began Phase I/IIa clinical trial in the US and Belgium; https://www.jnj.com/single-dose-of-johnson-johnson-covid-19-vaccine-candidate-demonstrates-robust-protection-in-pre-clinical-studies (https://www.jnj.com/single-dose-of-johnson-johnson-covid-19-vaccine-candidate-demonstrates-robust-protection-in-pre-clinical-studies)

July 31, 2020 - To date, the FDA has currently authorized 194 tests under EUAs; these include 159 molecular tests, 33 antibody tests, and 2 antigen tests; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-31-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-31-2020)

July 31, 2020 - Sanofi and GlaxoSmithKline announced an agreement under Operation Warp Speed for funding clinical trials and delivery of 100 million doses, with an option for 500 million more doses; https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine/ (https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine/) , https://www.hhs.gov/about/news/2020/07/31/hhs-dod-partner-sanofi-gsk-commercial-scale-manufacturing-demonstration-project-produce-millions-covid-19-investigational-vaccine-doses.html (https://www.hhs.gov/about/news/2020/07/31/hhs-dod-partner-sanofi-gsk-commercial-scale-manufacturing-demonstration-project-produce-millions-covid-19-investigational-vaccine-doses.html)

August 2, 2020 - NeuroRx's RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells in Phase II/III trials; https://www.bloomberg.com/press-releases/2020-08-02/rlf-100-aviptadil-clinical-trial-showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in (https://www.bloomberg.com/press-releases/2020-08-02/rlf-100-aviptadil-clinical-trial-showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in)

August 3, 2020 - AbCellera announced that its antibody, discovered in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and co-developed with Eli Lilly and Company (Lilly) as a potential treatment and prophylaxis for COVID-19, has begun Phase 3 clinical trials; https://www.abcellera.com/news/2020-08-03-abcellera-provides-covid-19-program-update (https://www.abcellera.com/news/2020-08-03-abcellera-provides-covid-19-program-update) , http://lilly.mediaroom.com/2020-08-03-Lilly-Initiates-Phase-3-Trial-of-LY-CoV555-for-Prevention-of-COVID-19-at-Long-Term-Care-Facilities-in-Partnership-with-the-National-Institute-of-Allergy-and-Infectious-Diseases-NIAID (http://lilly.mediaroom.com/2020-08-03-Lilly-Initiates-Phase-3-Trial-of-LY-CoV555-for-Prevention-of-COVID-19-at-Long-Term-Care-Facilities-in-Partnership-with-the-National-Institute-of-Allergy-and-Infectious-Diseases-NIAID) , - https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-test-antibody-treatment-hospitalized-covid-19-patients (https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-test-antibody-treatment-hospitalized-covid-19-patients) , https://www.nih.gov/news-events/news-releases/nih-clinical-trial-test-antibodies-other-experimental-therapeutics-mild-moderate-covid-19 (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-test-antibodies-other-experimental-therapeutics-mild-moderate-covid-19)

August 4, 2020 - Under the DPA, DOD in coordination with HHS signed a $104 million contract with Duopross Meditech Corporation, Cardinal Health Inc., Gold Coast Medical Supply, LP, HTL STREFA Inc., Quality Impact, Inc., and Medline Industries, Inc. to procure 500M syringes and safety needles for Covid-19 vaccinations; https://www.defense.gov/Newsroom/Releases/Release/Article/2302139/dod-awards-104-million-for-procurement-of-syringes-in-support-of-us-covid-19-va/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2302139/dod-awards-104-million-for-procurement-of-syringes-in-support-of-us-covid-19-va/)

August 5, 2020 - Johnson & Johnson announced an agreement between its Janssen Pharmaceutical Companies and the US government for large scale domestic manufacturing and delivery of 100 million doses of Janssen's Covid-19 vaccine, subject to successful testing and with an option to purchase an additional 200 million doses; https://www.janssen.com/johnson-johnson-announces-agreement-us-government-100-million-doses-investigational-covid-19-vaccine (https://www.janssen.com/johnson-johnson-announces-agreement-us-government-100-million-doses-investigational-covid-19-vaccine) , https://www.hhs.gov/about/news/2020/08/05/hhs-dod-collaborate-with-johnson-and-johnson-to-produce-millions-of-covid-19-investigational-vaccine-doses.html (https://www.hhs.gov/about/news/2020/08/05/hhs-dod-collaborate-with-johnson-and-johnson-to-produce-millions-of-covid-19-investigational-vaccine-doses.html)

August 7, 2020 - Pfizer announced a multi-year agreement with Gilead Sciences to manufacture and supply Gilead’s investigational antiviral remdesivir; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir)

August 10, 2020 - Vaxart filed for permission to start Phase I testing of its oral Covid-19 vaccine; https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-ind-filed-covid-19-vaccine (https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-ind-filed-covid-19-vaccine)

August 10, 2020 - Gilead applied to the FDA for approval of Remdisivir as a treatment for Covid-19; https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-veklury-remdesivir-for-the-treatment-of-covid19 (https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-veklury-remdesivir-for-the-treatment-of-covid19)

August 10, 2020 - Humanigen is expanding its Phase III Study of Lenzilumab to prevent and treat cytokine storm in COVID-19 patients to Brazil; https://www.humanigen.com/press/Humanigen-Expands-Phase-III-Study-of-Lenzilumab-in-COVID-19-to-Brazil (https://www.humanigen.com/press/Humanigen-Expands-Phase-III-Study-of-Lenzilumab-in-COVID-19-to-Brazil)

August 10, 2020 - Under the DPA, DOD in support of HHS signed an agreement with BioFire Defense, LLC that will triple its Covid-19 test manufacturing capacity; https://www.defense.gov/Newsroom/Releases/Release/Article/2307721/dod-hhs-announce-dpa-title-iii-agreement-with-biofire-defense-llc-to-expand-dom/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2307721/dod-hhs-announce-dpa-title-iii-agreement-with-biofire-defense-llc-to-expand-dom/)

August 10, 2020 - Two Phase III trials of Regeneron's monoclonal antibodies can prevent Covid-19 infection in healthy adults who are at risk of infection due to close contact at work or home with an infected person; https://www.nih.gov/news-events/news-releases/clinical-trials-monoclonal-antibodies-prevent-covid-19-now-enrolling (https://www.nih.gov/news-events/news-releases/clinical-trials-monoclonal-antibodies-prevent-covid-19-now-enrolling)

August 11, 2020 - Moderna announced that the U.S. government has secured 100 million doses of Moderna's Covid-19 vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-supply-agreement-us-government-initial-100 (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-supply-agreement-us-government-initial-100) , https://www.hhs.gov/about/news/2020/08/11/trump-administration-collaborates-with-moderna-produce-100-million-doses-covid-19-investigational-vaccine.html (https://www.hhs.gov/about/news/2020/08/11/trump-administration-collaborates-with-moderna-produce-100-million-doses-covid-19-investigational-vaccine.html)

August 12, 2020 - Pfizer and BioNTech announced that they have submitted an amended protocol to the FDA to expand the enrollment of their Phase III COVID-19 vaccine trial to up to approximately 44,000 participants, allowing for the enrollment of new populations; the company expects to reach its initial target of up to 30,000 participants next week; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19 (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19)

August 13, 2020 - HHS announced combined investments of $6.5 million in Aegis Sciences Corporation and Sonic Healthcare USA to expand capacity to conduct up to 4 million additional Covid-19 tests per month; https://www.hhs.gov/about/news/2020/08/13/hhs-invests-in-diagnostic-labs-to-expand-covid-19-testing-capacity-in-the-united-states.html (https://www.hhs.gov/about/news/2020/08/13/hhs-invests-in-diagnostic-labs-to-expand-covid-19-testing-capacity-in-the-united-states.html)

August 14, 2020 - Mayo Clinic and collaborators have published information about results of testing plasma transfusions in 35K+ patients between April 4 and July 4; https://newsnetwork.mayoclinic.org/discussion/convalescent-plasma-associated-with-reduced-covid-19-mortality-in-35000-plus-hospitalized-patients/ (https://newsnetwork.mayoclinic.org/discussion/convalescent-plasma-associated-with-reduced-covid-19-mortality-in-35000-plus-hospitalized-patients/)

August 14, 2020 - HHS and DoD announced that under Operation Warp Speed, McKesson Corp. will be the distributor of Covid-19 vaccines and related supplies; https://www.hhs.gov/about/news/2020/08/14/trump-administration-collaborates-mckesson-covid-19-vaccine-distribution.html (https://www.hhs.gov/about/news/2020/08/14/trump-administration-collaborates-mckesson-covid-19-vaccine-distribution.html) , https://www.defense.gov/Newsroom/Releases/Release/Article/2313808/trump-administration-collaborates-with-mckesson-for-covid-19-vaccine-distributi/ (https://www.defense.gov/Newsroom/Releases/Release/Article/2313808/trump-administration-collaborates-with-mckesson-for-covid-19-vaccine-distributi/)

August 14, 2020 - Vaxart announced that the FDA has reviewed of the Company’s Investigational New Drug (IND) application and approved a Phase 1 clinical trial of its oral COVID-19 vaccine candidate; enrollment will start in September; https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-fda-clearance-ind-application-oral-covid-19 (https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-fda-clearance-ind-application-oral-covid-19)

August 14, 2020 - Eli Lilly and Incyte announced that Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir alone; http://lilly.mediaroom.com/2020-09-14-Baricitinib-in-Combination-with-Remdesivir-Reduces-Time-to-Recovery-in-Hospitalized-Patients-with-COVID-19-in-NIAID-Sponsored-ACTT-2-Trial (http://lilly.mediaroom.com/2020-09-14-Baricitinib-in-Combination-with-Remdesivir-Reduces-Time-to-Recovery-in-Hospitalized-Patients-with-COVID-19-in-NIAID-Sponsored-ACTT-2-Trial) , https://investor.incyte.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery (https://investor.incyte.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery)

August 15, 2020 - The FDA issued an emergency use authorization (EUA) for Yale School of Public Health's SalivaDirect COVID-19 diagnostic test; a saliva sample can be collected in any sterile container, and the test does not require a step used in other saliva tests that has been susceptible to shortages; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-yale-school-public-health (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-yale-school-public-health)

August 17, 2020 - CytoDyn submitted its Top-line Report from its recently completed Phase 2 trial for COVID-19 patients with mild-to-moderate symptoms to the US FDA and requested emergency use approval; https://www.cytodyn.com/newsroom/press-releases/detail/460/cytodyn-submits-its-top-line-report-from-its-phase-2 (https://www.cytodyn.com/newsroom/press-releases/detail/460/cytodyn-submits-its-top-line-report-from-its-phase-2)

August 17, 2020 - Novavax announced the beginning of a Phase 2b clinical trial in South Africa of its COVID-19 vaccine candidate; https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-efficacy-trial-covid-19-vaccine-south-africa (https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-efficacy-trial-covid-19-vaccine-south-africa)

August 19, 2020 - Regeneron and Roche will collaborate to develope and manufacture Regeneron's two antibody "cocktail", increasing capacity by at least three and a half times; Regeneron will distribute inside the US and Roche will distribute outside the US; https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-roche-collaborate-significantly-increase-global (https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-roche-collaborate-significantly-increase-global)

August 20, 2020 - Under the DPA, HHS contracted with Becton Dickinson and Quidel Corporation through September to purchase diagnostic systems and assays for COVID-19 testing for ~14,000 nursing homes certified by the Centers for Medicare & Medicaid services; https://www.hhs.gov/about/news/2020/08/20/trump-administration-uses-defense-production-act-to-aid-our-most-vulnerable.html (https://www.hhs.gov/about/news/2020/08/20/trump-administration-uses-defense-production-act-to-aid-our-most-vulnerable.html)

August 21, 2020 - The FDA issued an emergency use authorization (EUA) to NovaSterilis, Inc. for its N95 respirator decontamination device; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-21-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-21-2020)

August 23, 2020 - Expanded Access Program for Convalescent Plasma discontinues enrollment as FDA authorizes its emergency use; the treatment has been used with more than 70K patients; https://newsnetwork.mayoclinic.org/discussion/expanded-access-program-for-convalescent-plasma-discontinues-enrollment-as-fda-authorizes-its-emergency-use/ (https://newsnetwork.mayoclinic.org/discussion/expanded-access-program-for-convalescent-plasma-discontinues-enrollment-as-fda-authorizes-its-emergency-use/)

August 24, 2020 - Novavax announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial of its Covid-19 vaccine; https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-2-portion-phase-12-clinical-trial-covid (https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-2-portion-phase-12-clinical-trial-covid)

August 24, 2020 - Belgian study following official guidance released March 13 of low dose hydrochloroquine (HCQ) only with 8075 Covid-19 patients (3533 were in the control group that did not receive HCQ) found that HCQ significantly reduced the death rate; https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%3Dihub (https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%3Dihub)

August 25, 2020 - The first participants have been dosed in a Phase I trial of a DARPA and BARDA funded AstraZeneca combination of two monoclonal antibodies for the prevention and treatment of COVID-19; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/phase-1-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/phase-1-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19.html)

August 25, 2020 - CytoDyn announced it has enrolled 195 in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms, the requisite number to perform an interim analysis of the 28-day phase of the trial; https://www.cytodyn.com/newsroom/press-releases/detail/466/cytodyn-reaches-enrollment-of-195-patients-in-its-phase-3 (https://www.cytodyn.com/newsroom/press-releases/detail/466/cytodyn-reaches-enrollment-of-195-patients-in-its-phase-3)

August 25, 2020 - HHSannounced the release of 1.5 million N95 respirators from the Strategic National Stockpile distribution to approximately 3,336 US nursing home facilities; https://www.hhs.gov/about/news/2020/08/25/trump-administration-release-1-5-million-n95-respirators-from-strategic-national-stockpile-distribution-nursing-homes.html (https://www.hhs.gov/about/news/2020/08/25/trump-administration-release-1-5-million-n95-respirators-from-strategic-national-stockpile-distribution-nursing-homes.html)

August 26, 2020 - FDA issued an EUA for Abbott Laboratories' BinaxNOW COVID-19 Ag Card, which can give test results in 15 minutes on a small card and costs $5 each; https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-authorizes-first-diagnostic-test-where-results-can-be-read-directly-testing-card (https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-authorizes-first-diagnostic-test-where-results-can-be-read-directly-testing-card)

August 27, 2020 - The Trump administration purchased 150 million of Abbott Laboratories' newly approved BinaxNOW COVID-19 Ag Card tests; https://www.upi.com/Top_News/US/2020/08/27/Trump-administration-buys-150M-card-based-COVID-19-tests-authorized-by-FDA/6241598539001/ (https://www.upi.com/Top_News/US/2020/08/27/Trump-administration-buys-150M-card-based-COVID-19-tests-authorized-by-FDA/6241598539001/) , https://www.hhs.gov/about/news/2020/08/27/trump-administration-will-deploy-150-million-rapid-tests-in-2020.html (https://www.hhs.gov/about/news/2020/08/27/trump-administration-will-deploy-150-million-rapid-tests-in-2020.html)

August 27, 2020 - To date, the FDA has currently authorized 226 tests under EUAs, including 182 molecular tests, 40 antibody tests, and 4 antigen tests; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-27-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-27-2020)

August 28, 2020 - The FDA issued an EUA allowing the use of remdesivir with Covid-19 patients in any stage of the disease; https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gileads-investigational-antiviral-veklury-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-p (https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gileads-investigational-antiviral-veklury-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-p)

August 31, 2020 - Vir Biotechnology and GlaxoSmithKline announced the first patient was dosed last week in a phase 2/3 study of an anti-Covid-19 monoclonal antibody, for the early treatment of COVID-19 in patients; https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/ (https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/) ; https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-gsk-start-phase-23-study-covid-19-antibody (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-gsk-start-phase-23-study-covid-19-antibody)

August 31, 2020 - AstaZeneca began Phase III testing of its Covid-19 vaccine in the US; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html)

September 2, 2020 - The Department of HHS is canceling some remaining orders for ventilators, explaining that the national stockpile has reached its maximum capacity of 120000; https://abcnews.go.com/Health/wireStory/hhs-cancelling-ventilator-contracts-stockpile-full-72765067 (https://abcnews.go.com/Health/wireStory/hhs-cancelling-ventilator-contracts-stockpile-full-72765067)

September 2, 2020 - The director of the CDC asked US state governors to prepare for large-scale distribution of a Covid-19 vaccine by November 1st; the distribution would be carried out by McKesson Corp.; https://www.nbcnews.com/news/us-news/cdc-tells-states-prepare-large-scale-distribution-covid-19-vaccine-n1239149 (https://www.nbcnews.com/news/us-news/cdc-tells-states-prepare-large-scale-distribution-covid-19-vaccine-n1239149)

September 2, 2020 - JAMA published a study showing that dexamethasone reduced the need for ventilator support in hospitalized COVID-19 patients; https://www.upi.com/Health_News/2020/09/02/Dexamethasone-other-corticosteroids-help-hospitalized-COVID-19-patients/4661599054386/ (https://www.upi.com/Health_News/2020/09/02/Dexamethasone-other-corticosteroids-help-hospitalized-COVID-19-patients/4661599054386/)

September 2, 2020 - Novavax's Covid-19 vaccine produced T-cells as well as antibodies; https://ir.novavax.com/news-releases/news-release-details/novavax-announces-publication-phase-1-data-covid-19-vaccine (https://ir.novavax.com/news-releases/news-release-details/novavax-announces-publication-phase-1-data-covid-19-vaccine)

September 3, 2020 - Sanofi and GSK started the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine; https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-03-07-00-00 (https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-03-07-00-00) , https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/ (https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/)

September 4, 2020 - The Oxford/AstraZenaca Covid-19 vaccine began Phase I/II testing in Japan with 250 subjects planned; https://www.dailymail.co.uk/news/article-8697471/Oxfords-coronavirus-vaccine-enters-human-trials-Japan.html (https://www.dailymail.co.uk/news/article-8697471/Oxfords-coronavirus-vaccine-enters-human-trials-Japan.html)

September 8, 2020 - CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and Sanofi announced a pledge to uphold the integrity of the scientific process in their work towards regulatory filings and approvals of COVID-19 vaccines; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/biopharma-leaders-unite-to-stand-with-science.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/biopharma-leaders-unite-to-stand-with-science.html) , https://www.janssen.com/biopharma-leaders-unite-stand-science (https://www.janssen.com/biopharma-leaders-unite-stand-science) , https://www.jnj.com/biopharma-leaders-unite-to-stand-with-science (https://www.jnj.com/biopharma-leaders-unite-to-stand-with-science) , https://www.merck.com/news/biopharma-leaders-unite-to-stand-with-science/ (https://www.merck.com/news/biopharma-leaders-unite-to-stand-with-science/) , https://investors.modernatx.com/news-releases/news-release-details/biopharma-leaders-unite-stand-science (https://investors.modernatx.com/news-releases/news-release-details/biopharma-leaders-unite-stand-science) , https://ir.novavax.com/news-releases/news-release-details/biopharma-leaders-unite-stand-science (https://ir.novavax.com/news-releases/news-release-details/biopharma-leaders-unite-stand-science) , https://www.pfizer.com/news/press-release/press-release-detail/biopharma-leaders-unite-stand-science (https://www.pfizer.com/news/press-release/press-release-detail/biopharma-leaders-unite-stand-science) ; this was the companies' response to - and anticipating further - politically motivated attempts to create doubt of the vaccine(s) likely to be approved in the near future

September 8, 2020 - Inovio announced that Thermo Fisher Scientific has signed a letter of intent to manufacture INOVIO's DNA COVID-19 vaccine; http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Adds-Thermo-Fisher-Scientific-To-Global-Manufacturing-Consortium/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Adds-Thermo-Fisher-Scientific-To-Global-Manufacturing-Consortium/default.aspx)

September 9, 2020 - HHS authorized state-licensed pharmacists to order and administer, and state-licensed or registered pharmacy interns acting under proper supervision to administer, COVID-19 vaccinations to persons ages 3 or older; https://www.hhs.gov/about/news/2020/09/09/trump-administration-takes-action-to-expand-access-to-covid-19-vaccines.html (https://www.hhs.gov/about/news/2020/09/09/trump-administration-takes-action-to-expand-access-to-covid-19-vaccines.html)

September 10, 2020 - NIH launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19; https://www.nih.gov/news-events/news-releases/nih-activ-initiative-launches-adaptive-clinical-trials-blood-clotting-treatments-covid-19 (https://www.nih.gov/news-events/news-releases/nih-activ-initiative-launches-adaptive-clinical-trials-blood-clotting-treatments-covid-19)

September 14, 2020 - University of Pittsburgh School of Medicine announced an antibody component that in a drug can be infused into tissue or inhaled that can neutralize the virus that causes Covid-19; the NIH provided some of the research funding; https://www.pittwire.pitt.edu/news/pitt-scientists-discover-tiny-antibody-component-highly-effective-preventing-and-treating-sars (https://www.pittwire.pitt.edu/news/pitt-scientists-discover-tiny-antibody-component-highly-effective-preventing-and-treating-sars) , https://www.upmc.com/media/news/040220-falo-gambotto-sars-cov2-vaccine (https://www.upmc.com/media/news/040220-falo-gambotto-sars-cov2-vaccine)

September 16, 2020 - Eli Lilly announced the randomized, double-blind, placebo-controlled Phase 2 study of a Covid-19 neutralizing antibody improved viral clearance from Day 11 for the placebo group to Day 3 for those who received the antibody; http://lilly.mediaroom.com/2020-09-16-Lilly-announces-proof-of-concept-data-for-neutralizing-antibody-LY-CoV555-in-the-COVID-19-outpatient-setting (http://lilly.mediaroom.com/2020-09-16-Lilly-announces-proof-of-concept-data-for-neutralizing-antibody-LY-CoV555-in-the-COVID-19-outpatient-setting) , https://www.abcellera.com/news/2020-09-16-interim-data-phase-2-clinical-trials (https://www.abcellera.com/news/2020-09-16-interim-data-phase-2-clinical-trials)

September 17, 2020 - Eli Lilly and Amgen announced a global antibody manufacturing collaboration for Lilly's anti-COVID-19 antibody to significantly increase supply capacity; http://lilly.mediaroom.com/2020-09-17-Lilly-and-Amgen-Announce-Manufacturing-Collaboration-for-COVID-19-Antibody-Therapies (http://lilly.mediaroom.com/2020-09-17-Lilly-and-Amgen-Announce-Manufacturing-Collaboration-for-COVID-19-Antibody-Therapies) , https://www.amgen.com/media/news-releases/2020/09/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies/ (https://www.amgen.com/media/news-releases/2020/09/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies/)

September 23, 2020 - Johnson & Johnson announced the start of its Phase III trial for its COVID-19 vaccine candidate developed by its Janssen Pharmaceutical Companies; the trial will enroll up to 60,000 volunteers across three continents; https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate (https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate) ; https://www.janssen.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-janssens-covid-19-vaccine-candidate (https://www.janssen.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-janssens-covid-19-vaccine-candidate)

September 24, 2020 - Novavax announced that it has initiated its first Phase 3 study in the UK to evaluate the efficacy, safety and immunogenicity of Novavax’ COVID-19 vaccine along with Novavax’ adjuvant; https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united (https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united)

September 24, 2020 - OncoImmune announced that it has closed enrollment of its Phase III clinical trial of CD24Fc and released topline results from the interim efficacy analysis; data from 203 participants (75% of the planned enrollment) show that severe or critical COVID-19 patients treated with CD24Fc exhibited significantly faster recovery and significantly reduced disease progression to death or respiratory failure than those receiving placebo; http://oncoimmune.com/index.php?option=com_k2&view=item&id=1101:oncoimmune-s-saccovid-cd24fc-exhibits-superb-therapeutic-efficacy-a-potential-breakthrough-in-treating-severe-and-critical-covid-19&Itemid=316 (http://oncoimmune.com/index.php?option=com_k2&view=item&id=1101:oncoimmune-s-saccovid-cd24fc-exhibits-superb-therapeutic-efficacy-a-potential-breakthrough-in-treating-severe-and-critical-covid-19&Itemid=316)

September 25, 2020 (updated October 4th) - Johnson & Johnson's Covid-19 vaccine produced T-cells as well as antibodies; https://www.jnj.com/johnson-johnson-posts-interim-results-from-phase-1-2a-clinical-trial-of-its-janssen-covid-19-vaccine-candidate (https://www.jnj.com/johnson-johnson-posts-interim-results-from-phase-1-2a-clinical-trial-of-its-janssen-covid-19-vaccine-candidate)

September 28, 2020 - The Trump Administration detailed the national distribution plan for the Abbott BinaxNOW Ag Card rapid test to assist Governors' efforts to continue to safely reopen their states; K-12 teachers and students, higher education, critical infrastructure, first responders, and other priorities as governors deem fit; https://www.hhs.gov/about/news/2020/09/28/trump-administration-deploys-abbott-binaxnow-tests-to-states.html (https://www.hhs.gov/about/news/2020/09/28/trump-administration-deploys-abbott-binaxnow-tests-to-states.html)

September 29, 2020 - Regeneron announced the first data from a seamless Phase 1/2/3 trial of its antibody cocktail showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19; https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and (https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and)

October 2, 2020 - Regeneron confirmed that REGN-COV2 Antibody treatment was provided to President Trump under Compassionate Use request; https://investor.regeneron.com/index.php/static-files/fd58ba6a-f401-47b0-9d65-cfb01c313ec6 (https://investor.regeneron.com/index.php/static-files/fd58ba6a-f401-47b0-9d65-cfb01c313ec6)

October 6, 2020 - Vir Biotechnology and GlaxoSmithKline announced the global expansion to Phase 3 of its COVID-19 Monoclonal antibody Efficacy Trial; https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/ (https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/) , https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-gsk-announce-global-expansion-phase-3 (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-gsk-announce-global-expansion-phase-3)

October 7, 2020 - Regeneron requested EUA from the FDA for its REGN-COV2 antibody treatment for Covid-19; https://investor.regeneron.com/static-files/6feab76b-176d-402d-bf30-d40462e68b7b (https://investor.regeneron.com/static-files/6feab76b-176d-402d-bf30-d40462e68b7b) ; additional test data submitted October 28, https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates (https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates)

October 7, 2020 - Eli Lilly announced that in Phase 2 trials combination therapy with two of Lilly's and AbCellera's SARS-CoV-2 neutralizing antibodies (LY-CoV555 and LY-CoV016) reduced viral load, symptoms and COVID-related hospitalization and ER visits; in monotherapy, a 700 mg dose of LY-CoV555 produced similar clinical effects; Phase 3 testing began August 3rd based on the combination therapy and monotherapy data, Lilly has submitted a request to the FDA for EUA for monotherapy and will submit a request for EUA for combination therapy in November; http://lilly.mediaroom.com/index.php?s=9042&item=138100 (http://lilly.mediaroom.com/index.php?s=9042&item=138100)

October 8, 2020 - Eli Lilly and Incyte shared additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir alone; http://lilly.mediaroom.com/index.php?s=9042&item=138103 (http://lilly.mediaroom.com/index.php?s=9042&item=138103) , https://investor.incyte.com/press-releases/press-releases/2020/Baricitinib-has-Significant-Effect-on-Recovery-Time-Most-Impactful-in-COVID-19-Patients-Requiring-Oxygen/default.aspx (https://investor.incyte.com/press-releases/press-releases/2020/Baricitinib-has-Significant-Effect-on-Recovery-Time-Most-Impactful-in-COVID-19-Patients-Requiring-Oxygen/default.aspx)

October 8, 2020 - The CoVIg-19 Plasma Alliance, a collaboration of leading plasma companies, announced that patients are being enrolled in the inpatient treatment Phase 3 clinical trial of several hyperimmune intravenous immunoglobulin candidates, sponsored by the NIAID, part of the NIH; https://www.cslbehring.com/newsroom/2020/first-patient-enrolled-in-nih-covid19-phase-3-trial (https://www.cslbehring.com/newsroom/2020/first-patient-enrolled-in-nih-covid19-phase-3-trial) , https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-covid-19-human-immune-globulin-product (https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-covid-19-human-immune-globulin-product) , https://www.grifols.com/en/view-news/-/news/grifols-anti-sars-cov-2-hyperimmune-globulin-begins-clinical-trial-in-patients-with-covid-19 (https://www.grifols.com/en/view-news/-/news/grifols-anti-sars-cov-2-hyperimmune-globulin-begins-clinical-trial-in-patients-with-covid-19)

October 9, 2020 - AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US; the LAABs have been engineered to increase the durability of the therapy for six to 12 months following a single administration; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html)

October 9, 2020 - HHS and DoD announced an agreement with AstraZeneca for late-stage development and large-scale manufacturing of the company's AZD7442, a cocktail of two monoclonal antibodies, to treat or prevent infection with the COVID-19 virus; https://www.hhs.gov/about/news/2020/10/09/trump-administration-expands-collaboration-with-astrazeneca-to-develop-and-manufacture-an-investigational-monoclonal-antibody-to-prevent-covid-19.html (https://www.hhs.gov/about/news/2020/10/09/trump-administration-expands-collaboration-with-astrazeneca-to-develop-and-manufacture-an-investigational-monoclonal-antibody-to-prevent-covid-19.html)

October 12, 2020 - Mesoblast announced the Phase 3 trial of remestemcel-L in ventilator-dependent patients with acute respiratory distress syndrome due to COVID19 has surpassed 50% enrollment; Remestemcel-L is being developed for prevention of cytokine storm; http://investorsmedia.mesoblast.com/static-files/687288c5-03f9-441f-a9e0-407dcfa86fc9 (http://investorsmedia.mesoblast.com/static-files/687288c5-03f9-441f-a9e0-407dcfa86fc9)

October 13, 2020 - Medigen and Dynavax announced that Medigen has obtained a Taiwan government subsidy for initiating a Phase 1 clinical trial in Taiwan; the first participant was dosed with Medigen's COVID-19 vaccine plus Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October; https://investors.dynavax.com/news-releases/news-release-details/medigens-covid-19-vaccine-combined-dynavaxs-cpg-1018-adjuvant (https://investors.dynavax.com/news-releases/news-release-details/medigens-covid-19-vaccine-combined-dynavaxs-cpg-1018-adjuvant)

October 13, 2020 - Vaxart announced the first subject has been dosed in its Phase 1 study of its oral tablet COVID-19 vaccine candidate; https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-dosing-first-subject-phase-1-clinical-trial-its (https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-dosing-first-subject-phase-1-clinical-trial-its)

October 13, 2020 - HHS and the DoD awarded a $481 million agreement to Cue Health to expand U.S. production capacity for a cartridge-based point-of-care COVID-19 molecular test that produces results in about 20 minutes; https://www.hhs.gov/about/news/2020/10/13/trump-administration-makes-major-investment-to-increase-availability-of-fast-molecular-poc-test.html (https://www.hhs.gov/about/news/2020/10/13/trump-administration-makes-major-investment-to-increase-availability-of-fast-molecular-poc-test.html)

October 13, 2020 - HHS and DoD announced an agreement with Cytiva to expand the company’s manufacturing capacity for consumable products such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and XDR bioreactors that are essential in producing COVID-19 vaccines; https://www.hhs.gov/about/news/2020/10/13/trump-administration-expands-manufacturing-capacity-cytiva-components-covid-19-vaccines.html (https://www.hhs.gov/about/news/2020/10/13/trump-administration-expands-manufacturing-capacity-cytiva-components-covid-19-vaccines.html)

October 16, 2020 - HHS and DoD announced agreements with CVS and Walgreens to provide and administer COVID-19 vaccines to residents of long-term care facilities nationwide with no out-of-pocket costs; https://www.hhs.gov/about/news/2020/10/16/trump-aministration-partners-cvs-walgreens-provide-covid-19-vaccine-protect-vulnerable-americans-long-term-care-facilities-nationwide.html (https://www.hhs.gov/about/news/2020/10/16/trump-aministration-partners-cvs-walgreens-provide-covid-19-vaccine-protect-vulnerable-americans-long-term-care-facilities-nationwide.html)

October 21, 2020 - HHS issued guidance authorizing qualified pharmacy technicians and State-authorized pharmacy interns to administer COVID-19 vaccines when made available, and COVID-19 tests; https://www.hhs.gov/about/news/2020/10/21/trump-administration-takes-action-further-expand-access-vaccines-covid-19-tests.html (https://www.hhs.gov/about/news/2020/10/21/trump-administration-takes-action-further-expand-access-vaccines-covid-19-tests.html)

October 22, 2020 - Gilead announced that the US FDA has approved antiviral drug Veklury (remdesivir) for treatment of patients with COVID-19 requiring hospitalization (not just emergency use); https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid19 (https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid19) , https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19)

October 22, 2020 - Moderna announced that it has completed enrollment of 30,000 participants in the Phase 3 study of its COVID-19 vaccine candidate, in collaboration with NIAID (part of NIH) and BARDA (part of the US Department of HHS); to date, more than 25,650 participants have received their second vaccination; https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-3-cove-study-mrna-vaccine (https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-3-cove-study-mrna-vaccine)

October 23, 2020 - The FDA today authorised the restart of Phase III trials in the US, following the resumption of trials in the UK, Brazil, South Africa, and Japan in recent weeks; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/fda-authorises-restart-of-the-covid-19-azd1222-vaccine-us-phase-iii-trial.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/fda-authorises-restart-of-the-covid-19-azd1222-vaccine-us-phase-iii-trial.html)

October 23, 2020 - The independent Data Safety and Monitoring Board overseeing the Johnson & Johnson Covid-19 vaccine study recommended resuming trial recruitment; after consultation with the US FDA, preparations to resume the trial in the US are now underway; https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us (https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us) , https://www.janssen.com/johnson-johnson-prepares-resume-phase-3-ensemble-trial-its-janssen-covid-19-vaccine-candidate-us (https://www.janssen.com/johnson-johnson-prepares-resume-phase-3-ensemble-trial-its-janssen-covid-19-vaccine-candidate-us)

October 28, 2020 - Eli Lilly announced an initial agreement with the US government to supply 300,000 doses of bamlanivimab (LY-CoV555), an investigational neutralizing antibody, for $375 million if it is granted an EUA by the FDA; Lilly submitted a request for an EUA for mild to moderate COVID-19 in high-risk patients in early October; the agreement is for delivery over the two months following an EUA plus an option for the purchase of up to an additional 650,000 doses through June 30, 2021, under the same terms; http://lilly.mediaroom.com/index.php?s=9042&item=138111 (http://lilly.mediaroom.com/index.php?s=9042&item=138111) , https://www.hhs.gov/about/news/2020/10/28/hhs-dod-collaborate-plans-purchase-lilly-investigational-therapeutic-treat-covid-19.html (https://www.hhs.gov/about/news/2020/10/28/hhs-dod-collaborate-plans-purchase-lilly-investigational-therapeutic-treat-covid-19.html)

October 28, 2020 - 285 tests have been authorized by FDA under EUAs; these include 222 molecular tests, 56 antibody tests, and 7 antigen tests; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-october-28-2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-october-28-2020)

November 09, 2020 - Novavax announced that the FDA has granted Fast Track Designation for the Company’s COVID-19 vaccine; https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-granted-fast-track-designation-us-fda (https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-granted-fast-track-designation-us-fda)

November 09, 2020 - The FDA) today granted Emergency Use Authorization for Eli Lilly and Company's neutralizing antibody bamlanivimab (LY-CoV555) 700 mg; it is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test who are at high risk for progressing to severe COVID-19 and/or hospitalization; 300,000 doses were also purchased by the US government; http://lilly.mediaroom.com/index.php?s=9042&item=138119 (http://lilly.mediaroom.com/index.php?s=9042&item=138119) , https://www.abcellera.com/news/2020-11-09-bamlanivimab-us-fda-eua (https://www.abcellera.com/news/2020-11-09-bamlanivimab-us-fda-eua) , https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19)

November 9, 2020 -  Pfizer and BioNTech announced their mRNA-based SARS-CoV-2 vaccine has demonstrated evidence of efficacy against COVID-19; the first interim efficacy analysis conducted by an external, independent Data Monitoring Committee concluded that the vaccine efficacy rate was above 90% at 7 days after the second dose; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against)

November 10, 2020 - Medicago announced the results of its Phase I test with 180 subject had resulted in 100% developing antibodies and adverse reaction were moderate or mild and of short duration; https://www.medicago.com/en/newsroom/medicago-announces-positive-phase-1-results-for-its-covid-19-vaccine-candidate/ (https://www.medicago.com/en/newsroom/medicago-announces-positive-phase-1-results-for-its-covid-19-vaccine-candidate/)

November 12, 2020 - Medicago and GSK are pleased to announce the start of Phase 2/3 clinical trials of its vaccine candidate for COVID-19 with GSK's pandemic adjuvant; https://www.medicago.com/en/newsroom/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/ (https://www.medicago.com/en/newsroom/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/) , https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/ (https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/)

November 12, 2020 - HHS announced partnerships with large chain pharmacies and networks that represent independent pharmacies and regional chains to get safe and effective vaccines supported by Operation Warp Speed into communities and to people as quickly as possible with no out-of-pocket costs; https://www.hhs.gov/about/news/2020/11/12/trump-administration-partners-chain-independent-community-pharmacies-increase-access-future-covid-19-vaccines.html (https://www.hhs.gov/about/news/2020/11/12/trump-administration-partners-chain-independent-community-pharmacies-increase-access-future-covid-19-vaccines.html)

November 15, 2020 - In addition to the single-dose regimen 60K participant Phase III study, Janssen has now initiated a two-dose regimen 30K participant Phase III study; https://www.janssen.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-its-janssen-covid-19-vaccine (https://www.janssen.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-its-janssen-covid-19-vaccine) , https://www.jnj.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate (https://www.jnj.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate)

November 16, 2020 - Biological E. Limited (India), Dynavax Technologies, and Baylor College of Medicine announced that BE has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India; https://investors.dynavax.com/news-releases/news-release-details/biological-e-limited-starts-phase-iii-clinical-trial-its-covid (https://investors.dynavax.com/news-releases/news-release-details/biological-e-limited-starts-phase-iii-clinical-trial-its-covid)

November 16, 2020 - Moderna announced that the independent, NIH-appointed Data Safety Monitoring Board for the Phase 3 study of its vaccine candidate against COVID-19 has informed Moderna that the trial has met the statistical criteria in the study protocol for efficacy, with a vaccine efficacy of 94.5%; https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy (https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy)

November 16, 2020 - Inovio announced that it has received clearance from the FDA to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for its COVID-19 vaccine candidate; the trial will be funded by the DoD; http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Initiation-of-Phase-2-Segment-of-its-Phase-23-Clinical-Trial-for-its-COVID-19-DNA-Vaccine-Candidate-INO-4800-Trial-Will-Be-Funded-by-the-U.S.-Department-of-Defense/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Initiation-of-Phase-2-Segment-of-its-Phase-23-Clinical-Trial-for-its-COVID-19-DNA-Vaccine-Candidate-INO-4800-Trial-Will-Be-Funded-by-the-U.S.-Department-of-Defense/default.aspx)

November 17, 2020 - CytoDyn announced it has filed a protocol with the FDA for a Phase 2 clinical trial for leronlimab as a treatment for COVID-19 patients suffering from significant symptoms several months after recovering from Covid-19; https://www.cytodyn.com/newsroom/press-releases/detail/486/cytodyn-files-protocol-with-u-s-fda-for-phase-2-clinical (https://www.cytodyn.com/newsroom/press-releases/detail/486/cytodyn-files-protocol-with-u-s-fda-for-phase-2-clinical)

November 17, 2020 - FDA issued an emergency authorization for Lucira Health's rapid coronavirus test, the first that can be administered entirely at home; https://www.upi.com/Health_News/2020/11/18/FDA-authorizes-first-at-home-COVID-19-test/2511605687738/ (https://www.upi.com/Health_News/2020/11/18/FDA-authorizes-first-at-home-COVID-19-test/2511605687738/) , https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home) , https://2nyvwd1bf4ct4f787m3leist-wpengine.netdna-ssl.com/wp-content/uploads/2020/11/FDA-Authorizes-First-Prescription-At-Home-Molecular-Test-for-COVID-19-released-20201118.pdf (https://2nyvwd1bf4ct4f787m3leist-wpengine.netdna-ssl.com/wp-content/uploads/2020/11/FDA-Authorizes-First-Prescription-At-Home-Molecular-Test-for-COVID-19-released-20201118.pdf)

November 18, 2020 - Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their COVID-19 vaccine candidate met all of the study’s primary efficacy endpoints; analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection;  the companies also announced that the safety milestone required by the FDA for Emergency Use Authorization (EUA) has been achieved; Pfizer and BioNTech plan to submit a request within days for an EUA; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine)

November 19, 2020 - Eli Lilly and Incyte announced that the FDA issued an EUA for the emergency use of baricitinib to be used in combination with remdesivir in hospitalized adult and pediatric patients two years of age or older with COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation; http://lilly.mediaroom.com/index.php?s=9042&item=138125 (http://lilly.mediaroom.com/index.php?s=9042&item=138125) , https://investor.incyte.com/press-releases/press-releases/2020/Baricitinib-Receives-Emergency-Use-Authorization-from-the-FDA-for-the-Treatment-of-Hospitalized-Patients-with-COVID-19/default.aspx (https://investor.incyte.com/press-releases/press-releases/2020/Baricitinib-Receives-Emergency-Use-Authorization-from-the-FDA-for-the-Treatment-of-Hospitalized-Patients-with-COVID-19/default.aspx) , https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19)

November 20, 2020 - Pfizer and BioNTech announced they will submit a request today to the FDA) for Emergency Use Authorization (EUA) of their SARS-CoV-2 vaccine candidate, which will potentially enable use of the vaccine in high-risk populations in the US by mid-late December 2020; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization)

November 20, 2020 - The FDA has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee on December 10 to discuss the request for EUA of a COVID-19 vaccine from Pfizer and BioNTech; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-covid-19-vaccine (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-covid-19-vaccine)

November 21, 2020 - Regeneron's cocktail of monoclonal antibodies, REGN-COV2, received EUA from the FDA; there is an existing contract for Regeneron to supply 300,000 doses to the US government; https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive (https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive) , https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19)

November 21, 2020 - AstraZeneca announced that an independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine; one dosing regimen showed 62% efficacy while the other 90%; AstraZeneca will immediately submit the data to authorities around the world that have a framework for conditional or early approval; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html) , https://www.vaccitech.co.uk/oxford-university-breakthrough-on-global-covid-19-vaccine/ (https://www.vaccitech.co.uk/oxford-university-breakthrough-on-global-covid-19-vaccine/)

November 25, 2020 - AstraZeneca and Oxford University acknowledged a manufacturing error and an age group distribution issue affecting the calculated efficacy of their Covid-19 vaccine; https://www.nbcnewyork.com/news/coronavirus/astrazeneca-manufacturing-error-clouds-vaccine-study-results/2746793/ (https://www.nbcnewyork.com/news/coronavirus/astrazeneca-manufacturing-error-clouds-vaccine-study-results/2746793/)

November 26, 2020 - AstraZeneca CEO said that further research was needed on its COVID-19 vaccine after errors affecting the calculation of the efficacy of its vaccine were revealed; the additional testing may not affect regulatory approval in Europe; https://medicalxpress.com/news/2020-11-additional-astrazeneca-vaccine-company.html (https://medicalxpress.com/news/2020-11-additional-astrazeneca-vaccine-company.html)

November 30, 2020 - Moderna announced that the primary efficacy analysis of the Phase 3 study of its Covid-19 vaccine confirms the high efficacy of 94.1% of the first interim analysis; Moderna is submitting for an EUA with the FDA and apply for Conditional Marketing Authorization with the European Medicines Agency; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study)

November 30, 2020 - The FDA scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee on Dec. 17 to discuss the request for emergency use authorization for a COVID-19 vaccine from Moderna; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-second-covid-19-vaccine (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-second-covid-19-vaccine)

December 1, 2020 - Mesoblast Limited announced that the US FDA has granted Fast Track designation for remestemcel-L for treating acute respiratory distress syndrome (ARDS) due to COVID-19; http://investorsmedia.mesoblast.com/static-files/046bf826-c5bf-4606-a0b2-0420f8c7a933 (http://investorsmedia.mesoblast.com/static-files/046bf826-c5bf-4606-a0b2-0420f8c7a933)

December 2, 2020 - The US government has purchased 650,000 additional doses of Eli Lilly's SARS-CoV-2 neutralizing antibody bamlanivimab; this purchase brings the total doses purchased by the U.S. government to 950,000; http://lilly.mediaroom.com/index.php?s=9042&item=138129 (http://lilly.mediaroom.com/index.php?s=9042&item=138129)

December 07, 2020 - Inovio announced it has dosed its first subject in a Phase 2 clinical trial of its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial; http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Doses-First-Subject-in-Phase-2-Segment-of-its-INNOVATE-Phase-23-Clinical-Trial-for-INO-4800-its-DNA-Medicine-to-Prevent-COVID-19/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Doses-First-Subject-in-Phase-2-Segment-of-its-INNOVATE-Phase-23-Clinical-Trial-for-INO-4800-its-DNA-Medicine-to-Prevent-COVID-19/default.aspx)

December 10, 2020 -  Pfizer and BioNTech announced that the US FDA Vaccines and Related Biological Products Advisory Committee voted 17 to 4 in support of the FDA granting Emergency Use Authorization (EUA) for the companies’ COVID-19 vaccine; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-fda-advisory-committee-vote (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-fda-advisory-committee-vote)

December 10, 2020 - Moderna announced that the first adolescent participants have been dosed in the Phase 2/3 study of Moderna’s COVID-19 vaccine in adolescents ages 12 to less than 18; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-covid (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-covid)

December 11, 2020 - Sanofi and GlaxoSmithKline announced a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults by increasing the concentration of the antigen; https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/ (https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/) ; https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00 (https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00)

December 11, 2020 - The FDA granted Emergency Use Authorization to the Pfizer/BioNTech vaccine; https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 (https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19) ; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization)

December 11, 2020 - US government exercised its option to purchase an additional 100 million doses of Moderna’s COVID-19 vaccine; https://investors.modernatx.com/news-releases/news-release-details/us-government-exercises-1st-option-additional-100-million-doses (https://investors.modernatx.com/news-releases/news-release-details/us-government-exercises-1st-option-additional-100-million-doses) , https://www.hhs.gov/about/news/2020/12/11/trump-administration-purchases-additional-100-million-doses-covid-19-investigational-vaccine-moderna.html (https://www.hhs.gov/about/news/2020/12/11/trump-administration-purchases-additional-100-million-doses-covid-19-investigational-vaccine-moderna.html)

December 15, 2020 - Inovio announced that it and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from DARPA to develop anti-SARS-CoV-2-specific DNA-encoded monoclonal antibodies which could function as both a therapeutic and preventive treatment for COVID-19; http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-to-Develop-DNA-encoded-Monoclonal-Antibody-dMAb-Candidates-to-Treat-COVID-19-with-Funding-from-the-Defense-Advanced-Research-Projects-Agency-DARPA-and-the-Department-of-Defenses-DoD-Joint-Program-Executive-Office-for-Chemical-Biological-Radiol/default.aspx (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-to-Develop-DNA-encoded-Monoclonal-Antibody-dMAb-Candidates-to-Treat-COVID-19-with-Funding-from-the-Defense-Advanced-Research-Projects-Agency-DARPA-and-the-Department-of-Defenses-DoD-Joint-Program-Executive-Office-for-Chemical-Biological-Radiol/default.aspx)

December 15, 2020 - The FDA issued EUA for the first over-the-counter fully at-home diagnostic test for COVID-19, the Ellume COVID-19 Home Test, which was developed with $30 million in support from the NIH; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic) , https://www.hhs.gov/about/news/2020/12/15/hhs-secretary-azar-statement-fda-authorization-first-fully-at-home-over-the-counter-covid-19-test.html (https://www.hhs.gov/about/news/2020/12/15/hhs-secretary-azar-statement-fda-authorization-first-fully-at-home-over-the-counter-covid-19-test.html)

December 15, 2020 - CytoDyn announced it had reached full enrollment of Vyrologix (leronlimab-PRO 140) in its Phase 3 registrational trial for patients with severe-to-critical COVID-19; https://www.cytodyn.com/newsroom/press-releases/detail/491/cytodyn-completes-enrollment-for-phase-3-registrational (https://www.cytodyn.com/newsroom/press-releases/detail/491/cytodyn-completes-enrollment-for-phase-3-registrational)

December 17, 2020 - The FDA's Vaccines and Related Biological Products Advisory Committee recommended that the FDA grant an Emergency Use Authorization for the Moderna’s COVID-19 vaccine; https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-advisory-committee-vote-supporting (https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-advisory-committee-vote-supporting) , https://www.fda.gov/news-events/press-announcements/fda-statement-vaccines-and-related-biological-products-advisory-committee-meeting-0 (https://www.fda.gov/news-events/press-announcements/fda-statement-vaccines-and-related-biological-products-advisory-committee-meeting-0)

December, 17 2020 - Vir Biotechnology and GlaxoSmithKline today announced that the first patient has been dosed in a Phase 3 trial of their monoclonal antibody that was selected based on its potential to neutralise the virus, kill infected cells, provide a high barrier to resistance and achieve high concentrations in the lungs in the treatment of hospitalised adults with COVID-19; https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/ (https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/) ; https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-gsk-announce-start-nih-sponsored-activ-3 (https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-gsk-announce-start-nih-sponsored-activ-3)

December 17, 2020 - The Janssen COVID-19 single-dose vaccine candidate Phase III trial is now fully enrolled with approximately 45,000 participants; https://www.janssen.com/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-fully-enrolled (https://www.janssen.com/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-fully-enrolled)

December 18, 2020 - Moderna's vaccine received Emergency Use Authorization from the FDA; https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-fda-authorization-moderna-covid-19-vaccine-us (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-fda-authorization-moderna-covid-19-vaccine-us) , https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid (https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid)

December 23, 2020 - Merck announced an agreement with the US Government to support the development, manufacture and initial distribution of MK-7110 (formerly OncoImmune CD24Fc, Merck acquired OncoImmune in November), its treatment for patients with severe and critical Covid-19 upon receiving EUA from the FDA; Merck will receive up to $356 million for manufacturing and supplying  up to 100,000 doses of MK-7110 to the US Government through June 30, 2021 as part of Operation Warp Speed; https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-initial-doses-of-investigational-biological-therapy-for-the-treatment-of-patients-with-severe-and-critical-covid-19/ (https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-initial-doses-of-investigational-biological-therapy-for-the-treatment-of-patients-with-severe-and-critical-covid-19/) , https://www.hhs.gov/about/news/2020/12/23/hhs-dod-collaborate-with-merck-continue-development-large-scale-manufacturing-investigational-covid-19-treatment.html (https://www.hhs.gov/about/news/2020/12/23/hhs-dod-collaborate-with-merck-continue-development-large-scale-manufacturing-investigational-covid-19-treatment.html)

December 23, 2020 - Pfizer and BioNTech announced an agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 Vaccine from production facilities in the US; as in the original July 2020 agreement, $1.95 billion will be paid for the additional doses; https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-us-100-million-additional-doses (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-us-100-million-additional-doses) , https://www.hhs.gov/about/news/2020/12/23/trump-administration-purchases-additional-100-million-doses-covid-19-investigational-vaccine-pfizer.html (https://www.hhs.gov/about/news/2020/12/23/trump-administration-purchases-additional-100-million-doses-covid-19-investigational-vaccine-pfizer.html)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 15, 2020, 05:17:09 pm

https://www.statnews.com/2020/03/02/coronavirus-drugs-and-vaccines-in-development/ (https://www.statnews.com/2020/03/02/coronavirus-drugs-and-vaccines-in-development/)

A detailed guide to the coronavirus drugs and vaccines in development
By DAMIAN GARDE // MARCH 2, 2020

Quote

Here’s a guide to some of the most talked-about efforts to treat or prevent coronavirus infection, with details on the science, history, and timeline for each endeavor.

Gilead Sciences
Approach: Treatment
Stage: Phase 3
...
Moderna Therapeutics
Approach: Vaccine
Stage: Phase 1
...
CureVac
Approach: Vaccine
Stage: Preclinical
...
GlaxoSmithKline
Approach: Vaccine
Stage: Preclinical
...
Inovio Pharmaceuticals
Approach: Vaccine
Stage: Preclinical
...
Johnson & Johnson
Approach: Vaccine and treatment
Stage: Preclinical
...
Regeneron Pharmaceuticals
Approach: Treatment
Stage: Preclinical
...
Sanofi
Approach: Vaccine
Stage: Preclinical
...
Vir Biotechnology
Approach: Treatment
Stage: Preclinical

There is an Israeli firm whose experimental vaccine isn't on that list, https://www.jpost.com/HEALTH-SCIENCE/Israeli-scientists-In-three-weeks-we-will-have-coronavirus-vaccine-619101 (https://www.jpost.com/HEALTH-SCIENCE/Israeli-scientists-In-three-weeks-we-will-have-coronavirus-vaccine-619101) .

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 15, 2020, 05:19:56 pm

https://spectrum.ieee.org/the-human-os/biomedical/bionics/darpas-firebreak-treatment-for-the-coronavirus
By Eliza Strickland // 05 Mar 2020 | 17:00 GMT

DARPA Races To Create a "Firebreak" Treatment for the Coronavirus

When DARPA launched its Pandemic Preparedness Platform (P3) program two years ago, the pandemic was theoretical. It seemed like a prudent idea to develop a quick response to emerging infectious diseases. Researchers working under the program sought ways to confer instant (but short-term) protection from a dangerous virus or bacteria.

Today, as the novel coronavirus causes a skyrocketing number of COVID-19 cases around the world, the researchers are racing to apply their experimental techniques to a true pandemic playing out in real time. “Right now, they have one shot on goal,” says DARPA program manager Amy Jenkins. “We’re really hoping it works.”

The P3 program’s plan was to start with a new pathogen and to “develop technology to deliver medical countermeasures in under 60 days—which was crazy, unheard of,” says Jenkins. The teams have proven they can meet this ambitious timeline in previous trials using the influenza and Zika viruses. Now they’re being asked to pull off the same feat with the new coronavirus, which more formally goes by the name SARS-CoV-2 and causes the illness known as COVID-19.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Free Vulcan on March 15, 2020, 11:02:12 pm

Des Moines mayor declares state of emergency over Iowa's coronavirus 'community spread'

Des Moines Mayor Frank Cownie has declared a state of emergency, prohibiting gatherings of more than 250 people on public property.

Cownie signed the proclamation Sunday, less than a day after Iowa Gov. Kim Reynolds announced the state's first case of "community spread" of the novel coronavirus. The designation means COVID-19 has spread from an unknown source and isn't linked to travel.

Reynolds announced the case was linked to Dallas County, which includes Des Moines' western suburbs. In a news conference Sunday, Cownie said that case "opened a lot of people’s eyes."

https://www.desmoinesregister.com/story/news/2020/03/15/coronavirus-iowa-des-moines-mayor-declares-state-emergency/5054544002/ (https://www.desmoinesregister.com/story/news/2020/03/15/coronavirus-iowa-des-moines-mayor-declares-state-emergency/5054544002/)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Cyber Liberty on March 16, 2020, 12:36:19 am

 :2popcorn:

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Cyber Liberty on March 16, 2020, 12:38:33 am

Prohibiting public assembly is not going to end well.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Cyber Liberty on March 16, 2020, 12:44:08 am

Quote from: Free Vulcan on March 15, 2020, 11:02:12 pm

Des Moines mayor declares state of emergency over Iowa's coronavirus 'community spread'

Des Moines Mayor Frank Cownie has declared a state of emergency, prohibiting gatherings of more than 250 people on public property.

Cownie signed the proclamation Sunday, less than a day after Iowa Gov. Kim Reynolds announced the state's first case of "community spread" of the novel coronavirus. The designation means COVID-19 has spread from an unknown source and isn't linked to travel.

Reynolds announced the case was linked to Dallas County, which includes Des Moines' western suburbs. In a news conference Sunday, Cownie said that case "opened a lot of people’s eyes."

https://www.desmoinesregister.com/story/news/2020/03/15/coronavirus-iowa-des-moines-mayor-declares-state-emergency/5054544002/ (https://www.desmoinesregister.com/story/news/2020/03/15/coronavirus-iowa-des-moines-mayor-declares-state-emergency/5054544002/)

Mayor Dumbass is a Democrat, any surprise?

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 16, 2020, 03:04:38 pm

Added to OP timeline:

Quote

An NIH clinical trial of Remdesivir begun: February 25, 2020, at University of Nebraska Medical Center, https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: TomSea on March 16, 2020, 05:50:36 pm

Great idea to have this.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: libertybele on March 16, 2020, 05:54:04 pm

Quote from: PeteS in CA on March 16, 2020, 03:04:38 pm

Added to OP timeline:

Hopefully this vaccine will work and not just be a bandaid giving people false hope -- that will only spread this virus till its out of control.

Much like the flu vaccine -- every year they project which flu virus they think well be effective -- it is hit or miss every year.  Oh, and then they cover their butts by saying even the wrong strain of flu vaccine will help.  B.S.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 16, 2020, 07:57:20 pm

Quote from: libertybele on March 16, 2020, 05:54:04 pm

Hopefully this vaccine will work and not just be a bandaid giving people false hope -- that will only spread this virus till its out of control.

Much like the flu vaccine -- every year they project which flu virus they think well be effective -- it is hit or miss every year.  Oh, and then they cover their butts by saying even the wrong strain of flu vaccine will help.  B.S.

The item to which you were referring was about testing a treatment rather than a vaccine. But a test of Moderna's experimental vaccine also began today. It was just 64 days ago that China identified the coronavirus to WHO, and both a treatment and a vaccine are in testing.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: truth_seeker on March 16, 2020, 11:34:40 pm

Episode 853 Scott Adams: Simultaneous Sipping, #Coronavirus, The Nursing Home Pillow Fight


11,574 views•Mar 16, 2020

Morecommon sense thinking

Error 404 (Not Found)!!1 (http://www.youtube.com/watch?v=5OTNnd7pFJc#)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: libertybele on March 16, 2020, 11:40:36 pm

Quote from: PeteS in CA on March 16, 2020, 07:57:20 pm

The item to which you were referring was about testing a treatment rather than a vaccine. But a test of Moderna's experimental vaccine also began today. It was just 64 days ago that China identified the coronavirus to WHO, and both a treatment and a vaccine are in testing.

The other stat that I heard is that it will be at least a year before they have a vaccine that can be administered to the general population.

This is going to be a very loooong year!

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 17, 2020, 01:09:46 am

Quote from: libertybele on March 16, 2020, 11:40:36 pm

The other stat that I heard is that it will be at least a year before they have a vaccine that can be administered to the general population.

This is going to be a very loooong year!

As I posted in another thread, the FDA's testing and approval process is haunted by Thalidomide and DES. To use an analogy I've read elsewhere, if "safety" and "speed" are two pans in a pan balance, the FDA process starts with an anvil in the "safety" pan.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: truth_seeker on March 17, 2020, 04:33:02 am

Quote from: Cyber Liberty on March 16, 2020, 12:38:33 am

Prohibiting public assembly is not going to end well.

How so?


How about a temporary short term measure, to save lives?

BTW South Coast Plaza, a favorite of visitors from Asia, closed today.

An Asian owned gun store in San Gabrial Valley, reported increased gun sales. I presume they are selling to area Asians, fearing attacks over their ethnicity.

Way beyond Ironic, since many medical personnel are Asians, walking into the fire every day to help people.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Cyber Liberty on March 17, 2020, 06:30:23 am

Quote from: truth_seeker on March 17, 2020, 04:33:02 am

How so?


How about a temporary short term measure, to save lives?

BTW South Coast Plaza, a favorite of visitors from Asia, closed today.

An Asian owned gun store in San Gabrial Valley, reported increased gun sales. I presume they are selling to area Asians, fearing attacks over their ethnicity.

Way beyond Ironic, since many medical personnel are Asians, walking into the fire every day to help people.

A temporary measure will be OK, unless/until people start to get the notion the National Government is lying about the need.  :shrug:

Title: Re: Coronavirus and Covid-19 Related Events
Post by: truth_seeker on March 17, 2020, 06:49:02 am

Quote from: Cyber Liberty on March 17, 2020, 06:30:23 am

A temporary measure will be OK, unless/until people start to get the notion the National Government is lying about the need.  :shrug:

In the real world, peope are dying, shopping panic is taking place, govt. from highest to most local is implementing shelter-in-place" isolation, to "flatten the curve" and minimize the spread.

I think they have studied nations that did well, (So. Korea) and those that did poorly (Italy)

I hear the strong indication is the shutdown is the best course of action.

My wife's friend living in Harbin China reported they were free after 6 weeks of confinement, indicating the isolation worked there.

Finally I may be wrong. We remain in the :Fog of War" and determining the "truth" is a work in progress

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Formerly Once-Ler on March 17, 2020, 08:21:40 am

I missed this earlier...just in case you did too.

www.youtube.com/watch?v=9UTvLwv28wY (http://www.youtube.com/watch?v=9UTvLwv28wY#)

Trump urges public to avoid crowds of 10 or more people
•Streamed live 12 hours ago
Fox News

He looks lucid.  He coudn't avoid patting his own back for where we find ourselves, but he has a course of action, and a health guideline.  His experts were informative, and President Trump also answered a lot of questions well.  He said most the media has been fair.  He said the Senate is negotiating with the House on a package.  He said he is working closely with the state governors.  He said the best thing he could do for the Stock Market is to get us through this virus.

I think that is a message that voters want to hear.  This was a really good press conference for President Trump  happy77

He is now ranting about the media on twitter in his tireless effort to combat COVID-19.   :thud:

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 17, 2020, 02:59:10 pm

SF Bay Area counties began a three week quasi-lockdown, necessary trips only allowed, except for necessary businesses (e.g. stores, banks, medical offices and hospitals). Mrs. S in CA is working at home and I'll probably just be at home. The three week "shelter in place" duration extends beyond when our daughter is scheduled to fly back to China, so I'm not sure how she'll be affected.

https://www.sccgov.org/sites/phd/DiseaseInformation/novel-coronavirus/Pages/order-health-officer-031620.aspx (https://www.sccgov.org/sites/phd/DiseaseInformation/novel-coronavirus/Pages/order-health-officer-031620.aspx)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Formerly Once-Ler on March 17, 2020, 05:37:13 pm

www.youtube.com/watch?v=Z5jdgafH7eM (http://www.youtube.com/watch?v=Z5jdgafH7eM#)

Trump, White House Coronavirus Task Force holds press briefing
•Streamed live 2 hours ago

Fox News

After a good performance yesterday President Trump was back to his usual unscripted barrage of vague.

"Progress is being made.  A very substantial increase in testing. 
The states are very much involved, and they have been involved from the begining, but we're stepping it up as much as we can.
I am speaking to lots of people and meeting lots of people.  Everybody is working strongly. 
The testing procedures are going well, and I think it's going to be something really great if it's done properly."
Then he kissed Gov Cuomo's ass

He eventually announced he was voiding Hippa laws concerning telehealth, and would not enforce infractions.

His back up dancers really shined today.
Pence was great at praising the President and good at promoting the 15-day guideline. 
He announced a public service ad campaign from the CDC, and a plea from private business for industrial masks. 
Mnuchin announced the purchase of a trillion dollar from the Fed and a 90 day tax extension.  Mnuchin also said he has talked with Pelosi twice today
Adml Brett Giroir USPSH said 31,878 test had been conducted by public labs like the CDC and 27,000 clinical test have been conducted, with 8,200 conducted yesterday. 
Since the first confirmed US test about 2 months ago on Jan 20th we have barely performed 50K tests. 
It's a pathetic figure because South Korea has been doing 10K per day for weeks but then they didn't go home for 4 day weekends like Majority Leader McConnell.

Dr. Birx asked young people to stop bar hoping, and promised the administration was committed to a real time website documenting statistics. 
She admitted that "Remember, all of these tests, the high speed tests were approved last Friday, last Friday night, and last Thursday night," when asked why less than 60K tests had been administered.
I didn't mind that much because I know they were lying their asses off weeks ago when they promised a million tests.

Dr Fauci was great.  "You don't want to put your loved ones at risk." I trust him.

Trump - "We are looking to save the maximum number of lives" which was awesome, but then he said he thought it was a pandemic before calling it a pandemic was cool

Near the end President Trump heaped great praise on the advisors standing next to him.  Then he moved on to the Congress "Democrats and Republicans." 
It was very classy and smart, but then Trump got into his usual rat/media ain't fair to me whine, and he was pulled for his nap.

90 minutes of questions and answers.  I'm impressed.  All in all this should have been a very good presser for the President.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Formerly Once-Ler on March 18, 2020, 07:16:05 pm

www.youtube.com/watch?v=KXL6HoBIsAo (http://www.youtube.com/watch?v=KXL6HoBIsAo#)

Trump, Coronavirus Task Force hold a press conference at White House
Fox News

A third really good press conference lasting a hour with another press conference announced for later today or tomorrow morning.  I almost hate to be critical at all, because I think these press conferences have been good for the President, the people, and the markets, but the President was as usual the weakest speaker.  He said stuff like "it's the invisible enemy, that's always the toughest enemy, the invisible enemy, but we're going to defeat the invisible enemy.  I think we are going to do it even faster than we thought. and it will be a complete victory. It will be a total victory."  On the other hand he announced invoking the defense production act.  That sounds very important, even though nobody really explained why.  His advisers were excellent.  Lots of news, statistics, policy reinforcement, and announcements.

The President consistently defended the 15 day guidelines, he consistently spoke about bipartisanship, and he shouted out to Gov Cuomo several times.  I found all of that comforting and reinforcing my unrealistic fantasy that President Trump is focused on this virus, and the panic surrounding it, to the exclusion of all else.

I missed Dr Fauci, and Mnuchin.  I'm also waiting for the introduction of the head of the Pandemic Response Office that a fellow Briefer informed me was not dissolved by President Trump in 2018.  @Mesaclone   

2 things did aggravate me.  President Trump said the virus snuck up on us, and he wastes a lot of time calling the virus "the Chinese virus" and then unconvincingly defending it as not racist.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 18, 2020, 11:52:34 pm

Quote from: PeteS in CA on March 15, 2020, 05:15:12 pm

China informed WHO of the outbreak in Wuhan of unknown cause: December 31, 2019, https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/)

Covid-19 identified to WHO: January 11 and 12, 2020, https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)

China/WHO claims no evidence of  human to human transmission of corona virus: January 14, 2020, https://twitter.com/WHO/status/1217043229427761152 (https://twitter.com/WHO/status/1217043229427761152) ,

Quote

World Health Organization (WHO)
@WHO
Jan 14
Preliminary investigations conducted by the Chinese authorities have found no clear evidence of human-to-human transmission of the novel #coronavirus (2019-nCoV) identified in #Wuhan, #China.

The US started screening arriving passengers from China: January 17, 2020, JFK, SFO, LAX https://www.businessinsider.com/new-disease-virus-china-us-airports-screening-cdc-2020-1 (https://www.businessinsider.com/new-disease-virus-china-us-airports-screening-cdc-2020-1) ; O'Hare and Hartsfield-Jackson January 22, 2020, https://www.washingtonpost.com/nation/2020/01/21/us-screenings-coronavirus-expanded-airports-atlanta-chicago/ (https://www.washingtonpost.com/nation/2020/01/21/us-screenings-coronavirus-expanded-airports-atlanta-chicago/)

Pharmaceuticals company working with US government to develop vaccine: January 22, 2020, Moderna, https://www.cnbc.com/2020/01/22/moderna-is-working-on-a-vaccine-for-chinas-deadly-coronavirus.html (https://www.cnbc.com/2020/01/22/moderna-is-working-on-a-vaccine-for-chinas-deadly-coronavirus.html)

Wuhan and other cities in Hubei Province shut down travel: January 23, 2020, https://news.cgtn.com/news/2020-01-27/5-million-people-left-Wuhan-before-the-lockdown-where-did-they-go--NACCu9wItW/index.html (https://news.cgtn.com/news/2020-01-27/5-million-people-left-Wuhan-before-the-lockdown-where-did-they-go--NACCu9wItW/index.html)

US personnel evacuated from Wuhan: January 29, 2020 https://abcnews.go.com/US/us-chartering-evacuation-flight-wuhan-coronavirus-zone-california/story?id=68571310 (https://abcnews.go.com/US/us-chartering-evacuation-flight-wuhan-coronavirus-zone-california/story?id=68571310)

State Department raised the travel advisory for China to Level 4, do not travel: January 31, 2020, https://www.usatoday.com/story/travel/2020/01/31/coronavirus-china-flight-ban-delta-cuts-all-flights-white-house/4620989002/ (https://www.usatoday.com/story/travel/2020/01/31/coronavirus-china-flight-ban-delta-cuts-all-flights-white-house/4620989002/)

Trump declared a public health emergency: January 31, 2020, https://abcnews.go.com/Health/delta-suspends-us-flights-china-amid-coronavirus/story?id=68666037 (https://abcnews.go.com/Health/delta-suspends-us-flights-china-amid-coronavirus/story?id=68666037)

People entering the US from China forbidden: Announced January 31, 2020, effective February 2, 2020, https://www.cnn.com/2020/02/02/us/coronavirus-us-travel-restrictions/index.html (https://www.cnn.com/2020/02/02/us/coronavirus-us-travel-restrictions/index.html) This effectively ended flights from and to China, for obvious reasons. The current date for flights to resume is March 30, 2020.

An NIH clinical trial of Remdesivir begun: February 25, 2020, at University of Nebraska Medical Center, https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins)

Experimental vaccine submitted for testing: February 26, 2020, Moderna, https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html (https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html)

Testing labs allowed to use tests whose FDA Emergency Use Authorization requests are still pending: February 29, 2020, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics)

Army signed agreement with Gilead on experimental COVID-19 treatment: March 10, 2020, https://www.militarytimes.com/news/your-military/2020/03/10/army-signs-agreement-with-drug-giant-gilead-on-experimental-covid-19-treatment/ (https://www.militarytimes.com/news/your-military/2020/03/10/army-signs-agreement-with-drug-giant-gilead-on-experimental-covid-19-treatment/), Remdesivir

OyaGen, Inc. announced experimental treatment studied by National Institute of Allergy and Infectious Diseases: 3/10/2020, http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf (http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf) , "OYA1", not yet tested on humans

People entering the US from Europe forbidden: Announced March 11,2020, effective March 13, 2020, https://www.msn.com/en-us/news/world/travelers-rush-into-us-ahead-of-ban-on-europe-arrivals/ar-BB1173CZ (https://www.msn.com/en-us/news/world/travelers-rush-into-us-ahead-of-ban-on-europe-arrivals/ar-BB1173CZ)

Eli Lilly announced partnership with research company to develop a treatment/vaccine as part of the DARP program: March 13, 2020, https://www.msn.com/en-us/finance/companies/eli-lilly-joins-race-to-develop-coronavirus-treatment/ar-BB116BNR (https://www.msn.com/en-us/finance/companies/eli-lilly-joins-race-to-develop-coronavirus-treatment/ar-BB116BNR)

Trump declared National Emergency: March 13, 2020, https://www.msn.com/en-us/news/politics/what-trumps-emergency-declaration-over-coronavirus-means-for-arizona/ar-BB11a6RO (https://www.msn.com/en-us/news/politics/what-trumps-emergency-declaration-over-coronavirus-means-for-arizona/ar-BB11a6RO)

Testing begins of Moderna's experimental coronavirus vaccine: March 16, 2020, at Kaiser Permanente Washington Health Research Institute, https://www.kpwashingtonresearch.org/news-and-events/recent-news/news-2020/kaiser-permanente-launches-coronavirus-vaccine-study-seattle (https://www.kpwashingtonresearch.org/news-and-events/recent-news/news-2020/kaiser-permanente-launches-coronavirus-vaccine-study-seattle)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 19, 2020, 12:02:29 am

Courtesy of @Hoodat and DailyCaller.com I added this to the OP timeline:

China/WHO claims no evidence of  human to human transmission of corona virus: January 14, 2020, https://twitter.com/WHO/status/1217043229427761152 ,

Quote

World Health Organization (WHO)
@WHO
Jan 14
Preliminary investigations conducted by the Chinese authorities have found no clear evidence of human-to-human transmission of the novel #coronavirus (2019-nCoV) identified in #Wuhan, #China.

I did save a Snip of the Tweet in case it disappears. Intentional or unintentional, this very wrong information was a hindrance to countries trying to gauge appropriate action and would likely have caused some delay. Depending on when WHO did their about-face, Trump's January 17th action, the beginning of screening passengers arriving from China, may have been despite WHO's very wrong information.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: TomSea on March 19, 2020, 03:52:23 am

Japanese flu drug reportedly shows promise against coronavirus in clinical trials  -  https://thehill.com/changing-america/well-being/prevention-cures/488321-japanese-flu-drug-reportedly-shows-promise

I think this is how we are posting to this thread.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: TomSea on March 19, 2020, 05:00:19 pm

Israeli researchers announce new, faster COVID-19 testing method
https://www.jns.org/israeli-researchers-successfully-test-new-faster-covid-19-testing-method/ (https://www.jns.org/israeli-researchers-successfully-test-new-faster-covid-19-testing-method/)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 19, 2020, 05:06:36 pm

https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_pdf/-char/en (https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_pdf/-char/en)

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Quote

Summary:

The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.

Title: Dose of Dr. Drew
Post by: truth_seeker on March 20, 2020, 02:50:16 am

Dose of Dr. Drew 3/1932020

Error 404 (Not Found)!!1 (http://www.youtube.com/watch?v=NFBzd21JESE#)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Smokin Joe on March 20, 2020, 05:44:09 am

Quote from: PeteS in CA on March 19, 2020, 05:06:36 pm

https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_pdf/-char/en (https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_pdf/-char/en)

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Related: French study finds anti-malarial and antibiotic combo could reduce COVID-19 duration
https://techcrunch.com/2020/03/19/french-study-finds-anti-malarial-and-antibiotic-combo-could-reduce-covid-19-duration/ (https://techcrunch.com/2020/03/19/french-study-finds-anti-malarial-and-antibiotic-combo-could-reduce-covid-19-duration/)

Dated March 19.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 20, 2020, 09:52:47 pm

Jackpot!

https://pjmedia.com/trending/timeline-the-trump-administrations-decisive-actions-to-combat-the-coronavirus-pandemic/

TIMELINE: The Trump Administration's Decisive Actions To Combat the Coronavirus Pandemic
BY MATT MARGOLIS MARCH 19, 2020

Quote

The liberal media digs up various “experts” to trash him. Democrats, including presidential candidates, repeat lies about the Trump administration’s response, and you can’t go anywhere on social media without seeing liberal minions regurgitating disinformation or just by default trashing anything the administration does.

But, the truth of the Trump administration's response is far different from the picture they’re trying to paint. When the World Health Organization was first alerted to the virus, Democrats were in the middle of their impeachment witch hunt, but Trump was taking action immediately to protect Americans. Most of these actions probably went unnoticed because of the media's and Democrats' obsession with impeachment. The Trump campaign posted a timeline of events relating to the coronavirus that shows definitively how the Trump administration has been taking charge of the situation from the earliest days through the present, which I will post below:

Looks like lots of good stuff for my OP timeline, and some digging on my part to find articles that nail down the dates.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Cyber Liberty on March 22, 2020, 07:57:58 pm

I put up a poll:

For How Long Do You Expect To Be "Socially Isolated?" (http://www.gopbriefingroom.com/index.php/topic,395692.0.html)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Texas Yellow Rose on March 23, 2020, 12:48:36 am

Quote from: PeteS in CA on March 19, 2020, 05:06:36 pm

https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_pdf/-char/en (https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_pdf/-char/en)

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Dr William Grace, Oncologist, is using Hydroxychloroquine a less toxic version of Chloroquine.

https://therightscoop.com/watch-ny-doctor-says-his-hospital-already-using-chloroquine-for-coronavirus-patients-and-have-had-zero-deaths/?fbclid=IwAR3N4Ctiz6APtlWzYDmzIQqkWUyloVpUs6dgb067YckFopyejGRAB5ZCIoQ (https://therightscoop.com/watch-ny-doctor-says-his-hospital-already-using-chloroquine-for-coronavirus-patients-and-have-had-zero-deaths/?fbclid=IwAR3N4Ctiz6APtlWzYDmzIQqkWUyloVpUs6dgb067YckFopyejGRAB5ZCIoQ)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Smokin Joe on March 24, 2020, 08:18:12 am

Quote from: Texas Yellow Rose on March 23, 2020, 12:48:36 am

Dr William Grace, Oncologist, is using Hydroxychloroquine a less toxic version of Chloroquine.

https://therightscoop.com/watch-ny-doctor-says-his-hospital-already-using-chloroquine-for-coronavirus-patients-and-have-had-zero-deaths/?fbclid=IwAR3N4Ctiz6APtlWzYDmzIQqkWUyloVpUs6dgb067YckFopyejGRAB5ZCIoQ (https://therightscoop.com/watch-ny-doctor-says-his-hospital-already-using-chloroquine-for-coronavirus-patients-and-have-had-zero-deaths/?fbclid=IwAR3N4Ctiz6APtlWzYDmzIQqkWUyloVpUs6dgb067YckFopyejGRAB5ZCIoQ)

Some where I read it was being used in concert with Zithromax, with great success. I can see wanting a prophylactic antibiotic while the immune system is depressed and the patient has lungs full of fluid, just to prevent opportunistic bacterial infections.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 24, 2020, 04:35:20 pm

In addition to the Japanese study/paper linked up-thread,

https://docs.google.com/document/d/e/2PACX-1vR1adodKPhWalV9djnerI2x_v1LGgGyhZZxpl0O5r-ZNyDdagqFq1rTCxXBqaeicfxgvypDOqKCZVyV/pub (https://docs.google.com/document/d/e/2PACX-1vR1adodKPhWalV9djnerI2x_v1LGgGyhZZxpl0O5r-ZNyDdagqFq1rTCxXBqaeicfxgvypDOqKCZVyV/pub)   (this is in Spanish)

https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR2JbbZU_Hl7uLjuOTDhrNnmczzyEFvnIhY8QHv9ghY5fYBvX0IsmnhD07w (https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR2JbbZU_Hl7uLjuOTDhrNnmczzyEFvnIhY8QHv9ghY5fYBvX0IsmnhD07w)

The Trump-Haters of DU have transitioned from Full-CT to Trump-Hatred-Alternate-Universe over the prospect of lives being saved during Trump's Presidency:

https://www.democraticunderground.com/100213140100 (https://www.democraticunderground.com/100213140100)

Quote

milestogo (7,613 posts)

This is what happens when you take medical advice from a lying fool:

Coronavirus prevention: Nigeria's Lagos state battling chloroquine poisoning

and

https://www.democraticunderground.com/100213160752 (https://www.democraticunderground.com/100213160752)

Quote

Stuart G (25,256 posts)

If Trump is promoting a useless drug, then in my opinion, it is an impeachable offense.

..If Trump has been told it is useless by experts who know, then that is it, and that is all.

Quote

Wounded Bear (34,766 posts)

1. Not just useles, it's bleep dangerous...

Re the post by "Wounded Bear": his F-bomb is uncensored on DU; he does admit that Chloroquine is under serious study; he lyingly claimed Trump represents Chloroquine as a "miracle cure".

DU-grade Progs seem to be in Alternate-Universe-grade denial about the possibilities of Chloroquine. I'm tempted to use the ROFL emoji, but hate-driven morons like them could kill people by persuading them to refuse treatment with Chloroquine (if it is proved effective).

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Cyber Liberty on March 24, 2020, 04:56:13 pm

Quote from: PeteS in CA on March 24, 2020, 04:35:20 pm

In addition to the Japanese study/paper linked up-thread,

https://docs.google.com/document/d/e/2PACX-1vR1adodKPhWalV9djnerI2x_v1LGgGyhZZxpl0O5r-ZNyDdagqFq1rTCxXBqaeicfxgvypDOqKCZVyV/pub (https://docs.google.com/document/d/e/2PACX-1vR1adodKPhWalV9djnerI2x_v1LGgGyhZZxpl0O5r-ZNyDdagqFq1rTCxXBqaeicfxgvypDOqKCZVyV/pub)   (this is in Spanish)

https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR2JbbZU_Hl7uLjuOTDhrNnmczzyEFvnIhY8QHv9ghY5fYBvX0IsmnhD07w (https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR2JbbZU_Hl7uLjuOTDhrNnmczzyEFvnIhY8QHv9ghY5fYBvX0IsmnhD07w)

The Trump-Haters of DU have transitioned from Full-CT to Trump-Hatred-Alternate-Universe over the prospect of lives being saved during Trump's Presidency:

https://www.democraticunderground.com/100213140100 (https://www.democraticunderground.com/100213140100)

and

https://www.democraticunderground.com/100213160752 (https://www.democraticunderground.com/100213160752)

Re the post by "Wounded Bear": his F-bomb is uncensored on DU; he does admit that Chloroquine is under serious study; he lyingly claimed Trump represents Chloroquine as a "miracle cure".

DU-grade Progs seem to be in Alternate-Universe-grade denial about the possibilities of Chloroquine. I'm tempted to use the ROFL emoji, but hate-driven morons like them could kill people by persuading them to refuse treatment with Chloroquine (if it is proved effective).

I think a couple of the posters on the DUmmy threads are candidates for the Skinner Tombstone.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Smokin Joe on March 24, 2020, 09:50:31 pm

Quote from: PeteS in CA on March 24, 2020, 04:35:20 pm

In addition to the Japanese study/paper linked up-thread,

https://docs.google.com/document/d/e/2PACX-1vR1adodKPhWalV9djnerI2x_v1LGgGyhZZxpl0O5r-ZNyDdagqFq1rTCxXBqaeicfxgvypDOqKCZVyV/pub (https://docs.google.com/document/d/e/2PACX-1vR1adodKPhWalV9djnerI2x_v1LGgGyhZZxpl0O5r-ZNyDdagqFq1rTCxXBqaeicfxgvypDOqKCZVyV/pub)   (this is in Spanish)

https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR2JbbZU_Hl7uLjuOTDhrNnmczzyEFvnIhY8QHv9ghY5fYBvX0IsmnhD07w (https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR2JbbZU_Hl7uLjuOTDhrNnmczzyEFvnIhY8QHv9ghY5fYBvX0IsmnhD07w)

The Trump-Haters of DU have transitioned from Full-CT to Trump-Hatred-Alternate-Universe over the prospect of lives being saved during Trump's Presidency:

https://www.democraticunderground.com/100213140100 (https://www.democraticunderground.com/100213140100)

and

https://www.democraticunderground.com/100213160752 (https://www.democraticunderground.com/100213160752)

Re the post by "Wounded Bear": his F-bomb is uncensored on DU; he does admit that Chloroquine is under serious study; he lyingly claimed Trump represents Chloroquine as a "miracle cure".

DU-grade Progs seem to be in Alternate-Universe-grade denial about the possibilities of Chloroquine. I'm tempted to use the ROFL emoji, but hate-driven morons like them could kill people by persuading them to refuse treatment with Chloroquine (if it is proved effective).

I would be surprised if the Kenyan medical community was not familiar with an antimalarial drug and its potential side effects.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on March 29, 2020, 05:53:26 pm

I just posted a fairly substantial update to my OP timeline.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on April 05, 2020, 06:15:46 pm

Re the info-dump below, the main sources are:

https://www.axios.com/timeline-the-early-days-of-chinas-coronavirus-outbreak-and-cover-up-ee65211a-afb6-4641-97b8-353718a5faab.html (https://www.axios.com/timeline-the-early-days-of-chinas-coronavirus-outbreak-and-cover-up-ee65211a-afb6-4641-97b8-353718a5faab.html)

https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back (https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back)

https://www.nationalreview.com/the-morning-jolt/chinas-devastating-lies/ (https://www.nationalreview.com/the-morning-jolt/chinas-devastating-lies/)

https://crsreports.congress.gov/product/pdf/R/R46354 (https://crsreports.congress.gov/product/pdf/R/R46354)

https://www.hudson.org/features/coronavirus (https://www.hudson.org/features/coronavirus)

First some notes. I double-checked the source for each listed event.

* The first event on National Review's list (12/6) is not confirmed by the linked Lancet article. There is nothing resembling what NR quoted, supposedly from Lancet. While some Prog orgs claim NR lied, my guess is that either Lancet edited their article or the incorrect link is in NR's article. Other sources have information consistent with or ante-dating NR's 12/6 date.

* The South China Morning Post is over a century old, and is based in Hong Kong. The Straits Times is ~175 years old and is based in Singapore. Their information is vaguely sourced, to some degree, that's the nature of getting information from inside China.

* Some of NR's source articles are behind paywalls. While I found alternative sources for some, others I simply omitted. I won't support paywalls by paying or linking blocked information.

* Some source articles are Chinese language. I used Google Translate to verify the content.

* The Congressional Research Service article is long. The timeline is some 29 pages long and incredibly detailed. It provides footnotes for every entry, but some of the urls have typos. As best I know, all of the urls in my timeline below are valid.

So, put down your coffee and hold on to your seat:

Late summer and early fall 2019 (September/October) - Satellite picture showed a large spike in auto traffic around Wuhan hospitals indicating some sort of significant health-related event; https://abcnews.go.com/International/satellite-data-suggests-coronavirus-hit-china-earlier-researchers/story?id=71123270 (https://abcnews.go.com/International/satellite-data-suggests-coronavirus-hit-china-earlier-researchers/story?id=71123270) , https://webcache.googleusercontent.com/search?q=cache:k5nQb5uZcJAJ:https://www.theepochtimes.com/china-saw-covid-19-like-patients-months-before-official-timeline-internal-documents_3537965.html+&cd=1&hl=en&ct=clnk&gl=us (https://webcache.googleusercontent.com/search?q=cache:k5nQb5uZcJAJ:https://www.theepochtimes.com/china-saw-covid-19-like-patients-months-before-official-timeline-internal-documents_3537965.html+&cd=1&hl=en&ct=clnk&gl=us)
https://www.theepochtimes.com/china-saw-covid-19-like-patients-months-before-official-timeline-internal-documents_3537965.html (https://www.theepochtimes.com/china-saw-covid-19-like-patients-months-before-official-timeline-internal-documents_3537965.html)

October 7-24, 2019 - No cellphone activity detected in a high security area of the Wuhan Institute of Virology; this suggests the possibility of a contamination event that triggered a shutdown for decontamination; this may or may not be relevant to the outbreak in Wuhan, but the it is possible that this was the origin of the outbreak; https://www.nbcnews.com/politics/national-security/report-says-cellphone-data-suggests-october-shutdown-wuhan-lab-experts-n1202716 (https://www.nbcnews.com/politics/national-security/report-says-cellphone-data-suggests-october-shutdown-wuhan-lab-experts-n1202716)

November 17, 2019 - Possible first contraction of coronavirus (9 cases reported in November); https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back (https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back)  Earlier? https://www.scmp.com/news/china/science/article/3080380/coronavirus-outbreak-may-have-started-september-say-british (https://www.scmp.com/news/china/science/article/3080380/coronavirus-outbreak-may-have-started-september-say-british)

November 2019 - Nine cases reported; https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back (https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back)

December 1, 2019 - Pneumonia patients in study published by Lancet, earliest illness onset; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext) , https://www.cdc.gov/coronavirus/2019-ncov/downloads/Huang-2019-nCoV-clinical-features-Lancet-1-24-2020.pdf (https://www.cdc.gov/coronavirus/2019-ncov/downloads/Huang-2019-nCoV-clinical-features-Lancet-1-24-2020.pdf)

December 8, 2019 - Pneumonia patients in study published by NEJM, earliest illness onset; https://www.nejm.org/doi/10.1056/NEJMoa2001316 (https://www.nejm.org/doi/10.1056/NEJMoa2001316) , http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 (http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51)

December 10, 2019 - Early Wuhan patient Wei Guixian starts feeling ill; https://www.wsj.com/articles/how-it-all-started-chinas-early-coronavirus-missteps-11583508932 (https://www.wsj.com/articles/how-it-all-started-chinas-early-coronavirus-missteps-11583508932)

December 12, 2019 - Pneumonia patients in study published by NEJM, at least one early admission; https://www.nejm.org/doi/10.1056/NEJMoa2001316 (https://www.nejm.org/doi/10.1056/NEJMoa2001316)

December 16, 2019 - Pneumonia patients studied by Lancet, at least one early admission; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)

December 19, 2019 - Pneumonia patients studied by NEJM, earliest patient with infected person contact, not the meat market; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)

December 21, 2019 - Cluster of pneumonia cases in Wuhan recognized; http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c (http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c)

December 25, 2019 - Recognition of infection of hospital staff reported; https://mp.weixin.qq.com/s/IzzCnz4Yr2jEIYZePiu_ow (https://mp.weixin.qq.com/s/IzzCnz4Yr2jEIYZePiu_ow)  (Chinese language)

December 27, 2019 - Guangzhou genomics company (one of several) partly sequence virus DNA, recognized as similar to SARS (a corona virus); https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china (https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china)

December 27, 2019 - Zhang Jixian, a doctor at a Hubei Provincial hospital informed health authorities it was a new coronavirus; https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back (https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back) , http://www.xinhuanet.com/english/2020-04/16/c_138982435.htm (http://www.xinhuanet.com/english/2020-04/16/c_138982435.htm)

December 27, 2019 - Vision Medicals, the genomics company to which Wuhan Central Hospital sent samples from a patient on December 24, calls with the results; According to Dr. Zhao Su, “They just called us and said it was a new coronavirus”; https://www.caixinglobal.com/2020-02-29/in-depth-how-early-signs-of-a-sars-like-virus-were-spotted-spread-and-throttled-101521745.html (https://www.caixinglobal.com/2020-02-29/in-depth-how-early-signs-of-a-sars-like-virus-were-spotted-spread-and-throttled-101521745.html)

December 29, 2019 - BGI Genomics is the first known entity to complete sequencing of the novel coronavirus virus,
based on the sample sent to it on December 26; https://www.caixinglobal.com/2020-02-29/in-depth-how-early-signs-of-a-sars-like-virus-were-spotted-spread-and-throttled-101521745.html (https://www.caixinglobal.com/2020-02-29/in-depth-how-early-signs-of-a-sars-like-virus-were-spotted-spread-and-throttled-101521745.html)

December 30, 2019 - Ai Fen, director of Wuhan Central Hospital, posted a WeChat message about the new SARS-like virus and reprimanded; https://www.theguardian.com/world/2020/mar/11/coronavirus-wuhan-doctor-ai-fen-speaks-out-against-authorities (https://www.theguardian.com/world/2020/mar/11/coronavirus-wuhan-doctor-ai-fen-speaks-out-against-authorities)

December 30, 2019 - Li Wenliang sent WeChat message to fellow doctors, warning to protect themselves from infection; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30382-2/fulltext (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30382-2/fulltext)

December 31, 2019 - Wuhan Municipal Health Commission claimed no evidence of human-human transmission or infected medical staff; http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989 (http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989)  (Chinese language, second paragraph)

December 30, 2019 (12/31, China) - Wuhan Municipal Health Commission issued an “urgent notice” intended only for medical institutions in Wuhan  ordering hospitals to compile statistics on all cases of pneumonia of unknown cause admitted in the previous week and report them by email, 3:10 PM, China time; the notice is leaked online within 12 minutes; Wuhan Municipal Health Commission issued a second “urgent notice” to medical institutions, instructing them on how to manage patients, 6:50 PM, China time; the notice is leaked online within 10 minutes; http://www.bjnews.com.cn/news/2019/12/31/668421.html (http://www.bjnews.com.cn/news/2019/12/31/668421.html) , http://www.ccdi.gov.cn/toutiao/202003/t20200319_213880.html (http://www.ccdi.gov.cn/toutiao/202003/t20200319_213880.html) (both, Chinese language; China is on the other side of the International dateline)

December 30, 2019 (12/31, China) - A listserv Program for Monitoring Emerging Diseases (ProMED) user posted a machine translation of Yicai’s article, 11:59 PM EST (December 30, US)/12:59 PM China time (December 31, China); https://promedmail.org/promed-post/?id=6864153 (https://promedmail.org/promed-post/?id=6864153)

December 31, 2019 - Yicai, the financial news arm of state-owned Shanghai Media Group, and Xin Jing Bao, another Chinese news organization, confirmed the authenticity of the documents with Wuhan CDC, and published reports, December 31, 2019 morning China time; https://www.yicai.com/news/100451932.html (https://www.yicai.com/news/100451932.html) , http://www.bjnews.com.cn/news/2019/12/31/668430.html (http://www.bjnews.com.cn/news/2019/12/31/668430.html) (both, Chinese language; China is on the other side of the International dateline)

December 31, 2019 - Wuhan Municipal Health Commission posted its first public statement on the outbreak, December 31, 2019 1:38 PM China time; https://www.ecdc.europa.eu/sites/default/files/documents/Risk%20assessment%20-%20pneumonia%20Wuhan%20China%2017%20Jan%202020.pdf (https://www.ecdc.europa.eu/sites/default/files/documents/Risk%20assessment%20-%20pneumonia%20Wuhan%20China%2017%20Jan%202020.pdf)

December 31, 2019 - WHO headquarters in Geneva found a translation of a Chinese news report on ProMED about the outbreak in Wuhan,  requested WHO China Country Office to follow up with Chinese authorities; WHO's China office found a Wuhan Municipal Health Commission media statement about the outbreak in Wuhan; December 31, 2019; https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-20apr2020.pdf?sfvrsn=b5656a70_2 (https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-20apr2020.pdf?sfvrsn=b5656a70_2) (00:16:31) ; https://www.who.int/news-room/detail/29-06-2020-covidtimeline (https://www.who.int/news-room/detail/29-06-2020-covidtimeline)

January 1, 2020 - Genomics company employee ordered by Hubei Provincial Health Commission official to stop testing and destroy samples; https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china (https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china)

January 2, 2020 - 14 of 41 studied patients had no direct connection to the Huanan seafood market; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)

January 2, 2020 - A doctor in Wuhan advised her hospital to set up a special clinic normally used for patients who are infectious and could transmit their disease; https://mp.weixin.qq.com/s/IzzCnz4Yr2jEIYZePiu_ow (https://mp.weixin.qq.com/s/IzzCnz4Yr2jEIYZePiu_ow)  (Chinese language)

January 2, 2020 - Just after 8 AM China time, a senior official of Wuhan Central Hospital subjects Dr. Ai Fen to what she later describes as “an unprecedented and very severe rebuke.” The official tells her not to speak to anyone, including her husband, about the pneumonia cases; https://tinyurl.com/sggfhq8 (https://tinyurl.com/sggfhq8) (Chinese language)

January 2, 2020 (China) - Using samples from Wuhan’s Jinyintan Hospital, the Wuhan Institute of Virology identifies the novel coronavirus and sequences its genome; https://www.wsj.com/articles/how-it-all-started-chinas-early-coronavirus-missteps11583508932 (https://www.wsj.com/articles/how-it-all-started-chinas-early-coronavirus-missteps11583508932) (behind paywall)

January 3, 2020 (China) - China's National Health Commission ordered institutions not to publish any information and ordered labs to transfer samples to testing institutions (without designating an institution) or to destroy them; https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china (https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china)

January 3, 2020 (China) - Wuhan Municipal Health Commission claimed no evidence of human-human transmission or infected medical staff; http://wjw.wuhan.gov.cn/front/web/showDetail/2020010309017 (http://wjw.wuhan.gov.cn/front/web/showDetail/2020010309017)  (Chinese language)

January 3, 2020 (China) - Li Wenliang detained by Wuhan police for "spreading false rumors"; https://www.theguardian.com/global-development/2020/feb/07/coronavirus-chinese-rage-death-whistleblower-doctor-li-wenliang (https://www.theguardian.com/global-development/2020/feb/07/coronavirus-chinese-rage-death-whistleblower-doctor-li-wenliang)  Died of Covid-19, February 7, 2020

January 5, 2020 (China) - Team led by Prof. Yong-zhen Zhang of Fudan University in Shanghai identified a novel coronavirus and sequenced its genome; https://www.thehindu.com/sci-tech/health/shanghai-lab-that-first-sequenced-coronavirus-genome-shut-down/article30951570.ece (https://www.thehindu.com/sci-tech/health/shanghai-lab-that-first-sequenced-coronavirus-genome-shut-down/article30951570.ece)

January 5, 2020 (China) - Wuhan Municipal Health Commission claimed no evidence of human-human transmission or infected medical staff; http://wjw.wuhan.gov.cn/front/web/showDetail/2020010509020 (http://wjw.wuhan.gov.cn/front/web/showDetail/2020010509020)  (Chinese language)

January 5, 2020 -  WHO statement, “Based on the preliminary information from the Chinese investigation team, no evidence of significant human-to-human transmission and no health care worker infections have been reported”; https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/)

January 5, 2020 - WHO advises: "WHO does not recommend any specific measures for travellers"; "WHO advises against the application of any travel or trade restrictions on China based on the current information available on this event"; https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/)

January 6, 2020 (China) - Wuhan Municipal People’s Congress opens - five days involving 515 of the city’s most important citizens, including the city’s entire top leadership; 2020, https://chinamediaproject.org/2020/02/10/questions-for-hubeis-delegates/ (https://chinamediaproject.org/2020/02/10/questions-for-hubeis-delegates/)

January 7, 2020 (China) - A China CDC team sequences the genome of the novel coronavirus. CCTV announced this on January 9; http://news.cctv.com/2020/01/09/ARTI1qaoXDCwfiFM5UPAnNy9200109.shtml (http://news.cctv.com/2020/01/09/ARTI1qaoXDCwfiFM5UPAnNy9200109.shtml) (Chinese language)

January 7, 2020 - Fudan University team submited an article to the peer-reviewed journal Nature detailing the team’s sequencing of the novel coronavirus; (published January 28); https://www.nature.com/articles/s41586-020-2008-3.pdf (https://www.nature.com/articles/s41586-020-2008-3.pdf)

January 8, 2020 - US and Chinese CDC Directors speak by phone about “technological exchanges and cooperation,” according to China’s official timeline; http://www.xinhuanet.com/english/2020-04/06/c_138951662.htm (http://www.xinhuanet.com/english/2020-04/06/c_138951662.htm)

January 9, 2020 - "WHO advises against the application of any travel or trade restrictions on China based on the information currently available"; https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china (https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china)

January 10, 2020 (China) - Wuhan Institute of Virology and other institutions have produced testing kits; http://www.xinhuanet.com/english/2020-04/06/c_138951662.htm (http://www.xinhuanet.com/english/2020-04/06/c_138951662.htm)

January 10, 2020 (China) - After unknowingly treating a patient with coronavirus, Li Wenliang had symptoms; https://www.bbc.com/news/world-asia-china-51403795 (https://www.bbc.com/news/world-asia-china-51403795) (human-human transmission!)

January 10, 2020 - WHO statement, "It is generally considered that entry screening offers little benefit" ... "From the currently available information, preliminary investigation suggests that there is no significant human-to-human transmission, and no infections among health care workers have occurred" and "WHO advises against the application of any travel or trade restrictions on China based on the information currently available on this event"; https://www.who.int/news-room/articles-detail/who-advice-for-international-travel-and-trade-in-relation-to-the-outbreak-of-pneumonia-caused-by-a-new-coronavirus-in-china (https://www.who.int/news-room/articles-detail/who-advice-for-international-travel-and-trade-in-relation-to-the-outbreak-of-pneumonia-caused-by-a-new-coronavirus-in-china)

January 11, 2020 (China) - Team from Fudan University in Shanghai shared the genomic sequence of the novel coronavirus with the world; https://twitter.com/edwardcholmes/status/1215802670176276482?s=20 (https://twitter.com/edwardcholmes/status/1215802670176276482?s=20) , http://virological.org/t/novel-2019-coronavirus-genome/319 (http://virological.org/t/novel-2019-coronavirus-genome/319)

January 10, 2020 - WHO tweeted, “WHO has received the genetic sequences for the novel #coronavirus (2019-nCoV) from the Chinese authorities"; https://twitter.com/WHO/status/1216108498188230657 (https://twitter.com/WHO/status/1216108498188230657)

January 11, 2020 (China) - Wuhan Municipal Health Commission claimed no evidence of human-human transmission or infected medical staff; http://wjw.wuhan.gov.cn/front/web/showDetail/2020011109035 (http://wjw.wuhan.gov.cn/front/web/showDetail/2020011109035)  (Chinese language)

January 12, 2020 - WHO claimed, "At this stage, there is no infection among healthcare workers, and no clear evidence of human to human transmission"; https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)

January 12, 2020 - WHO advises against the application of any travel or trade restrictions on China; https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)

January 13, 2020 - WHO claimed "there has been no suggestion of human to human transmission of this new coronavirus"; https://www.who.int/thailand/news/detail/13-01-2020-thailand-responding-to-the-novel-coronavirus (https://www.who.int/thailand/news/detail/13-01-2020-thailand-responding-to-the-novel-coronavirus)

January 14, 2020 - Head of China’s National Health Commission, Ma Xiaowei, gave an assessment of the situation in a confidential teleconference with provincial health officials; according to a memo obtained by AP, he commented to the effect that "clustered cases suggest that human-to-human transmission is possible"; https://apnews.com/68a9e1b91de4ffc166acd6012d82c2f9 (https://apnews.com/68a9e1b91de4ffc166acd6012d82c2f9)

January 14, 2020 (China) - Wuhan Municipal Health Commission claimed no cases among related contacts; http://wjw.wuhan.gov.cn/front/web/showDetail/2020011409039 (http://wjw.wuhan.gov.cn/front/web/showDetail/2020011409039)  (Chinese language)

January 14, 2020 - WHO claimed "there is no clear evidence of human-to-human transmission"; https://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand-ex-china/en/ (https://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand-ex-china/en/)

January 14, 2020 - WHO claimed no evidence of  human to human transmission of corona virus; https://twitter.com/WHO/status/1217043229427761152 (https://twitter.com/WHO/status/1217043229427761152) , "World Health Organization (WHO)
@WHO
Jan 14
Preliminary investigations conducted by the Chinese authorities have found no clear evidence of human-to-human transmission of the novel #coronavirus (2019-nCoV) identified in #Wuhan, #China."

January 15, 2020 (China) - Wuhan Municipal Health Commission claimed, "Existing investigative results indicate no clear evidence of person-to-person transmission. We cannot rule out the possibility of limited person-to-person transmission, but the risk of sustained person-to-person transmission is low"; http://wjw.wuhan.gov.cn/front/web/showDetail/2020011509040 (http://wjw.wuhan.gov.cn/front/web/showDetail/2020011509040) , http://wjw.wuhan.gov.cn/xwzx_28/gsgg/202004/t20200430_1199594.shtml (http://wjw.wuhan.gov.cn/xwzx_28/gsgg/202004/t20200430_1199594.shtml) (Chinese language)

January 15, 2020 - WHO Western Pacific Tweeted, "According to the latest information we have, there is no clear evidence of sustained human-to-human transmission and there are no infections reported among health care workers."; https://twitter.com/WHOWPRO/status/1217646741677166593 (https://twitter.com/WHOWPRO/status/1217646741677166593)

January 15, 2020 - First confirmed US case left Wuhan to come to the US; confirmed January 21, 2020, https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html (https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html)

Mid-January, 2020 - Chinese consulates around the world were instructed to purchase massive quantities of PPE, especially masks; at the same time China and WHO were still stating publicly there was no evidence of human-human transmission; https://globalnews.ca/news/6858818/coronavirus-china-united-front-canada-protective-equipment-shortage/ (https://globalnews.ca/news/6858818/coronavirus-china-united-front-canada-protective-equipment-shortage/)

January 16, 2020 - WHO advises against the application of any travel or trade restrictions; https://www.who.int/csr/don/16-january-2020-novel-coronavirus-japan-ex-china/en/ (https://www.who.int/csr/don/16-january-2020-novel-coronavirus-japan-ex-china/en/)

January 17, 2020 (China) - Wuhan Municipal Health Commission claimed no cases among related contacts; http://wjw.wuhan.gov.cn/front/web/showDetail/2020011809064 (http://wjw.wuhan.gov.cn/front/web/showDetail/2020011809064)  (Chinese language)

January 18, 2020 (China) - Tens of thousands gather for Wuhan's Lunar New Year banquet; https://www.thestar.com.my/news/regional/2020/02/06/wuhan-neighbourhood-sees-infections-after-40000-families-gather-for-potluck (https://www.thestar.com.my/news/regional/2020/02/06/wuhan-neighbourhood-sees-infections-after-40000-families-gather-for-potluck) , http://www.chinanews.com/sh/2020/01-19/9064003.shtml (http://www.chinanews.com/sh/2020/01-19/9064003.shtml)  (Chinese language)

January 19, 2020 - China and WHO claim that how the virus is transmitted is unknown; https://www.bbc.com/news/health-51168333 (https://www.bbc.com/news/health-51168333)

January 19/20, 2020 (China) - Wuhan Municipal Health Commission claimed no cases among related contacts; 2020, http://wjw.wuhan.gov.cn/front/web/showDetail/2020012009077 (http://wjw.wuhan.gov.cn/front/web/showDetail/2020012009077)  (Chinese language)

January 20, 2020 - Wuhan establishes a “Novel Coronavirus Infection Pneumonia Epidemic Prevention and Control Command Center” headed by Wuhan Mayor Zhou Xianwang; http://www.xinhuanet.com/2020-01/21/c_1125487978.htm (http://www.xinhuanet.com/2020-01/21/c_1125487978.htm)

January 20, 2020 - First acknowledgement by China and WHO of human-human transmission of coronavirus; https://abcnews.go.com/Health/human-human-transmission-coronavirus-reported-china/story?id=68403105 (https://abcnews.go.com/Health/human-human-transmission-coronavirus-reported-china/story?id=68403105) , https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china (https://www.straitstimes.com/asia/east-asia/how-early-signs-of-the-coronavirus-were-spotted-spread-and-throttled-in-china)

January 22, 2020 - Head of Chinese National Health Commission’s High-Level Expert Group, Dr. Zhong Nanshan, publicly confirms for the first time that the novel coronavirus is being transmitted from person to person and that medical personnel have been infected; https://abcnews.go.com/Health/human-human-transmission-coronavirus-reported-china/story?id=68403105 (https://abcnews.go.com/Health/human-human-transmission-coronavirus-reported-china/story?id=68403105)

January 22, 2020 - WHO delegation reported human-human transmission had happened (January 20-21), announced by WHO; https://www.who.int/china/news/detail/22-01-2020-field-visit-wuhan-china-jan-2020 (https://www.who.int/china/news/detail/22-01-2020-field-visit-wuhan-china-jan-2020)

January 22, 2020 - WHO Emergency Committee convened under the International Health Regulations (2005) is unable to reach consensus on whether the outbreak constitutes a Public Health Emergency of International Concern; The committee requests to reconvene in 10 days’ time; https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) (https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))

January 23, 2020 (China) - Wuhan and other cities in Hubei Province shut down travel; http://m.news.cctv.com/2020/01/20/ARTIF4Fl7LEu8TRqIsnde93B200120.shtml (http://m.news.cctv.com/2020/01/20/ARTIF4Fl7LEu8TRqIsnde93B200120.shtml) (Chinese language) , http://www.mot.gov.cn/jiaotongyaowen/202001/t20200123_3328008.html (http://www.mot.gov.cn/jiaotongyaowen/202001/t20200123_3328008.html) (Chinese language) , https://news.cgtn.com/news/2020-01-27/5-million-people-left-Wuhan-before-the-lockdown-where-did-they-go--NACCu9wItW/index.html (https://news.cgtn.com/news/2020-01-27/5-million-people-left-Wuhan-before-the-lockdown-where-did-they-go--NACCu9wItW/index.html)

January 23, 2020 (China) - The provinces of Zhejiang, Guangdong, and Hunan are the first to raise their public health emergency response levels to Level I), the highest of four levels in China’s public health emergency management system; The Level I alert makes provincial governments responsible for coordinating emergency measures; https://www.chinadaily.com.cn/a/202001/25/WS5e2c02e3a310128217273375.html (https://www.chinadaily.com.cn/a/202001/25/WS5e2c02e3a310128217273375.html) , http://www.ccdi.gov.cn/toutiao/202001/t20200124_210321.html (http://www.ccdi.gov.cn/toutiao/202001/t20200124_210321.html) (Chinese language)

January 24, 2020 - WHO updates its advice for international travelers; on January 10 it advised against entry screening for travelers, it now notes that “the majority of exported cases were detected through entry screening”; https://www.who.int/news-room/articles-detail/updated-who-advice-for-international-traffic-in-relation-to-the-outbreak-of-the-novel-coronavirus-2019-ncov (https://www.who.int/news-room/articles-detail/updated-who-advice-for-international-traffic-in-relation-to-the-outbreak-of-the-novel-coronavirus-2019-ncov)

January 24, 2020 - "WHO advises against the application of any restrictions of international traffic"; https://www.who.int/news-room/articles-detail/updated-who-advice-for-international-traffic-in-relation-to-the-outbreak-of-the-novel-coronavirus-2019-ncov-24-jan/ (https://www.who.int/news-room/articles-detail/updated-who-advice-for-international-traffic-in-relation-to-the-outbreak-of-the-novel-coronavirus-2019-ncov-24-jan/)

January 25, 2020 (China) - China’s Politburo Standing Committee meets for the third time since January 7, the first meeting at which the novel coronavirus is contemporaneously acknowledged to be on the agenda; http://www.xinhuanet.com/english/2020-01/25/c_138733753.htm (http://www.xinhuanet.com/english/2020-01/25/c_138733753.htm)

January 25, 2020 (China) - 30 of mainland China’s 31 provincial-level jurisdictions have raised their public health alerts to Level I (Tibet is the exception); http://www.bjnews.com.cn/news/2020/01/26/679868.html (http://www.bjnews.com.cn/news/2020/01/26/679868.html) (Chinese language)

January 26, 2020 (China) - Communist Party of China announced a new top-level Party body for combating the epidemic; Premier Li Keqiang, the Party’s second-most senior official, heads the body; https://jamestown.org/program/the-ccps-new-leading-small-group-for-countering-the-coronavirus-epidemic-and-the-mysterious-absence-of-xi-jinping/ (https://jamestown.org/program/the-ccps-new-leading-small-group-for-countering-the-coronavirus-epidemic-and-the-mysterious-absence-of-xi-jinping/)

January 27, 2020 (China) - Wuhan Mayor Zhou Xianwang acknowledges (on national TV) having failed to disclose information “in a timely manner”, estimated that 5 million people left Wuhan before travel restrictions went into effect; https://gaodawei.wordpress.com/2020/01/27/wuhan-mayor-zhou-reporting-delays-caused-by-center-i-acted-fast-once-i-got-authorization/ (https://gaodawei.wordpress.com/2020/01/27/wuhan-mayor-zhou-reporting-delays-caused-by-center-i-acted-fast-once-i-got-authorization/)

January 27, 2020 - WHO advises against the application of any restrictions of international traffic; https://www.who.int/news-room/articles-detail/updated-who-advice-for-international-traffic-in-relation-to-the-outbreak-of-the-novel-coronavirus-2019-ncov (https://www.who.int/news-room/articles-detail/updated-who-advice-for-international-traffic-in-relation-to-the-outbreak-of-the-novel-coronavirus-2019-ncov)

January 28, 2020 (China) - Xi Jinping and WHO Director-General Tedros Adhanom Ghebreyesus meet in Beijing; WHO requests that China “share biological material with WHO,” indicating China has not shared biological samples with WHO;, https://www.who.int/news-room/detail/28-01-2020-who-china-leaders-discuss-next-steps-in-battle-against-coronavirus-outbreak (https://www.who.int/news-room/detail/28-01-2020-who-china-leaders-discuss-next-steps-in-battle-against-coronavirus-outbreak)

January 28, 2020 - WHO raises its global level risk assessment to “high,” one rung below its “very high” risk assessment for China; https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200128-sitrep-8-ncov-cleared.pdf (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200128-sitrep-8-ncov-cleared.pdf)

January 30, 2020 - WHO Director-General Tedros states, "WHO doesn’t recommend limiting trade and movement"; https://www.who.int/dg/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov) (https://www.who.int/dg/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov))

January 30, 2020 - World Health Organization declared coronavirus a public health emergency of international concern; https://www.cnn.com/2020/01/30/health/coronavirus-who-public-health-emergency-international-concern-declaration/index.html (https://www.cnn.com/2020/01/30/health/coronavirus-who-public-health-emergency-international-concern-declaration/index.html)

January 31, 2020 - WHO spokesperson Tarik Jašarevic stated that travel restrictions are "not something that WHO usually recommends"; https://www.statnews.com/2020/01/31/as-far-right-calls-for-china-travel-ban-health-experts-warn-coronavirus-response-would-suffer/ (https://www.statnews.com/2020/01/31/as-far-right-calls-for-china-travel-ban-health-experts-warn-coronavirus-response-would-suffer/)

February 2, 2020 (China) - Gauden Galea, WHO representative in China, told CCTV that the World Health Organization did not find enough evidence to impose restrictions on China's travel and trade; https://news.cgtn.com/news/2020-02-01/WHO-calls-for-no-restrictions-on-China-s-trade-and-travel-NIQrW7w3kI/index.html (https://news.cgtn.com/news/2020-02-01/WHO-calls-for-no-restrictions-on-China-s-trade-and-travel-NIQrW7w3kI/index.html)

February 3, 2020 - WHO Director-General states that a travel ban is not needed; https://www.reuters.com/article/us-china-health-who-idUSKBN1ZX1H3 (https://www.reuters.com/article/us-china-health-who-idUSKBN1ZX1H3) , https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-technical-briefing-on-2019-novel-coronavirus (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-technical-briefing-on-2019-novel-coronavirus)

February 4, 2020 - The Civil Aviation Administration of China urged domestic carriers to continue flying international routes; https://www.channelnewsasia.com/news/asia/wuhan-coronavirus-china-airlines-resume-global-flights-cancel-12390606 (https://www.channelnewsasia.com/news/asia/wuhan-coronavirus-china-airlines-resume-global-flights-cancel-12390606)

February 11, 2020 - "WHO did not recommend any travel or trade restrictions"; https://www.who.int/news-room/articles-detail/key-considerations-for-repatriation-and-quarantine-of-travellers-in-relation-to-the-outbreak-of-novel-coronavirus-2019-ncov/ (https://www.who.int/news-room/articles-detail/key-considerations-for-repatriation-and-quarantine-of-travellers-in-relation-to-the-outbreak-of-novel-coronavirus-2019-ncov/)

February 16-24, 2020 - WHO delegation visited China but did not investigate Chinese censorship of Covid-19 data; https://www.who.int/docs/default-source/coronaviruse/transcripts/joint-mission-press-conference-script-english-final.pdf?sfvrsn=51c90b9e_2 (https://www.who.int/docs/default-source/coronaviruse/transcripts/joint-mission-press-conference-script-english-final.pdf?sfvrsn=51c90b9e_2) , pages 16 and 17 of the transcript

February 29, 2020 - "WHO continues to advise against the application of travel or trade restrictions to countries experiencing COVID-19 outbreaks"; https://www.who.int/news-room/articles-detail/updated-who-recommendations-for-international-traffic-in-relation-to-covid-19-outbreak (https://www.who.int/news-room/articles-detail/updated-who-recommendations-for-international-traffic-in-relation-to-covid-19-outbreak)

March 3, 2020 - WHO Director-General claimed, "COVID-19 does not transmit as efficiently as influenza, from the data we have so far"; https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020 (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020)

March 3, 2020 - World Health Organization declared the coronavirus outbreak a global pandemic; https://www.cnbc.com/2020/03/11/who-declares-the-coronavirus-outbreak-a-global-pandemic.html (https://www.cnbc.com/2020/03/11/who-declares-the-coronavirus-outbreak-a-global-pandemic.html)

April 13, 2020 - WHO MERS specialist states she suspected from the start that human-human transmission may have been happening; https://www.youtube.com/watch?v=NCy-qvcDDl4 (https://www.youtube.com/watch?v=NCy-qvcDDl4) starting around 23:00

Title: Re: Coronavirus and Covid-19 Related Events
Post by: LegalAmerican on April 09, 2020, 06:02:46 pm

Covid-19 is just another cold/flu virus.  I've had it twice.  It is 'new'. The whole world is being scammed.  It will come out in time.
I used all my natural anti-viral supplements.  Silver, ZINC, Elderberry tincture, green tea.

Error 404 (Not Found)!!1 (http://www.youtube.com/watch?v=0YvNRno-JB8#)

Title: Re: Coronavirus and Covid-19 Related Events
Post by: Neverdul on April 09, 2020, 07:56:02 pm

Quote from: LegalAmerican on April 09, 2020, 06:02:46 pm

Covid-19 is just another cold/flu virus.  I've had it twice.  It is 'new'. The whole world is being scammed.  It will come out in time.
I used all my natural anti-viral supplements.  Silver, ZINC, Elderberry tincture, green tea.

Error 404 (Not Found)!!1 (http://www.youtube.com/watch?v=0YvNRno-JB8#)

@LegalAmerican

You've had COVID-19 twice?  **nononono* You poor thing!

Dearest Peggy, I would have thought that you being deep inside a remote Siberian troll farm, that you'd not be exposed at all. That you not only got it once, but got it twice tells me it is much, much worse than imagined.

As to the “silver”. Was that per chance Alex Jones’ nano-silver toothpaste? Is he actually exporting that to Russia now?

Please take care Peggy, please stay well and please say hello to Jake from State Farm for me and tell him I really like his pants.

BTW – Andrew Kaufmam is board certified in Psychiatry. Because when it comes to infectious disease, the very first person I want to consult is a psychiatrist. But you might want to consult him, albeit for other reasons.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on April 11, 2020, 02:43:16 pm

It's said that one of the problems in studying History is that they keep making more of it. That certainly is true wrt this coronavirus. This website, https://www.donaldjtrump.com/media/timeline-the-trump-administrations-decisive-actions-to-combat-the-coronavirus/ (https://www.donaldjtrump.com/media/timeline-the-trump-administrations-decisive-actions-to-combat-the-coronavirus/) , is the Trump campaign webpage giving a timeline of Trump Administration actions, and it is updated regularly. I have used it as a source for events from about mid March onward, but: I have selected events I thought most significant and that I could provide a verifying article. I will be trying this weekend to bring my OP timeline up to date.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on April 20, 2020, 12:57:31 am

Yeppers, China is handling this coronavirus so-o-o-o-oooooooo well!

Czech Republic rejected defective coronavirus tests from China: 3/26/2020, https://www.praguemorning.cz/80-of-rapid-covid-19-tests-the-czech-republic-bought-from-china-are-wrong/ (https://www.praguemorning.cz/80-of-rapid-covid-19-tests-the-czech-republic-bought-from-china-are-wrong/)

Spain rejected defective coronavirus tests from Shenzhen Bioeasy Biotechnology: 3/26/2020, https://www.businessinsider.com/coronavirus-spain-says-rapid-tests-sent-from-china-missing-cases-2020-3 (https://www.businessinsider.com/coronavirus-spain-says-rapid-tests-sent-from-china-missing-cases-2020-3)

Turkey rejected defective sample coronavirus tests from Shenzhen Bioeasy Biotechnology: 3/27/2020, https://www.middleeasteye.net/news/coronavirus-turkey-faulty-chinese-kits-not-use (https://www.middleeasteye.net/news/coronavirus-turkey-faulty-chinese-kits-not-use)

Georgia (nation) rejected defective coronavirus tests from Shenzhen Bioeasy Biotechnology: 3/27/2020, https://agenda.ge/en/news/2020/953 (https://agenda.ge/en/news/2020/953)

Slovakia rejected defective coronavirus tests from China: 4/1/2020, https://www.bloomberg.com/news/articles/2020-04-01/faulty-virus-tests-cloud-china-s-european-outreach-over-covid-19 (https://www.bloomberg.com/news/articles/2020-04-01/faulty-virus-tests-cloud-china-s-european-outreach-over-covid-19)

UK rejected defective coronavirus tests from China: 4/6/2020, https://www.telegraph.co.uk/news/2020/04/06/government-seeks-refund-millions-coronavirus-antibody-tests/ (https://www.telegraph.co.uk/news/2020/04/06/government-seeks-refund-millions-coronavirus-antibody-tests/)

Australia seizing defective masks and PPE from China: starting around 3/11/2020, https://www.abc.net.au/news/2020-04-01/coronavirus-chinese-ppe-border-force-intercepted/12085908 (https://www.abc.net.au/news/2020-04-01/coronavirus-chinese-ppe-border-force-intercepted/12085908)

Netherlands rejected defective masks from China: 3/28/2020, https://www.bbc.com/news/world-europe-52092395 (https://www.bbc.com/news/world-europe-52092395)

Austria rejected defective masks from China: 4/6/2020, https://www.diepresse.com/5796725/chinesische-schutzmasken-fur-sudtirol-waren-unbrauchbar (https://www.diepresse.com/5796725/chinesische-schutzmasken-fur-sudtirol-waren-unbrauchbar) (German language)

Canada rejected defective masks from China: 4/7/2020, https://torontosun.com/news/local-news/over-62000-defective-masks-sent-to-toronto-long-term-care-workers (https://torontosun.com/news/local-news/over-62000-defective-masks-sent-to-toronto-long-term-care-workers)

Defective tests, defective PPE, but Chinese statistics are reliable? *****rollingeyes*****

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on June 06, 2020, 03:23:48 pm

Over the past couple of months I'd added a few items to my US and China/WHO timelines without noting it by bumping this thread. Over the past couple of weeks I've been fitfully rooting through this Congressional Research Service report, and this AM I updated both timelines.

The additions to the US timeline give a fuller picture of things done in January, 2020 by the Trump Administration, more evidence of the ludicrous falseness of the Dems' and MSM's (I know, repetitive and redundant) Trump did nothing for 2 months narrative.

The additions to the China/WHO timeline were jaw-dropping for me. The bureaucratic cover-ups at all levels ... the attacks of doctors trying to do their jobs and warn their colleagues and communities ... the shutting down of unauthorized research, the multi-layered delays in communicating key information to the world (and only doing so after the key information was leaked to the West) ... outrageous.

At the same time, a picture emerges that Wuhan officials, Hubei Province officials, and national officials were very slow to take the organizational steps to fight the virus within China. Some of the Trump Administration's organizational actions preceded China's similar actions, and some followed China's by a few days. Before concluding that the Trump Administration was following as much as leading, keep in mind that in January what was then believed to be the first US Covid-19 case was diagnosed on January 20th; at that time China had hundreds of cases, and on that date China/WHO had finally admitted that human-human transmission had happened. In the context of what was known when, the Trump Administration was clearly leading. And in the context of the Dems' shampeachment, leading was politically risky.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on August 02, 2020, 02:47:02 pm

Other than the stat that this thread has had nearly 6400 Views, I don't know who viewed it when and how often. A good number of the Views are me, because I have updated the US and China timelines frequently and substantially, but haven't posted announcements for the updates. Today's update to the US timeline includes some key info to understanding the rather fast Covid-19 vaccine development and testing. Here are those key items and a couple of articles that expand on them:

February 6, 2017 - DARPA launched the Pandemic Prevention Platform, an effort to create a standardized process to create medical countermeasures to a viral outbreak within 60 days, preventing the outbreak from becoming a pandemic; https://www.darpa.mil/news-events/2017-02-06a (https://www.darpa.mil/news-events/2017-02-06a)

February 22, 2018 - DARPA names the research institutions that will be participating in DARPA's Pandemic Prevention Platform, launched in 2017; https://globalbiodefense.com/2018/02/22/stopping-pandemic-x-darpa-names-researchers-working-to-halt-outbreaks/ (https://globalbiodefense.com/2018/02/22/stopping-pandemic-x-darpa-names-researchers-working-to-halt-outbreaks/)

https://spectrum.ieee.org/the-human-os/biomedical/bionics/darpas-firebreak-treatment-for-the-coronavirus (https://spectrum.ieee.org/the-human-os/biomedical/bionics/darpas-firebreak-treatment-for-the-coronavirus) :

DARPA Races To Create a “Firebreak” Treatment for the Coronavirus

Quote

When DARPA launched its Pandemic Preparedness Platform (P3) program two years ago, the pandemic was theoretical. It seemed like a prudent idea to develop a quick response to emerging infectious diseases. Researchers working under the program sought ways to confer instant (but short-term) protection from a dangerous virus or bacteria.

Today, as the novel coronavirus causes a skyrocketing number of COVID-19 cases around the world, the researchers are racing to apply their experimental techniques to a true pandemic playing out in real time. ...
...
Robert Carnahan, who works with Crowe at the Vanderbilt Vaccine Center ...
...
Jenkins says that all of the P3 groups (the others are Greg Semposki’s lab at Duke University, a small Vancouver company called AbCellera, and the big pharma company AstraZeneca[/b]) have made great strides in technologies that rapidly identify promising antibodies. ...
...
Moderna was involved in a related DARPA program known as ADEPT that has since ended. The company’s work on mRNA-based therapies has led it in another interesting direction—last week, the company made news with its announcement that it was testing an mRNA-based vaccine for the coronavirus.

DARPA's partners began working on vaccines in January 2020 as part of a program launched in 2017 and begun in 2018. AstraZeneca and Moderna are two of the three companies whose vaccines are in Phase III testing. AbCellera is partnered with Eli Lilly, and their antibody treatment is in Phase I testing, https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment (https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment) .

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development)

Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

Quote

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and the Coalition for Epidemic Preparedness Innovations (CEPI), today announced a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV).

Under the terms of the agreement, Moderna will manufacture an mRNA vaccine against 2019-nCoV, which will be funded by CEPI. The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, collaborated with Moderna to design the vaccine. NIAID will conduct IND-enabling studies and a Phase 1 clinical study in the U.S.

https://www.abcellera.com/news/2020-01-abcellera-mobilizing-a-response-to-novel-coronavirus (https://www.abcellera.com/news/2020-01-abcellera-mobilizing-a-response-to-novel-coronavirus) :

AbCellera is mobilizing a response to the novel coronavirus outbreak as part of its DARPA P3 program

Quote

JANUARY 28, 2020
AbCellera confirms that it is mobilizing its pandemic response platform against the ongoing outbreak of a novel coronavirus (2019-nCoV) originating in Wuhan, China. Since 2018, under the DARPA Pandemic Prevention Platform (P3) program, AbCellera has been leading a team of partners to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera’s rapid, high-throughput therapeutic antibody discovery technology will be used to discover coronavirus-neutralizing antibodies that could ultimately be deployed to stop transmission of the 2019-nCoV outbreak.

IOW, our current state in which three vaccines are in the final stage of pre-authorization tests is the result of a DARPA (Defense Advanced Research Projects Agency) program launched in 2017 and begun in 2018. Of those three vaccines, at least two - AstraZeneca and Moderna - are from participants in DARPA's Pandemic Prevention Platform program, AstraZeneca and Moderna. Another participant, AbCellera (with partner Eli Lilly), has an antibody treatment in Phase I testing. Moderna and AbCellera both began their Covid-19 work under the aegis of that DARPA program in January, 2020.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on August 03, 2020, 02:22:21 pm

A note regarding including Clover Pharmaceuticals' vaccine candidate in the US timeline ... Clover is a Chinese company, and I have been ignoring Chinese vaccines for obvious reasons. However, Clover is partnering with two US companies, GlaxoSmithKline and Dynavax, which produce adjuvants. Adjuvants strengthen the effectiveness of vaccines, allowing smaller doses and more doses per batch. So these companies are participants in trials who have a financial stake in the testing being done properly. I think at least some of the testing is being done in Australia. A Canadian vaccine developer, Medicago, is also working with GSK and Dynavax.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: LegalAmerican on August 13, 2020, 12:19:12 am

NICE. 

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on August 20, 2020, 01:24:36 pm

I just posted a couple of very significant additions to my China timeline, above.

One shows that in a January 14th discussion among Chinese health officials, the head of China’s National Health Commission stated, contrary to China's and WHO's pronouncements to the world, that there were definite indications that human-human transmission was happening. China did not admit this to the world until some 6 days later.

The other addition is that the Civil Aviation Administration of China on February 4th urged Chinese carriers to continue international flights. China shut down domestic travel out of Wuhan and the rest of Hubei Province on January 23rd!

Significant updates to my US timeline are also coming, hopefully this weekend. I'm rooting through this White House report, https://www.whitehouse.gov/wp-content/uploads/2020/08/OTMP-DPA-Report-FINAL-8.13.20.pdf (https://www.whitehouse.gov/wp-content/uploads/2020/08/OTMP-DPA-Report-FINAL-8.13.20.pdf) . It gives many instances of Trump using the DPA (contrary to Dem insinuations he isn't), from March to the present, to facilitate the production of medications and medical supplies. Among those medical supplies are the PPE on which some here have claimed Trump did not work to supply. The updates are very nutsy-boltsy, but their volume and detail show that Trump and his Administration have done a lot, under Trump's direction.

Title: Re: Coronavirus and Covid-19 Related Events
Post by: PeteS in CA on August 26, 2020, 01:16:11 pm

The US timeline in the OP of this thread has gotten yuge, :cool: . In my Word-compatible file it's over 31 pages in 12-point Arial font, and will grow a couple of pages (again!), probably this coming weekend. While its size dramatizes the fact that a lot is being done and accomplished, it's also getting really hard to use to research some specific topic or issue. I've posted "canned" extracts that address a number of specific topics, "gotcha" issues that the Dems and other anti-Trump commonly raise or that I think are very likely to be raised. Each has its own thread here in the Exclusive Content >> News forum:

Trump Did Nothing for Two Months? - January (http://www.gopbriefingroom.com/index.php/topic,412484.0.html)

Trump Did Nothing for Two Months? - February (http://www.gopbriefingroom.com/index.php/topic,412485.0.html)

Trump Did Not Use the Defense Production Act? (http://www.gopbriefingroom.com/index.php/topic,412702.0.html)

Trump Did Nothing About Masks, Gowns, and Gloves (PPE)? (http://www.gopbriefingroom.com/index.php/topic,412486.0.html)

Trump Did Nothing About Ventilators? (http://www.gopbriefingroom.com/index.php/topic,412487.0.html)

What Happened to Covid-19 Tests?! (http://www.gopbriefingroom.com/index.php/topic,412820.0.html)

Untested Trump Vaccine? (http://www.gopbriefingroom.com/index.php/topic,412701.0.html)

Did Trump Take Covid-19 Seriously - Trump Actions and Donkey Brayings (http://www.gopbriefingroom.com/index.php/topic,412821.0.html)

China & WHO's Deception Adventure (http://www.gopbriefingroom.com/index.php/topic,412910.0.html)